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Alzheimer’s disease (AD) is the leading cause of dementia but despite being 
identified over a century ago, current treatments remain limited. To date, no disease-
modifying therapies are available.  
 
Soluble, intracellular forms of β-amyloid (Aβ), a protein associated with AD, have 
been identified and intracellular targets of Aβ are being investigated as potential 
targets for new drugs. Amyloid binding alcohol dehydrogenase (ABAD) was 
previously identified as a mitochondrial target of Aβ and is known to be up-regulated 
in AD. This interaction results in production of reactive oxygen species and cell 
death. Using a small peptide, known as the “decoy peptide”, disruption of this 
interaction has been shown to reverse biochemical and behavioural symptoms in an 
AD mouse model. 
 
The work reported in this thesis describes the approaches taken to develop methods 
for in vitro and ex vivo study of the interaction between ABAD and Aβ. A 
fluorogenic assay for measuring the intracellular activity of ABAD in living cells 
was developed and using this technique, the intracellular inhibition of ABAD by Aβ 
was observed for the first time. Surface plasmon resonance was used to measure 
binding between ABAD and Aβ and also showed the first quantitative analysis of 
direct binding of the decoy peptide to Aβ42. In order to synthesise small molecule 
inhibitors of ABAD activity with the aim of developing a molecular probe of the 
enzyme’s activity, compounds were identified by screening a fragment-based library. 
Subsequent optimisation of the compound structure led to a 10-fold improvement in 
the IC50 and has resulted in a lead compound for future development. A similar 
screening strategy was employed to identify potential small molecule inhibitors of 
the ABAD-Aβ interaction.  
 
This research has resulted in a range of tools and methods for studying ABAD 
activity and interactions, which will greatly benefit future work on developing 
compounds that inhibit the ABAD-Aβ interaction to provide a novel method for 
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A  adenine 
A (or Ala) alanine 
aa  amino acids 
Aβ   amyloid-β peptide 
Aβ20   amyloid-β peptide, residues 1–20 
Aβ(25–35) amyloid-β peptide, residues 25–35 
Aβ40   amyloid-β peptide, residues 1–40 
Aβ42   amyloid-β peptide, residues 1–42 
ABAD  amyloid binding alcohol dehydrogenase 
AcAcCoA S-acetoacetyl coenzyme A 
Ampr  ampicillin resistance 
Abs  absorbance 
AD  Alzheimer’s disease 
ADDL  amyloid-derived diffusible ligand 
aq.  aqueous 
ApoE  apolipoprotein E 
APP  amyloid precursor protein 
BACE1 beta-site APP cleaving enzyme 
bis-Tris bis(2-hydroxyethyl)iminotris(hydroxymethyl)methane 
bp  base pairs 
BSA  bovine serum albumin 
C  cytosine 
C (or Cys) cysteine 
cDNA  complementary DNA 
CHANA cyclohexenyl amine naphthalene alcohol 
CHANK cyclohexenyl amine naphthalene ketone 
CHAPS 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
CM5  carboxymethylated dextran 
CoA  co-enzyme A 
COSY  correlation spectroscopy 
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COX8  subunit VIII of human cytochrome c oxidase 
CsA  cyclosporin A 
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CypD  cyclophilin D 
d  doublet 
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DCM  dichloromethane 
dd  doublet of doublets 
ddd  doublet of doublet of doublets 
DNA  deoxyribonucleic acid 
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DMEM Dulbecco’s modified essential medium 
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E (or Glu) glutamic acid 
E. coli  Escherichia coli 
ECL  enhanced chemiluminescence 
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EDTA  ethylenediaminetetraacetic acid 
Ep-I  endophilin-I 
ER  endoplasmic reticulum 
ERAB  ER-associated amyloid-binding protein (ABAD) 
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F (or Phe) phenylalanine 
FCC  flash column chromatography 
FCS   foetal calf serum 
fdu  5-fluorodeoxyuridine 
FI  field ionisation 
G  guanine 
 
 xix
G (or Gly) glycine 
GFP  green fluorescent protein 
H (or His) histidine 
HADH II human type II hydroxyacyl-CoA dehydrogenase (ABAD) 
HBS  HEPES buffered saline 
HEK293 human embryonic kidney cell line 
HEPES 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid, N-(2-
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HFIP  1,1,1,3,3,3-hexafluoroisopropanol 
His  6 × histidine tag 
His-ABAD His-tagged ABAD 
HIV  human immunodeficiency virus 
HMBC heteronuclear multi-bond correlation 
HNE  4-hydroxynonenyl 
HRMS  high resolution mass spectrometry 
HRP  horseradish peroxidase 
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HSQC  heteronuclear single quantum coherence 
HTS  high throughput screening 
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IR  infrared 
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KD  dissociation constant 
ITC  isothermal titration calorimetry 
L (or Leu) leucine 
LB  Luria broth 
LBA  Luria broth agar 
LDAO  lauryldimethylamine 0-oxide 
LRMS  low resolution mass spectrometry 
 
 xx
m  medium 
m  multiplet 
M (or Met) methionine 
mAPP  mutant amyloid precursor protein 
MEM  minimal essential medium 
MeOH  methanol 
MES  2-(0-morpholino)ethanesulfonic 
MQ  MilliQ-purified water 
mRNA  messenger RNA 
MS  mass spectrometry 
MTS  mitochondrial targeting sequence 
MW  molecular weight 
MWCO molecular weight cut off 
N (or Asn) asparagine 
NAD+  nicotinamide adenine dinucleotide 
NADH  nicotinamide adenine dinucleotide (reduced form) 
NBF  neutral buffered formalin 
NBS  0-bromosuccinimide 
NHS  0-hydroxysuccinimide 
NMDA 0-methyl-D-aspartate 
NMR  nuclear magnetic resonance 
NTA  nitrilotriacetic acid 
0-terminus amino terminus 
P (or Pro) proline 
PBS  phosphate buffered saline 
PAGE  polyacrylamide gel electrophoresis 
PCR  polymerase chain reaction 
PEG  polyethylene glycol 
PMSF  phenylmethylsulfonyl fluoride 
Prx-II  peroxiredoxin II 
PS1 (or 2) presenilin 1 (or 2) 
PTD  protein transduction domain 
 
 xxi
q  quartet 
Q (or Gln) glutamine 
R (or Arg) arginine 
Rf  retention factor 
RISC  RNA-induced silencing complex 
ROS  reactive oxygen species 
RNA  ribonucleic acid 
rpm  revolutions per minute 
RU  response units 
s  singlet 
s  strong 
S (or Ser) serine 
SAR  structure-activity relationship 
SCHAD human brain short-chain L-3-hydroxyacyl-CoA dehydrogenase 
(ABAD) 
SCX  strong cation exchange 
SD  standard deviation 
SEM  standard error of the mean 
SDS  sodium dodecyl sulfate 
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siRNA  short interference RNA 
SK-N-SH neuroblastoma cell line 
SOC  superoptimal broth with catabolite repression 
SPR  surface plasmon resonance 
SR-2  serum replacement 2 
SyproO Sypro Orange 
t  triplet 
T  thymine 
T (or Thr) threonine 
Tm  unfolding temperature (of protein) 
∆Tm  change in unfolding temperature (of protein) 
Tat  transactivator of transcription 
 
 xxii
TB  Terrific broth 
TBE  Tris-borate-EDTA buffer 
TBS  Tris-buffered saline 
TBS-T  Tris-buffered saline with 0.1% Tween20 
TEV  tobacco etch virus 
TFA  trifluoroacetic acid 
Tg  transgenic 
THF  tetrahydrofuran 
ThT  thioflavin T 
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TMS  trimethylsilane 
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TSA  thermal shift analysis 
Tris  Tris(hydroxymethyl)methylamine 
TRX  thioredoxin-1 
U  units 
U  uracil 
utABAD untagged ABAD 
UV  ultra violet 
V  velocity 
Vmax  maximal velocity 
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1.1 An introduction to Alzheimer’s disease 
 
Alzheimer’s disease (AD) is the leading cause of dementia, responsible for over two 
thirds of all dementia cases, and is thought to affect over 820,000 people in the 
United Kingdom1 and 35.6 million people world wide.2 An ageing population has 
resulted in a rapid increase in the number of people developing AD and other forms 
of dementia, resulting in a substantial burden on the social care system. The annual 
cost of treating dementia in the UK is estimated at £23 billion, a figure comparable to 
the combined cost of treating heart disease, stroke and cancer.1  
 
Currently approved treatments focus on managing AD-related symptoms rather than 
targeting the underlying cause; indeed, there is currently no cure for this debilitating 
disease and an effective treatment for AD is therefore badly needed. This aim has 
proved challenging for researchers, as the underlying disease mechanism is highly 
complex and remains poorly understood, despite the disease first being recognised 
over a century ago.3  
 
 
1.1.1 Symptoms, pathology and diagnosis of Alzheimer’s disease 
 
The term dementia encompasses a range of diseases, all of which are characterised 
by the loss of mental function, most notably memory. In addition to AD, this 
umbrella term includes a number of other conditions, such Lewy body disease, 
vascular dementia and fronto-temporal dementia. Patients with AD present a range of 
symptoms, including short-term memory deficits, difficulty with planning or solving 
problems, the inability to complete everyday tasks, problems with language and 
changes in mood or personality.4,5 Psychiatric symptoms, such as behavioural 
problems, sleep disturbance, hallucinations and depression may also occur.5-7 
 
AD results from the death of neurons in distinct areas of the brain, most notably the 
hippocampus and the frontal and temporal lobes, which are responsible for learning 
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and memory formation.8 Figure  1.1 shows shrinkage of the brain caused by AD and 
decreased metabolism in the affected areas.  
 
 
Figure  1.1: The effect of Alzheimer’s disease on the brain. A) Shrinkage of temporal lobe and 
frontal lobes in Alzheimer's brain (right) compared with normal brain (left); B) positron emission 
topography (PET) scans of normal (left) and Alzheimer’s (right) brains, showing decreased glucose 
metabolism in the temporal and frontal lobes of the Alzheimer’s brain. Reprinted by permission from 
Macmillan Publishers Ltd: Nature,8 Copyright 2004. 
 
The classical manifestation of AD is the presence of two proteins within the brain: 
extracellular plaques consisting of β-amyloid (Aβ)9,10 and intracellular tangles of 
hyperphosphorylated tau11 (Figure  1.2); confirmation of their presence post mortem 
remains the only conclusive diagnosis of the disease. However, several diagnostic 
tests are used to provide a probable diagnosis of AD upon presentation of symptoms 
to a clinician, for example, following the guidelines set out by the National Institute 
of Neurological and Communicative Disorders and Stroke and the Alzheimer’s 
Disease and Related Disorders Association working group (NINCDS-ADRDA).7 
The criteria for probable AD include, but are not limited to, the presence of 
dementia, as judged by a test such as the Mini-Mental State Examination (MMSE);12 
deficits in two or more areas of cognition; impaired activities of daily living; and 
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exclusion of other conditions, such as Parkinson’s disease, brain tumour or drug 
intoxication.7  
 
Aβ plaques and tau tangles (Figure  1.2) were historically thought to be the cause of 
AD and their presence defines the diagnosis of AD. However, there is little 
correlation between the quantity of plaques and the severity of cognitive dysfunction: 
individuals with high plaque loading may exhibit little or no cognitive dysfunction, 
while severe symptoms may be accompanied by relatively few plaques.13 This 
observation has led to an increase in interest in the role played by soluble, 







Figure  1.2: Pathological hallmarks of Alzheimer’s disease. A) Extracellular amyloid plaques; B) 
intracellular tau tangles. Scale bar = 100 µm. Reprinted by permission from Macmillan Publishers 
Ltd: Nature Reviews Molecular Cell Biology,14 copyright 2007. 
 
 
1.1.2 Causes of Alzheimer’s disease 
 
The underlying cause of most cases of AD remains elusive. In a small number of 
cases, thought to be less than 5% of all occurrences, AD is caused by an inherited 
genetic trait – so-called familial AD.15 Unlike the majority of sporadic cases, familial 
AD tends to manifest early in life (before the age of 65) and has been attributed to a 
number of specific genetic mutations, notably mutation of the amyloid precursor 
protein (APP) (discussed further in Section  1.2.1), presenilin 1 (PS1) and presenilin 2 
(PS2), which lead to elevated levels of Aβ. Individuals suffering from trisomy 21 
(Down’s syndrome) also display symptoms of AD early in life (< 50 years of age) 
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In the vast majority of AD cases, however, there is no clear cause, although some 
contributing risk factors have been identified. Genetic factors are able to influence 
the likelihood of developing of late onset AD, the best documented of which is the 
ApoE gene, whose association with AD was reported in 1993.18 ApoE is a plasma 
protein that is involved in the transport of cholesterol and other lipids and exists in 
three isoforms, ε2, ε3 and ε4. The ε2 and ε4 isoforms each contains a single mutation 
relative to ε3 (Cys-158-Arg and Cys-112-Arg, respectively).19 The prevalence of the 
ε4 allele is significantly higher in patients with late onset/sporadic AD, with an 
increased prevalence of the allele of around 0.40 in late-onset/sporadic AD 
populations compared to 0.16 ± 0.027 in the control population.18 More recently, 
CLU (ApoJ), PICALM and CR1 have also been identified as genetic factors that 
increase the likelihood of developing AD.20,21 It is, however, important to note that 
the presence of the ApoE ε4 allele or other risk alleles do not guarantee the 
development of the disease, but instead increase the risk of its occurrence. 
 
A number of studies have also identified behavioural and environmental risk factors 
which may increase one’s chance of developing Alzheimer’s disease. These include 
high mid-life cholesterol levels,22 elevated mid-life systolic blood pressure,22 low 
educational level,23 head injury, smoking, excessive alcohol consumption and 
depression;24 for a review of the epidemiology of AD see Mayeux.25 Due to the 
complex underlying causes of AD, it is difficult to predict who will be affected later 
in life and how this risk can best be minimised.  
 
 
1.1.3 Current treatments for Alzheimer’s disease 
 
Despite years of research, current drug treatments for AD are very limited in nature. 
They do not treat the underlying causes of the disease; instead they are designed to 
help alleviate the symptoms of AD by maximising the remaining function in the 
brain. This action results in a short term improvement or stabilisation of memory but 
the effects are often short lived and cognitive decline resumes as the treatment fails.26  
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Four drugs are currently licensed in the United Kingdom for treatment of AD (Table 
 1.1).27 Three of these drugs (Aricept, Exelon, Reminyl) are acetylcholinesterase 
inhibitors. The drugs work by preventing the breakdown of the neurotransmitter, 
acetylcholine, within the synaptic cleft, maintaining and strengthening the signal 
being transmitted between cholinergic neurons (Figure  1.3A). The fourth compound, 
Ebixa, is an 0-methyl-D-aspartate (NMDA) receptor antagonist, which blocks 
pathological stimulation of NMDA receptors by glutamate during AD (Figure  1.3B).  
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Figure  1.3: Mode of action of current AD treatments. A) Acetylcholinesterase inhibitors (Aricept, 
Exelon, Reminyl): the electrical impulse is transmitted across the synaptic cleft by the 
neurotransmitter, acetylcholine, which is recycled by the actions of acetylcholinesterase (top). In AD, 
level of acetylcholine released from the synapse is reduced, resulted in a diminished signal (middle). 
Treatment with an acetylcholinesterase inhibitor reduces the breakdown of acetylcholine, increasing 
its concentration at the post-synaptic neuron receptors and hence enhancing the transmitted signal. B) 
NMDA receptor antagonist (Memantine/Ebixa): Under normal conditions, the neurotransmitter, 
glutamate, transmits an inpulse via the NMDA receptor and is subsequently taken up by glial cells and 
recycled (top). In AD, uptake of glutamate by glial cells is inhibited by amyloid and the excess 
glutamate remaining at the post-synaptic membrane desensitises the postsynaptic cell to the 
transmitted signal, reducing its amplitude (middle). Treatment with memantine blocks the signal from 
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Drug treatment may also be used to relieve related symptoms, such as depression, 
anxiety, sleep disturbance and psychosis; however use of anti-psychotics for the 
treatment of dementia patients has proved controversial within the medical 
profession.30,31 In addition, non-pharmaceutical treatments such as nutritional 
improvements32 and exercise33 have been found to be beneficial.  
 
The challenge facing researchers today is, therefore, to better understand the causes 
of Alzheimer’s disease with the view to formulating an effective treatment. 
 
 
1.2 β-Amyloid and Alzheimer’s disease 
 
The observation of β-amyloid (Aβ) plaques in the brains of patients suffering from 
dementia was first noted in the early 20th century (for a historical review, see Maurer 
et al.
34 and Moeller & Graeber35). Production of Aβ is thought to be the underlying 
event in a cascade of events that lead to the development and progression of AD. 
This theory of AD is known as the amyloid cascade hypothesis and was first 
proposed in 1992 by Hardy and Higgins.36 It has been modified and elaborated on 
over the years as more experimental evidence supporting the hypothesis has come to 
light14,37 and is summarised in Figure  1.4. 
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Changes in A metabolism
• Increase in total A production
• Increase in the A 42/A 40 ratio
• Reduced A degradation/clearance
Oligomerization of A 42 and
initial (diffuse) A 42 deposits
Subtle effects of soluble A 42
oligomers on synaptic function
Inflammatory responses
(microglial and astrocytic activation)
and amyloid plaque formation
Progressive synaptic/neuronal injury




Widespread neuronal dysfunction and
cell death associated with
neurotransmitter def icits
Dementia with plaque and tangle
pathology
 
Figure  1.4: The amyloid cascade hypothesis for the progression of Alzheimer’s disease. A change 
in Aβ metabolism, such as increased Aβ production, increased Aβ42:Aβ40 ratio and reduced Aβ 
clearance, leads to elevated Aβ42 levels (green box) and triggers a cascade of cellular events, 
including formation of amyloid oligomerisation, synaptic damage, hyperphosphorylation of tau and 
neuronal dysfunction (yellow boxes). Eventually, widespread neuronal death occurs and the plaque 
and tangle pathology of AD can be seen (red box). Adapted by permission from Macmillan Publishers 
Ltd: Nature Reviews Molecular Cell Biology,14 copyright 2007. 
 
The amyloid cascade hypothesis does not explain all of the events occurring during 
AD; for example, the point at which tau pathology becomes relevant is a matter of 
much debate.38 However, the cascade hypothesis provides a framework for a strong 
argument for a build-up of Aβ as the underlying trigger for the development of AD. 
Significantly, focus has shifted away from Aβ plaques towards soluble oligomeric 
forms of the peptide, which are thought to exhibit greater toxic effect and would 
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account for the lack of correlation between Aβ plaque loading and cognitive deficits 
(see Section  1.1.1).  
 
 
1.2.1 Production of β-amyloid 
 
Aβ production results from the sequential cleavage of the amyloid precursor protein 
(APP) by two secretase enzymes, β- and γ-secretase. The β-secretase enzyme has 
been identified as beta-site APP-cleaving enzyme 1 (BACE1), which is a 
transmembrane aspartate protease,39 whilst the γ-secretase complex is made up of 
four proteins: presenilin 1, nicastrin, Aph-1 and Pen-2.40 
 
APP is a transmembrane protein consisting of a large (493–700 amino acids) 
extracellular domain, a single transmembrane domain and a short intracellular 
domain and can exist in a number of isoforms ranging in size from 563–770 amino 
acid residues.41,42 The native function of APP remains unknown, although there have 
been suggestions that it may be involved in cell recognition or act as a membrane 
receptor.41,43  
 
There are two processing pathways associated with APP, summarised in Figure  1.5. 
The first is cleavage by α-secretase within the transmembrane region of APP, 
yielding the non-toxic protein fragments, C83 and sAPPα. The alternative processing 
pathway involves cleavage by β- and γ-secretases to produce the toxic Aβ peptide. 
β-Secretase cleaves the protein in the ectodomain region, to generate sAPPβ and 
membrane-bound C99 fragments. The C99 fragment is then cleaved by γ-secretase in 
the transmembrane region to release the Aβ peptide. The exact position of γ-cleavage 
determines the final length of the Aβ peptide, most commonly 40 or 42 amino acids 
in length (Aβ40 and Aβ42, respectively). Processing through the α-cleavage pathway 
prevents the formation of Aβ from APP.  
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Figure  1.5: Processing of the amyloid precursor protein, APP. Under normal conditions, APP is 
cleaved by α-secretase to produce the non-toxic peptides, sAPPα and C83. In AD, amyloidogenic 
processing through sequential cleavage by β- and γ-secretases occurs: APP is cleaved by β-secretase 
to produce sAPPβ and C99. Membrane-bound C99 is then cleaved by γ-secretase, resulting in the 
formation of the toxic Aβ peptide. Reprinted by permission from Macmillan Publishers Ltd: Nature,8 
copyright 2004. 
 
The genetic mutations in APP that are responsible for familial AD cause enhanced 
cleavage by β- and γ-secretase, resulting in enhanced Aβ production. Some of the 
known mutations in APP can be seen in Figure  1.6.43  In addition to elevated Aβ 
levels, the relative proportions of Aβ isoforms may be altered. Under “normal” 
conditions, the most common form of Aβ produced by β- and γ-secretase cleavage is 
Aβ40. Under AD conditions, however, the ratio of Aβ42:Aβ40 is altered, with Aβ42 
levels being elevated.44,45 Mutations in PS1 and PS2 also cause elevated plasma 
levels of Aβ42 by changes in γ-secretase activity.46 




Figure  1.6: Amyloid precursor protein sequence, mutations and secretase cleavage sites. The 
boxed sequence represents the Aβ peptide. The shaded area represents the transmembrane portion of 
APP. Black boxes indicate known point mutations of APP that lead to familial AD. Long arrows 
indicate relevant secretase cleavage sites, while the dotted arrow shows the γ-secretase site required 
for Aβ42 production. Reprinted from Peptides, 23, G. Evin & A. Weidemann, Biogenesis and 




1.2.2 Forms of β-amyloid 
 
The term “β-amyloid” refers to several isoforms of the peptide; the most relevant of 
which are the 40 and 42 residue peptides, Aβ40 and Aβ42. In addition, these peptides 
can exist in various states of aggregation, from monomers, to soluble oligomers, to 
insoluble fibrillar structures. Each of these structures is likely to have different 
properties with regards to its biological effects and this issue has proved to be one of 
the biggest challenges for researchers working in the field of AD. 
 
The length of the Aβ peptide has a significant effect on its aggregation properties. Aβ 
has a hydrophilic 0-terminus and a hydrophobic C-terminus, therefore extension of 
the C-terminus from Aβ40 to Aβ42 leads to a greater degree of hydrophobicity 
within the peptide. This in turn causes an increase in the ability of the peptide to 
aggregate via the C-terminus. It has also been noted that Aβ42 is more rigid than 
Aβ40 at the C-terminus, reducing the entropic price of monomer ordering therefore 
increasing the likelihood of subsequent aggregation of Aβ42.47 
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Levels of Aβ42 are known to be elevated in AD patients and insoluble fibrils of the 
peptide form the main constituent of the amyloid plaques characteristic of the 
disease.9 Fibrils can form from several Aβ species, including Aβ42, Aβ40 and 
Aβ(11-25) and consist of a cross-β sheet structure.48-50  Fibrils can be visualised by 
various techniques, such as electron microscopy and atomic force microscopy, and 
have been shown to be long thin structures with a diameter of 2–12 nm (Figure 
 1.7A). 51-54 
 
Whilst it was historically thought that Aβ plaques were the cause of AD, in recent 
years the importance of soluble, intracellular Aβ species has come to light. The role 
of soluble Aβ may in part account for the lack of correlation between plaque load and 
disease severity; indeed, it has been found that measurement of total (soluble) 
amyloid has a much higher correlation with the degree of cognitive decline.13,55,56 
Therefore, it can be imagined that potential therapies, such as vaccination (see 
Section  1.2.3.2), that aim to dissolve plaques may not be a successful route to pursue.  
 
The main component of the amyloid plaques that are characteristic of AD has been 
shown to be insoluble fibrils of Aβ. It has been shown, however, that fibrillar Aβ is 
not the only source of toxicity arising from amyloid. It appears that treatment with 
intermediate forms of amyloid, such as dimers, trimers, oligomers and protofibrillar 
structures, can also exert deleterious effects in vitro54,57-59 and in vivo.60 A number of 
Aβ species have been identified from in vivo studies including: Aβ*56, a 56 kDa 
oligomer (corresponding to an Aβ dodecamer) isolated from the brain tissue of 
transgenic Tg2576 mice expressing a variant of APP linked to Alzheimer’s disease;60 
dimers isolated from human cerebral spinal fluid and primary cortical neurons;61 as 
well as a range (monomer–octomer) of water soluble oligomers and globular 
structures.45 
 
Several species have also been synthesised in the laboratory. In addition to naturally 
occurring species, such as protofibrils53,54,57 and low molecular weight oligomers 
(monomers to tetramer),54,57,62 novel species have also been prepared. One example 
of such a species is the Aβ-derived diffusible ligand (ADDL).51,59  ADDLs are 
Chapter 1. Introduction 
 15 
spherical globules prepared from Aβ42 with a diameter of ~3–8 nm and a mass of 
17–42 kDa, and are thought to correspond to trimer–24mer of Aβ42.51 These 
structures are stable for at least 24 hours without transformation into protofibrils or 
fibrillar material. As ADDLs are formed at very low concentrations (50 nM) at 
37 °C, it was thought that they have the potential to form under physiological 
conditions.59 ADDLs were found to be potent neurotoxins, able to cause neuronal 
death in vitro at nanomolar concentrations.59  
 
The structural differences between some of these Aβ species are exemplified in 
Figure  1.7, where the long thread-like nature of fibrils (A) is in direct contrast with 
the smaller oligomeric species (B and C).51 As a result, it is easy to understand how it 




Figure  1.7: Structural comparison of some synthetically-prepared aggregates of Aβ. Samples 
were imaged by AFM. A) Fibrils: prepared by incubation of Aβ42 in ddH2O for one week; B) Ring 
structures of Aβ42: prepared in F12 medium at 37 °C for 24 h; C) ADDLs/protofibrils: Aβ42 aged in 
PBS for 48 h at room temperature. Scale bar = 400 nm. Reprinted with permission from Chromy et 
al.
51 Copyright 2003 American Chemical Society. 
 
It has been proposed that many of these species may exist in equilibrium rather than 
in isolation.54 It is also known that the eventual formation of higher-order species 
most likely results by passing through smaller species.53,63 This process may be 
different for Aβ40 and Aβ42, as demonstrated by Bernstein et al. using ion mobility 
coupled with mass spectrometry (Figure  1.8).63 
 
Chapter 1. Introduction 
 16 
 
Figure  1.8: Mechanism of oligomerisation and eventual fibril formation for Aβ42 and for Aβ40. 
For Aβ40 (light spheres) the key structure is the tetramer (Te) that resists further monomer (M) or 
dimer (D) addition. In Aβ42 (dark spheres) an ‘open’ tetramer promotes the formation of the planar 
hexamer (paranucleus) and the stacked dodecamer, which resists further reaction. Reprinted by 
permission from Macmillan Publishers Ltd: Nature Chemistry,63 copyright 2009.  
 
 
1.2.3 β-Amyloid as a therapeutic target 
 
Unsurprising, the significant role played by Aβ in the progression of AD has made 
the peptide an obvious target in the hunt for new drug treatments for the disease. 
Three main strategies are currently being explored: prevention of Aβ formation; 




1.2.3.1 Prevention of β-amyloid production 
 
Prevention of Aβ formation is a strategy that could potentially be achieved through 
modulation of the APP cleavage pathway and as such, inhibition of both β- and γ-
secretases have been investigated for their AD-modifying properties.  
 
Investigation of the role of BACE1 (β-secretase) has been investigated through 
studies of the BACE1 knock-out mouse (BACE1-/-). Initial reports suggested that 
these animals are phenotypically identical to the wild-type animal, other than lacking 
any detectable Aβ, indicating that inhibition of this enzyme may not affect other 
pathways.64 Later studies showed schizophrenic-like behaviour, potentially linked to 
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alterations in neuregulin processing.65 A range of peptidomimetic BACE1 inhibitors 
have been reported in the literature,66-68  including a compound that was found to 
reduce Aβ production in vivo in the brains of Tg APP mice.68 More recently, a 
fragment-based approach has resulted in small molecule inhibitors in the low 
micromolar and nanomolar range,69,70 while work by Fukumoto et al. described a 
compound that reduced Aβ pathology and behavioural deficits in Tg2576 mice, an 
APP transgenic mouse model of AD.71 Despite this progress, to date only one 
compound targeting β-secretase, CTS-21166, has progressed into clinical trials.72 
 
γ-Secretase inhibitors are also a potential target; however, the nature of the 
γ-secretase complex, involving four individual proteins, means that mechanistic 
understanding of the enzyme is still limited. An additional complicating factor is the 
ability of γ-secretase to cleave other peptides, such as Notch receptor; therefore high 
substrate specificity for APP is required.73 It has been proposed that APP and Notch 
bind in different binding sites before a conformational change transfers the substrate 
into the active site for cleavage,74 allowing the inhibition of γ-secretase to be targeted 
selectively to APP.75 A recent phase III clinical trial of the γ-secretase inhibitor, 
semagacestat (Eli Lilly), was discontinued in 2010 after the drug was found to 
enhance the rate of disease progression,76 despite having shown great promise in 
phase II trials. Another compound, R-flurbiprofen (Flurizan), showed no 
improvement in AD patients during a phase III trial (reviewed by Citron77). 
 
 
1.2.3.2 0eutralisation and clearance of β-amyloid  
 
An Aβ-targeted strategy that has attracted a lot of attention is that of immunotherapy, 
involving either passive vaccination by injection of Aβ antibodies or active 
vaccination with Aβ itself. This approach was first published by Schenk et al. in 
1999, where the authors demonstrated that immunisation of mice over-expressing 
mAPP with Aβ42 peptide prevented the formation of Aβ plaques.78 Numerous 
further studies in mouse models of AD showed biochemical, physiological and 
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behavioural improvements following immunisation treatment.79-82 This area is more 
widely reviewed by Wisniewski & Konietzko.83 
 
Despite these early successes in animal models, the translation of immunotherapy 
into a treatment for human AD patients has proved problematic. AN1792 (Elan 
Pharmaceuticals) was trialled as an active vaccine but halted in phase II clinical trials 
when 18 out of 298 patients developed acute meningoencephalitis, although post 
mortem analysis of some subjects did reveal evidence of plaque clearance.83 
Bapineuzumab (Elan Pharmaceuticals, Wyeth), a passive vaccine, showed no overall 
improvement in patients during phase II but a significant improvement in MMSE 
was observed in patients who did not carry the ApoE ε4 allele. On the basis of this 
finding, Phase III trials of Bapineuzumab are currently underway.83 
 
Immunotherapy as a treatment for AD stemmed from the hypothesis that removal of 
Aβ plaques would be beneficial to patients. Given the previous discussion on the 
involvement of small soluble amyloid species (Section  1.2.2), the dissolution of 
amyloid plaques may not necessarily result in removal of toxic amyloid from the 
brain. Unless Aβ released from dissolved plaques is effectively sequestered, there is 
the potential for levels of soluble Aβ species to increase, thereby increasing toxic 
amyloid in the brain, rather than reducing it. 
 
 
1.2.4 Mitochondrial dysfunction resulting from β-amyloid exposure 
 
The involvement of mitochondrial dysfunction in the progression of AD is a rapidly 
emerging area of research. The mitochondria are responsible for the production of 
energy within all cells, including neurons. As can be seen in Figure  1.1 (Section 
 1.1.1), energy production in the AD brain is disrupted, indicated by decreased 
glucose metabolism.8 This supports the hypothesis that mitochondrial function is 
impaired in AD. 
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Aβ peptides have been found within the mitochondria of AD brains,84-86 although 
there is still much debate as to whether the peptide is produced within the 
mitochondria or transported into the mitochondria.87 Hansson Petersen identified the 
translocase of the outer membrane (TOM) complex as an import mechanism for the 
transport of externally applied Aβ40 and Aβ42 across the mitochondrial membrane.86 
Alternative proposed sources of mitochondrial Aβ include production in the 
mitochondrial-associated membranes, which represent close contact points between 
mitochondria and the endoplasmic reticulum (ER) and allow direct exchange of 
lipids and proteins between the organelles. It is known that this region of the cell is 
enriched in PS1 and PS2, raising the possibility that APP cleavage is possible.88 
Additionally, the components of the γ-secretase complex have been identified within 
the mitochondrion itself, allowing for potential production of Aβ within 
mitochondria.89 
 
Full length APP is associated with mitochondria in the brains of Alzheimer’s patients 
but is not seen in the mitochondria of non-demented brains.90 Anandatheerthavarada 
et al. identified a dual-localisation of APP, which has targeting sequences to both the 
ER (residues 1–36) and mitochondria (residues 36–61)91  and subsequent work by 
the same group revealed the association of APP with mitochondrial import channels 
in a transmembrane arrested form.92 This results in blockage of the transport pore, 
with the 0-terminal domain innermost. Interestingly, some of this trans-arrested APP 
was shown to be truncated at the C-terminus, missing the Aβ region of the protein.92  
 
Once in the mitochondria, Aβ can bind to a number of intracellular proteins, with the 
potential to activate a number of intracellular pathways. These include mitochondrial 
proteins such as SOD1,93 catalase94,95 and cyclophilin D;96-98 for a review 
mitochondrial Aβ-binding proteins, see Muirhead et al.87 Of particular interest is the 
interaction between Aβ and the mitochondrial enzyme, amyloid-binding alcohol 
deydrogenase (ABAD). ABAD has been shown to be up-regulated in AD and its 
interaction with Aβ has been shown to have detrimental effects on cell survival, a 
response which is reversed upon prevention of Aβ binding. This interaction, its 
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relevance to AD and its potential as a therapeutic target for AD is discussed in more 
detail below (Section  1.3). 
 
Oxidative stress resulting from Aβ exposure has a wide range of cellular 
consequences, particularly within mitochondria, and has been observed in human AD 
brains,99-102 AD mouse models103,104  and in vitro cell cultures.105 These changes 
include reduced cytochrome c oxidase activity,99,100,106 and increased production of 
reactive oxygen species (ROS), which, in turn, cause further damage, such as 
mutation of mitochondrial DNA106,107 and oxidation of proteins.108 It has also been 
noted that all isoforms of APP contain a copper binding site, which is able to reduce 
CuII to CuI.109 This reduction can result in elevated levels of ROS within APP-
expressing cells leading to increased oxidative stress.110   
 
Transgenic mouse models have provided a great insight into the mitochondrial events 
occurring. For example, it has been found that mice expressing the combined London 
and Swedish mutations of APP (see Figure  1.6) exhibit reduced ATP levels, 
cytochrome c oxidase activity and mitochondrial membrane potential as early as 
three months of age, before the appearance of amyloid plaques. By six months of 
age, elevated ROS were detected.103 Similarly, the “triple transgenic” model of AD 
(3×Tg, encoding mutations in APP, PS1 and tau)111 displayed decreased 
mitochondrial respiration and increased oxidative stress at three months of age.104 
 
Swerdlow and Khan have taken mitochondrial involvement in the progression of AD 
one step further and proposed the “mitochondrial cascade hypothesis” for sporadic 
AD.112,113 The authors hypothesise that rather than Aβ being responsible for the 
observed mitochondrial defects in AD (as in the amyloid cascade hypothesis), it is in 
fact underlying age-related mitochondrial deficits that trigger the production of Aβ 
after a threshold is passed.112,113 It remains unclear what the underlying cause of 
these mitochondrial deficits are and what causes the threshold to be reached in some 
people but not in others. However, whichever view is taken, it is strongly apparent 
from the literature that amyloid, mitochondrial dysfunction and the processes in AD 
are intricately intertwined.  
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1.3 Amyloid binding alcohol dehydrogenase 
 
ABAD was identified as an Aβ-binding protein through use of a yeast two-hybrid 
screen in 1997 105 and was identified independently as the human analogue of bovine 
hydroxyacyl-CoA dehydrogenase type II enzyme soon after.114 First identified in the 
endoplasmic reticulum (ER), it was originally named ER-associated amyloid-binding 
protein (ERAB); 105,115-117 however, its subsequent identification in the mitochondria 
and determination of its dehydrogenase activity led to its more descriptive name, 
amyloid binding alcohol dehydrogenase (ABAD).117∗ The protein is expressed in all 
tissue type, in particular in the heart and liver, and was found to be expressed in all 
regions of the brain; significantly, expression of ABAD in AD brains was found to 
be increased, compared to those of age-matched controls.105 
 
 
1.3.1 Function of amyloid binding alcohol dehydrogenase 
 
ABAD is a multifunctional enzyme, catalysing the reversible reduction of aldehydes 
and ketones and oxidation of alcohols, utilising NAD(H) as a co-factor (Figure  1.9). 
The enzyme exhibits a broad substrate selectivity and is known to act on a wide 
range of structurally diverse substrates, including simple alcohols,117,118,122 
steroids,115 hydroxysteroids,115,117,122 3-hydroxyacetyl-CoA derivatives such as 
acetoacetyl-CoA115,117,118 and D-β-hydroxybutyrate.117 The involvement of the co-
factor allows straightforward measurement of ABAD activity in vitro by monitoring 
the consumption/production of NADH, as demonstrated by several groups.114-
119,122,124  
 
                                                 
∗ ABAD is also known as human type II hydroxyacyl-CoA dehydrogenase (HADH II),117,118 17β-
hydroxysteroid dehydrogenase type 10 (HSD10)119,120, 121 and human brain short-chain L-3-
hydroxyacyl-CoA dehydrogenase (SCHAD).122,123 
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Figure  1.9: General reaction catalysed by amyloid-binding alcohol dehydrogenase (ABAD). The 
enzyme catalyses the oxidation of the alcohol with the corresponding reduction of the co-factor, 
NAD+, as well as the reverse reaction of ketone reduction to an alcohol.  
 
Given the mitochondrial localisation of ABAD, one of its main functions is thought 
to be in energy production and metabolic homeostasis, notably the third step of 
β-oxidation of fatty acids, which utilises its function as an L-3-hydroxyacyl-CoA 
dehydrogenase.114,118 This role may be particularly important in glucose-deficient 
environments, where alternative energy sources become more significant. For 
example, it has been found that the over-expression of ABAD in COS cells increases 
the cells’ ability to utilise ketones, such as D-β-hydroxybutyrate, in the absence of 
other energy sources.124 Similarly, transgenic mice over-expressing ABAD showed 
increased utilisation of D-β-hydroxybutyrate compared with non-transgenic animals, 
indicating their increased adaptability to metabolic challenges.124  
 
A proposed alternative role to energy homeostasis is in the metabolism of 
hydroxysteroids, such as oestradiol.115 The role of ABAD in metabolising sex 
steroids could be significant, as it is documented that women are more likely to 
suffer from AD than men,125 and that postmenopausal hormone replacement therapy 
can prove beneficial in delaying the onset of the disease.126 ABAD has also been 
shown to oxidise steroid modulators of the GABAA receptor to give inactive 
metabolites.127  
 
ABAD is also known to play a role in the degradation pathway of isoleucine. Patients 
with 2-methyl-3-hydroxybutyryl-CoA dehydrogenase (MHBD) deficiency lack 
function of the enzyme catabolising the penultimate step in isoleucine degradation. 
This enzyme was subsequently identified as being identical to ABAD.128 An 
Arg-130-Cys mutation was identified in four patients with MHBD deficiency and 
was found to cause neurological deficits, loss of mental and motor skills and 
psychomotor retardation. A Leu-122-Val mutation, identified in a single case, 
presented with only psychomotor retardation.128 Both mutations were shown to fully 
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(Arg-130-Cys) or substantially (Leu-122-Val) inactivate the enzyme, and the 
Arg-130-Cys was also thought to reduce the enzyme’s stability causing the lower 
protein levels observed in these patients.128 
 
It has been proposed that in the absence of Aβ, ABAD is able to play a 
cytoprotective role during periods of stress. For example, in mouse models of 
ischemic stress (stroke), ABAD expression was found to be increased in both ABAD 
transgenic (Tg ABAD) and non-transgenic (non-Tg) mice following 45 minutes of 
transient middle cerebral artery occlusion. However, the transgenic animals showed 
fewer effects of the stroke, including reduced neurological deficits and increased 
ATP levels124 and were hence thought to be protected to some degree by the elevated 
levels of ABAD. Conversely, ABAD levels were shown to be decreased in the 
ventral midbrain of Parkinson’s disease (PD) patients, as well as in the ventral 
midbrain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice, 
used as a model of PD. However, MPTP-treated mice over-expressing ABAD were 
protected against apoptosis and the loss of dopaminergic neurons in this brain region, 





1.3.2 Structure of ABAD 
 
The crystal structure of ABAD is well documented, with several structures of the 
enzyme published. These structures include the rat protein in complex with its co-
factor NAD,118 a human mutant (Cys-214-Arg) complexed with an inhibitor119 and 
the human protein in complex with Aβ.84 From these structures, information on the 
catalytic mechanism and its interaction with Aβ has been deduced. 
 
ABAD exists as a homo-tetramer, both in solution and in the crystal form, and is 
made up of four identical single domain monomers of 27 kDa.118 Tetramerisation has 
been shown by molecular modelling to stabilise the binding interface region.130 The 
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catalytic triad of Ser-155/Tyr-168/Lys-172 of ABAD is conserved across species 
(human, mouse, rat and bovine ABAD) as well as in several other short chain 
dehydrogenase reductase enzymes84,119 and mutation of these residues to glycine has 
been shown to inactivate the enzyme.117 The crystal structures of rat ABAD with the 
substrate 3-ketobutyrate or 17β-oestradiol bound within the active site shed light on 
the reaction mechanism.118 During the reduction of a ketone to the corresponding 
alcohol, the hydrogen atom of Tyr-168 is thought to coordinate to the carbonyl of the 
ketone substrate, increasing the electrophilicity of the carbonyl carbon atom. It is 
proposed that the ammonium group of Lys-172 interacts with the hydroxyl group of 
Tyr-168, increasing the acidity of this residue. The hydride equivalent that effects 
reduction is donated to the activated carbonyl by the NADH co-factor, leading, 
simultaneously, to deprotonation of Tyr-168 by the newly formed hydroxyl group. 
The hydroxyl group of Ser-155 is able to form a hydrogen bond to the deprotonated 
tyrosine, stabilising the resulting negative charge. This is demonstrated in Figure 
 1.10, which shows the interactions of the substrate 3-ketobutyrate with ABAD and 
NADH.118 The reported co-structures of ABAD with a substrate confirm the close 
proximity of the presumed catalytic residues to the substrate molecule (Figure  1.10). 





























Figure  1.10: The catalytic core of ABAD. A) Schematic diagram showing the proposed reaction 
mechanism for the reduction of 3-ketobutyrate (magenta) by NADH (green), catalysed by rat ABAD 
(black). H-bond lengths (dotted lines) are given in Angstroms. Reprinted from Journal of Molecular 
Biology, 303, A.J. Powell et al., Recognition of structurally diverse substrates by type II 3-
hydroxyacyl-CoA dehydrogenase (HADH II)/Amyloid-β binding alcohol dehydrogenase (ABAD), 
311–327, Copyright (2000), with permission from Elsevier.118 B) A PyMol representation of the X-ray 
crystal structure of rat ABAD bound to its co-factor and an acetoacetic acid substrate (PDB accession 
code 1E3W). The three conserved active site residues, Ser-155, Tyr-168 and Lys-172 (carbon = 
yellow), the NAD+/NADH co-factor (carbon = green) and the 3-ketobutyrate substrate (carbon = 
magenta) are represented as sticks. It can be seen that the ketone oxygen of the substrate interacts with 
Tyr-168 and is favourably oriented in order to receive / donate a hydride to / from the co-factor. Key: 
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Liu et al.131 have investigated the mechanism of the related enzyme, 3-hydroxyacyl-
CoA dehydrogenase (HAD), using fluorinated substrates. The authors determined 
that the oxidation of hydroxyacyl-CoA-linked substrates proceeds through an enolate 
intermediate, stabilised by Asn-208 and Ser-137, and that this enolate formation is 
essential for the reaction to occur (Scheme  1.1).131 Given the similarity of the active 
site residues, it is possible that oxidation of similar substrates by ABAD may occur 
through a similar mechanism.  
 
 
Scheme  1.1: Proposed mechanism of the oxidation reaction catalysed by HAD. 3-Hydroxyacyl-
CoA is reversibly oxidised to 3-ketoacyl-CoA through an enolate intermediate, which is stabilised by 
either Ser or Asn in the enzyme active site.131 
 
Compared to other short chain hydroxyacyl dehydrogenases (HADH type I), both 
rat118 and human ABAD84 were found to have two significant insertions at residues 
100–110 and 140–150. A model of the expected binding of a CoA-linked substrate to 
the active site suggests an interaction between the negatively charged phosphate 
groups of CoA and a group of positively charged residues within the residue 100–
110 region (Lys-99, His-102, Lys-104, Lys-105).118,119 CoA-linked substrates were 
found to be more efficiently oxidised than their non-CoA analogues.118 The region 
connecting the proposed CoA binding site and the active site is lined with 
hydrophobic residues, which is consistent with the binding of aliphatic chains. In 
contrast, few interactions were observed outside the active site with 17β-oestradiol as 
the substrate,118 perhaps corroborating the idea that sex steroids are not the main 
substrates for ABAD. 
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1.3.3 The ABAD-Aβ interaction 
 
ABAD was first identified as a binding partner of Aβ through a yeast two-hybrid 
screen, which highlighted four clones (three from HeLa and one from human brain) 
with identical cDNA sequences.105 Binding was confirmed through use of a radio 
ligand binding assay, showing that 125I-labelled His-tagged ABAD (125I-His-ERAB) 
bound to Aβ42 with a Kd of 88 ± 28 nM. Similar binding affinity was reported with 
unlabeled protein and with Aβ40 and Aβ20, but not Aβ(25–35).105 Investigation of 
direct binding between ABAD and Aβ both in vitro and in vivo has been carried out 
using a variety of techniques including ELISA,132-134 surface plasmon resonance 
(SPR),84,135 and co-immunoprecipitation.84,105,115 Kd values vary slightly between 
techniques, but are generally reported in the low to mid nanomolar range 
(ABAD/Aβ40: Kd = 64 ± 9 nM,
117 172 nM,135 38.4 ± 4.6 nM,84; ABAD/Aβ42: Kd = 
42 ± 8 nM,117 55.8 ± 10.9 nM84). 
 
The putative co-crystal structure of ABAD-Aβ was obtained by Lustbader et al.84 
and indicated that binding of Aβ results in a distortion of the active site and the 
NAD+ binding site.84 This hypothesis was confirmed by further experiments using 
SPR, which indicated a conformational change of the enzyme upon binding of Aβ. 
Additional investigation using saturation transfer difference NMR showed that 
NAD+ binding was inhibited in a dose dependent manner in the presence of Aβ.135  
Although no electron density for Aβ was observed within the co-crystal structure, its 
presence was confirmed by SDS-PAGE, indicating that the peptide was present in a 
disordered state. Significantly, the region of ABAD known as Loop D, which is one 
of two insertions seen in ABAD (Section  1.3.2) and comprises ABAD residues 100–
110, was also found to be disordered within the crystal structure. Further experiments 
using complementary techniques led to the hypothesis that this region is the binding 
site for Aβ. Mutagenesis studies revealed two groups of residues within Loop D as 
being important for Aβ binding: Ser-98, Lys-99, Thr-100 and Tyr-101; and Thr-108, 
His-109 and Thr-110. Replacement of combinations of these residues with alanine 
resulted in loss of Aβ binding (Table  1.2).84 
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Table  1.2: Effect of ABAD site directed mutations on binding of ABAD to Aβ. From Lustbader et 
al. (2004) Science, 304, 448-452.84 Reprinted with permission from AAAS. 
Site-directed ABAD mutation Aβ binding 
G93A + 
S98A, K99A + 
S98A, K99A, T100A, Y101A - 
S98A, K99A, Y101A - 
N102A + 
N102A, L103A + 




Prior to the work by Lustbader that resulted in the co-crystal structure, Milton95 had 
used an alternative method, known as the antisense peptide approach, in order to 
identify the region of ABAD that binds to Aβ. Antisense analysis is based on the 
theory that peptides encoded by complementary strand of DNA will bind to each 
other136 and involves reading the antisense DNA strand in a 3′–5′ direction. Reading 
the antisense strand of ABAD, the region corresponding to ABAD 99–108 contained 
a hydrophobic region similar to the Aβ binding region (residues 16–20). This region 
of the antisense strand was synthesised as a discrete peptide and was found to bind 
Aβ (Kd = 107 ± 21 nM) and inhibit Aβ cytotoxicity.
95 This is the same region of 
ABAD hypothesised to bind to Aβ based on crystallographic and mutagenesis 
studies.84 
 
One final piece of evidence supporting Loop D as the Aβ binding site came from 
SPR studies of peptide binding. The addition of a peptide encoding ABAD residues 
92–120 (termed the “decoy peptide”, or DP) was found to inhibit the binding of 
Aβ40 and Aβ42 to ABAD with Ki of 4.9 and 1.7 µM, respectively.
84 This inhibition 
was thought to occur by the decoy peptide binding to Aβ, indicating that these 
residues correspond to the ABAD binding site. This peptide was later taken as the 
basis for disrupting the ABAD-Aβ interaction in AD mouse models with the view to 
developing a novel drug strategy for treating AD (see Section  1.3.5).137-139 
 
The relevance of the ABAD-Aβ interaction to AD has been demonstrated through 
analysis of AD brains and mouse models displaying AD-like phenotypes. ABAD 
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expression was found to be up-regulated in the temporal lobe of AD brains, 
compared to age-matched controls.105 Further studies showed that ABAD and Aβ co-
localise in the mitochondria. Using confocal microscopy, Lustbader et al. observed 
the overlap of anti-Aβ and anti-ABAD antibodies in the cerebral cortex of 
Alzheimer’s patients (Figure  1.11). The mitochondrial localisation of this ABAD 
was verified by co-localisation with voltage-dependent anion channel, which was 
used as a mitochondrial marker. 84 
 
 
Figure  1.11: Co-localisation of ABAD and Aβ in human AD brain. Confocal microscopy revealed 
extensive co-localisation (yellow) of ABAD (red) and Aβ (green) in the cerebral cortex of human AD 
patients. From Lustbader et al. (2004) Science, 304, 448-452.84 Reprinted with permission from 
AAAS. 
 
Immunoprecipitation of Aβ followed by immunoblotting with anti-ABAD 
immunoglobin G detected enhanced levels of ABAD/Aβ complex in AD brains 
compared with age-matched non-demented brains. Similarly, enhanced ABAD-Aβ 
complex formation was observed in transgenic mice over-expressing mAPP 
(Tg mAPP) or mAPP and ABAD (Tg mAPP/ABAD) compared to wild-type 
controls.84  
 
In addition, it is interesting to note that elevated Aβ levels can lead to the 
up-regulation of ABAD. Transgenic mice over-expressing mAPP, such as Tg mAPP 
and the triple transgenic (over-expressing AD-linked mutations in APP, PS1 and 
tau)111 display increased ABAD expression in the hippocampus, compared with non-
transgenic littermates.104,140 This echoes the earlier observation that ABAD 
expression is increased in the temporal lobes of human AD brains, which exhibit 
enhanced levels of Aβ.105 
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1.3.4 Consequences of ABAD-Aβ binding 
 
As mentioned above, the binding of Aβ to ABAD results in a conformational change 
of the enzyme, distorting the active site and co-factor binding site.84,135 Indeed, it was 
shown that the presence of Aβ prevented the binding of NAD+ and that their 
presence was mutually exclusive.135 
 
Given this observation, it is unsurprising that the binding of Aβ has a direct effect on 
the enzymatic activity of ABAD. It was found that Aβ40 reduced ABAD activity 
with respect to S-acetoacetyl-CoA reduction117 and the oxidation of octanol,117 17β-
oestradiol117 and 3-hydroxybutyryl-CoA.116 The Ki values for this inhibition can be 
seen in Table  1.3. Similar results were reportedly obtained for inhibition by Aβ42.117 
 
Table  1.3: Inhibition of ABAD enzymatic activity by Aβ40 
Reference Substrate Co-factor Ki (µM) 
S-acetoacetyl-CoA NADH 1.6 ± 0.5 
octanol NAD+ 2.6 ± 0.3 
Yan et al.117 
Yan et al.117 
Yan et al.117 17β-oestradiol NAD+ 3.2 ± 0.2 
Oppermann et al.116 3-hydroxybutyryl-CoA NAD+ 1.2 
 
It is immediately apparent that the concentration of Aβ required for ABAD inhibition 
(micromolar) is much higher than that required simply for binding to ABAD 
(nanomolar). It is therefore proposed that binding alone is not sufficient to cause 
inhibition of ABAD and that additional aggregation of Aβ around the active site is 
required for inhibition, either to sterically hinder access to the active site, to induce 
the conformational change described above (Section  1.3.4), or both. Whether the 
initial seeding of Aβ onto ABAD results from binding of monomers or small 
oligomeric aggregates remains to be seen, although it has been reported that  ABAD 
does not bind Aβ monomers, only its oligomers.135 
 
In addition to inhibition by full-length Aβ40 or Aβ42, ABAD activity can also be 
inhibited by smaller truncated Aβ peptides (Figure  1.12).116 From these studies, Aβ 
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residues 12–24 were identified as being essential for enzyme inhibition. These 
residues are close to the region of residues 13–22 previously identified as being 
essential for aggregation of the peptide into oligomers.141 
 
 
Figure  1.12: Inhibition of ABAD 3-hydroxybutyryl-CoA oxidation by Aβ peptide fragments. 
Peptide fragments are numbered in accordance to the corresponding Aβ residues. ABAD was 
incubated with 160 µM 3-hydroxybutyrate-CoA, 250 µM NAD+ and 0.5 µM Aβ peptide. Enzymatic 
activity was measured by recording the change in NADH absorbance at 340 nm and expressed as a 
percentage inhibition of the uninhibited control (no Aβ peptide) reaction rate. Reprinted from FEBS 
Letters, 451, U.C.T. Oppermann et al., Binding of amyloid β-peptide to mitochondrial hydroxyacyl-
CoA dehydrogenase (ERAB): regulation of an SDR enzyme activity with implications for apoptosis in 
Alzheimer’s disease, 238–242, Copyright (1999), with permission from Elsevier.116 
 
At a cellular level, the effects of Aβ can also be seen. Upon addition of Aβ42 to 
neuroblastoma cells or following over-expression of mAPP in COS cells, the 
subcellular localisation of ABAD was found to change from the ER/mitochondria to 
the plasma membrane.105,117 The significance of this finding remains unclear and has 
not been explored further to date.  
 
COS cells transfected with a DNA plasmid encoding ABAD were found to exhibit 
higher Aβ-induced cellular stress when exposed to exogenous Aβ42 than 
untransfected cells, which produce very low levels of endogenous ABAD. Similarly, 
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COS and neuroblastoma (SK-N-SH) cells over-expressing both ABAD and Aβ 
displayed a higher occurrence of apoptosis than those over-expressing ABAD or Aβ 
alone. Blocking the binding of ABAD and Aβ by addition of anti-ABAD antibodies 
suppressed this Aβ-induced toxicity in SK-N-SH cells.105 Further experiments 
carried out by Yan et al.,117 provided evidence for the necessity of catalytically active 
ABAD in the presence of Aβ to causes these effects. They prepared a catalytically 
inactive mutant of ABAD (mtABAD; containing mutations of active site residues: 
Tyr-168-Gly and Lys-172-Gly); mtABAD retained Aβ binding properties despite a 
loss of enzymatic activity and the effects of its over-expression in the absence of Aβ 
were indistinguishable from those of the wild-type protein. COS cells 
over-expressing mtABAD/mAPP did not show increased cytotoxicity compared with 
mAPP alone, while those transfected with wild type ABAD/mAPP showed an 
increase in DNA fragmentation compared to mAPP alone. This result demonstrates 
the effects are not simply due to the loss of ABAD activity in the presence of Aβ but 
must result from a change in the function of the enzyme as a result of its binding.  
 
One proposed consequence of ABAD-Aβ binding is the cellular accumulation of 
toxic aldehydes. Increases in both 4-hydroxynonenal (HNE) and malondialdehyde 
(MDA) have been correlated with AD.142,143 The ability of ABAD to protect against 
the effects of these toxic aldehydes has been demonstrated by Murakami et al.,144 
who showed that SH-SY5Y cells transfected with ABAD and then treated with HNE 
for 24 hours show an improved survival compared to control-transfected cells. 
Similarly, HeLa cells transfected with ABAD are able to catabolise HNE better than 
control-transfected cells and are hence protected against oxidative stress induced by 
ROS resulting from the addition of H2O2 and antimycin A. Significantly, this 
cytoprotective function was lost in the presence of Aβ. Upon treatment with Aβ42, 
the catabolism of HNE by ABAD-transfected HeLa cells was inhibited, as was the 
protection against antimycin-induced production of ROS.144 Additionally, it was 
found that levels of HNE and MDA were elevated in COS cells over-expressing both 
ABAD and mAPP, while transfection of the catalytically inactive mtABAD and 
mAPP did not elicit this effect.117 This implies that formation of the ABAD-Aβ 
complex can alter the function of the enzyme, causing a shift from degrading HNE to 
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producing HNE and is most likely due to a change in the shape of the enzyme active 
site, altering its substrate preference. It has therefore been proposed that a native 
function of ABAD may be to remove toxic aldehydes such as HNE and MDA and 
that this function is impaired in the presence of Aβ, resulting in the disruption of 
normal cellular processes.144 
 
The resulting toxicity from over-expressing ABAD together with elevated Aβ has 
also been confirmed in an AD mouse model. Compared with neurons from non-Tg 
mice and mice over-expressing ABAD (Tg ABAD) or mAPP (Tg mAPP) alone, E18 
cortical neurons cultured from mice over-expressing ABAD and mAPP together 
(Tg mAPP/ABAD) were found to exhibit higher levels of hydrogen peroxide, 
decreased mitochondrial function and increased cell death,145 as well as elevated 
levels of radical species in intact brains.84 Mitochondrial dysfunction was observed 
in vivo, with Tg mAPP/ABAD animals showing decreased glucose utilisation and 
ATP production at nine months of age.145 Behavioural deficits were also observed in 
these animals. Tg mAPP/ABAD mice were found to have deficits in spatial and 
temporal memory compared with non-Tg, Tg mAPP and Tg ABAD mice, with 
impaired performance in the radial arm water maze as early as 4–5 months of age.84 
Yao et al. subsequently showed that ten-month old Tg mAPP mice showed deficits 
in the same test, compared with non-Tg animals.139 This finding suggests that the 
presence of elevated ABAD accelerates the cognitive decline in the presence of 
elevated Aβ. These results again emphasise that the combination of ABAD and Aβ is 
necessary for effects to be elicited and that these effects occur early in the disease 
process. 
 
Proteomic analysis of brains from transgenic mice has revealed potential downstream 
effects of elevated ABAD/Aβ through the up-regulation of two proteins. Expression 
of peroxiredoxin II (Prx-II) was found to be increased in whole brain extracts of 
eight-month old Tg mAPP and Tg ABAD/mAPP mice, with further analysis 
revealing localisation of this up-regulation in the cerebral cortex of the double 
transgenic animal.137 The relevance of this finding was demonstrated upon 
confirmation that Prx-II expression was also elevated in the cerebral cortex137 and 
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frontal cortex146 of human AD brains. Prx-II is an antioxidant protein,147 so it can be 
surmised that its up-regulation is a protective response to increased ROS as a result 
of elevated Aβ. A second protein, endophilin-I (Ep-I) was also found to be up-
regulated in the brains of Tg ABAD/mAPP mice compared with Tg ABAD and non-
Tg animals.138 This up-regulation was found in the cerebral cortex and the 
hippocampus of the mice, and in the temporal cortex of human AD brains.138 Ep-I is 
a pre-synaptic protein known for its involvement of synaptic vesicle biogenesis 148 
and it has previously been shown that its expression could also activate c-jun N-
terminal kinase (JNK) activation, which causes apoptosis.149 Increases in JNK 
activation have been a feature observed in AD patients150 and AD mouse models,151 
as well as in Aβ expressing cell culture models.152,153 Thus, the increase in Ep-I 
expression shown in the AD brain could be another mechanism for the activation of 
the JNK signalling pathway. Notably, the reported increases in both Prx-II and Ep-I 
were shown to be directly due to the binding of ABAD and Aβ, as interfering with 
this binding in living organisms resulted in the expression of these two proteins to be 
returned to normal (see Section  1.3.5).137,138 This observation therefore emphasises 
the importance of this interaction in vivo. 
 
Taking all these factors into consideration, it is evident that the interaction of ABAD 
and Aβ causes adverse effects at both a molecular and cellular level and is highly 
relevant to the progression of AD. 
 
 
1.3.5 The ABAD-Aβ interaction as a therapeutic target 
 
It has been established that the ABAD-Aβ interaction results in activation of 
downstream pathways that are detrimental to cell survival (Section  1.3.4). It is 
therefore logical to conclude that prevention of this interaction may halt the 
progression of these events and that the ABAD-Aβ complex may provide a new drug 
target for the treatment of AD. 
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Some preliminary studies reporting the identification of small molecule inhibitors of 
the complex have been published (Figure  1.13).132,133 The compounds are based on 
the amyloid β-sheet binding dye, thioflavin T (ThT) and the known 
immunosuppressant, frentizole, which has a related structure. Despite initial 
encouraging activity (IC50 values of 230 µM, 200 µM and 6 µM for ThT 1, frentizole 
2 and optimised compounds 3a and 3b, respectively), no data has since been 
available on either the selectivity or the in vivo activity of these compounds. 
Furthermore, compounds based on the structure of ThT are likely to act by targeting 
the β-sheet structure of Aβ so are unlikely to be able to target small soluble Aβ 
oligomers, the species that is of interest in the work reported in this thesis. These 
molecules do, however, provide evidence that small molecules can disrupt the 
ABAD-Aβ interaction.  
 
 
Figure  1.13: Structure of reported small molecule ABAD-Aβ complex inhibitors.
132-134 
 
The Aβ binding site of ABAD was predicted by Lustbader et al.84 to be the Loop D 
region (residues 100–110) of ABAD and it was subsequently found that addition of 
the decoy peptide (DP), a peptide spanning this region (residues 92–120), was able to 
inhibit the binding of Aβ40 and Aβ42 to ABAD with Ki of 4.9 and 1.7 µM, 
respectively, as demonstrated by an SPR binding study.84 It was therefore proposed 
that the DP had the potential to be used therapeutically to prevent the formation of 
the ABAD-Aβ complex in vivo.  
 
Cellular studies have demonstrated the protective effects of this peptide. Addition of 
the Tat domain from the human immunodeficiency virus (HIV) allowed the resulting 
Tat-DP fusion peptide to cross cell membranes, where it was found to attenuate 
Aβ-induced cell toxicity in cultured primary neurons from wild type, Tg ABAD and 
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Tg ABAD/mAPP animals, as shown by reductions in cytochrome c release, 
production of ROS, DNA fragmentation and LDH release.84  
 
In an attempt to stabilise the small peptide and increase its half-life, a separate study 
expressed the DP through a lentiviral system, fusing the peptide to the protein 
cytosolic thioredoxin-1 (TRX).154 TRX is a scavenger of reactive oxygen species and 
known to assist with protein folding and stability155,156 and so was predicted to 
complement the DP’s protective activity by scavenging ROS produced as a result of 
Aβ toxicity. This fusion peptide, ABAD(92–120)-TRX, was observed to be co-
localised with Aβ and, like Tat-DP, was found to significantly decrease Aβ toxicity; 
transfected cells exhibited decreased apoptosis, decreased LDH release and increased 
cell viability in response to Aβ or H2O2 treatment, compared with untransfected cells 
or those transfected with thioredoxin alone.154 
 
Significantly, the benefits of the DP were also observed in animal studies. DP(93–
116), was fused to the HIV Tat domain to allow transport across cell membranes and 
a mitochondrial targeting sequence to concentrate the peptide in the mitochondria 
[Tat-mito-DP(93–116)].  Tg mAPP mice treated with Tat-mito-DP(93–116) from the 
age of 7–10 months were found to have preserved mitochondrial function compared 
with animals treated with the reverse peptide (Tat-mito-RP).139 Similarly, 10–11-
month old double transgenic mice over-expressing mAPP and mito-DP(92–120) 
were found to have preserved mitochondrial function compared to Tg mAPP 
animals.139 Additionally, previously discovered up-regulated protein biomarkers of 
AD, Prx-II and Ep-I (see Section  1.3.4), were found to return to normal basal levels 
following treatment of transgenic animals with the decoy peptide.137,138 Six-month 
old Tg mAPP mice were treated with Tat-mito-DP(93–116) or a peptide encoding 
the reverse DP sequence (Tat-mito-RP) by intraperitoneal injection over two weeks. 
After treatment, Western blot analysis of the hippocampus showed elevated Prx-II 
and Ep-I protein levels in untreated Tg mAPP and Tat-mito-RP treated animals, 
compared with non-Tg controls. Animals treated with Tat-mito-DP showed 
significant decreases in Prx-II and Ep-I protein expression compared with Tat-mito-
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RP treated animals, with expression levels comparable to those of non-Tg 
animals.137,138  
 
Very recently the DP has been shown to reverse behavioural symptoms associated 
with transgenic AD model animals. Following on from the observation that ten-
month old Tg mAPP mice showed deficits in the radial-arm water maze test 
compared with non-Tg animals,84  Tg mAPP mice were treated with Tat-mito-
DP(93–116) (intraperitoneal injection for three months from the age of seven 
months), resulting in an improvement in spatial learning and memory compared with 
vehicle-treated animals. Similarly, as an independent method to highlight the 
significance of this interaction, 10–12 month old transgenic mice over-expressing the 
decoy peptide [mito-DP(92–120)] and mAPP showed less impairment than Tg 
mAPP mice.139  
 
These studies demonstrate that perturbing the ABAD-Aβ interaction can prevent 
downstream consequences of this interaction, making the ABAD-Aβ complex a 





The need for an effective method for treating AD has been highlighted through the 
lack of AD drugs able to act upon the underlying mechanisms of the disease. Recent 
studies have identified the ABAD-Aβ complex as being implicated in the 
progression of AD and hence its perturbation may provide a novel strategy for 
intervention. It has been shown that preventing this interaction can block and even 
reverse its resultant downstream effects. These studies have therefore provided 
evidence to support the hypothesis that the ABAD-Aβ interaction could provide a 
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1.5 Project aims 
 
The aim of research described in this thesis was to investigate the interaction 
between ABAD and Aβ as a therapeutic intervention strategy for the treatment of 
AD.  
 
More specifically, it was firstly planned to develop tools for the study of this 
interaction. This aspect involved designing and synthesising inhibitors of ABAD 
enzymatic activity and developing methods for the measurement and monitoring of 
the interaction, both in vitro and in a cell-based assay. 
 
Secondly, it was aimed to investigate methods of inhibiting ABAD-Aβ complex 
formation, both by developing the use of the decoy peptide and by identifying small 
molecule inhibitors of the interaction. 
 
Using these approaches it was hoped to gain a better understanding of the exact 
molecular nature of the ABAD-Aβ interaction and how it may be perturbed in order 
to prevent biochemical changes associated with the onset and progression of 
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2.1 Molecular biology techniques 
 
2.1.1 Culture media 
 
Luria broth (LB; Sigma): 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.5% (w/v) 
NaCl. 
LB-agar (Sigma): 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.5% (w/v) NaCl, 
1.5% (w/v) agar. 
Superoptimal broth with catabolite repression (SOC): 2% (w/v) typtone, 0.5% (w/v) 




2.1.2 Polymerase chain reaction  
 
Polymerase chain reaction (PCR) was performed using a Biometra TPersonal 
thermocycler (Biometra) in a 50 µL reaction volume containing 50–200 ng template 
DNA, 10 µM forward and reverse primers (Invitrogen), 25 µM dNTPs (Promega), 
2.6 U Expand High Fidelity DNA polymerase (Roche) and 1 × Expand High Fidelity 
polymerase buffer (supplied with DNA polymerase, Roche). 
 
Alternatively, PCR was performed in a 50 µL reaction volume containing 50–200 ng 
template DNA, 10 µM forward and reverse primers (Invitrogen), 20 µM dNTPs 
(Promega), 1.2 U Pfu Turbo DNA polymerase (Stratagene) and 1 × Pfu buffer 
(supplied with DNA polymerase) 
 
2.1.2.1 MTS-ABAD plasmid 
Forward primer: 5′-GCCAAGCTTAGCATGTCCGTCCTGACGCCG-3′ 
Reverse primer: 5′-CCGCTCGAGTCAAGGCTGCATACGAATGGC-3′ 
Template DNA: mito-ABAD-GFP (provided by M. Taylor157) 
Programme: Initial denature 94 °C, 10 min; denature 94 °C, 45 s; anneal 58 °C, 45 s; 
extend 72 °C, 1 min; final extension, 72 °C, 10 min; 30 cycles. 
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2.1.2.2 MTS-DP(93–116) plasmid 
Forward: 5′-TTTTGGATCCAGGCATCGCGGTGGCTAGC-3′ 
Reverse: 5′-CCTTCTGAAGGTCGCTACTCGCCGGCGTTTT-3′ 
Template DNA: mito-ABAD-GFP (provided by M. Taylor157) 
Programme: initial denaturation, 95 °C, 10 min; denaturation, 94 °C, 45 s; anneal, 
52 °C, 45 s; extend, 72 °C, 1 min; final extension, 72 °C, 10 min; 30 cycles. 
 





Template DNA: MTS-DP(93–116)  
Programme: initial denaturation, 94 °C, 10 min; denaturation, 94 °C, 45 s; anneal, 
56 °C, 45 s; extend, 72 °C, 1 min; final extension, 72 °C, 10 min; 30 cycles. 
 
 
2.1.3 Restriction digests 
 
Digests were performed using restriction enzymes and their appropriate buffers 
(Promega) on 3–5 ug DNA in a total volume of 50 µL for 4–16 hours. DNA cleanup 
was achieved using Wizard PCR and Gel cleanup kit (Promega).  
 
 
2.1.4 D*A purification by agarose gel electrophoresis 
 
DNA plasmid, fragments and PCR products were separated on the basis of molecular 
weight using agarose gel electrophoresis. Agarose [1–2% (w/v)] was melted in Tris-
borate ethylenediamine-tetraacetic acid (TBE) buffer with ethidium bromide 
(0.5 µg mL-1) and cast into an AGTI submarine gel casting apparatus unit (VWR). 
Samples were prepared with 20% (v/v) 6 × sample loading buffer (50% [v/v] 
glycerol, 49.75% [v/v] TBE, 0.25% [w/v] bromophenol blue) before loading into 
wells. Hyperladder I (New England Biolabs) was run in an adjacent well to allow for 
estimation of DNA fragment size. Gel electrophoresis was run in TBE at 60 V for 
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60–75 min. Analytical gels were visualised with a UV lamp and photographed with a 
digital camera (Mitsubishi 85 mm lens, Thistle Scientific). For preparative gels to 
isolate DNA fragments generated by PCR or restriction digest, DNA was visualised 
by a low intensity UV lamp and the appropriate bands excised from the gel using a 
sterile scalpel. DNA was isolated from the gel band using Wizard PCR and Gel 
cleanup kit (Promega) according to the manufacturer’s instructions. 
 
 
2.1.5 D*A ligation 
 
Ligations were carried out using 0.5 µL T4 ligase (Promega), 1 µL vector DNA and 
0–10 µL insert DNA in a total volume of 20 µL at 4 °C overnight or at room 
temperature for 1 h. 
 
 
2.1.6 Preparation of competent cells 
 
E. coli DH5α or BL21 CodonPlus glycerol stocks were used to inoculate a culture in 
LB (5 mL), which was incubated overnight (37 °C, 210 rpm, 16 h). In the case of 
BL21 cultures, chloramphenicol was added before incubating. This culture (1 mL) 
was diluted into 50 mL fresh LB and incubated (37 °C, 100 rpm, 2–3 h) until 
Abs600 nm 0.3–0.4.  The cells were centrifuged (J6-MC, rotor 4.2, 3500 rpm, 10 min, 
4 °C), the supernatant removed and the pellet resuspended in ice-cold CaCl2 by 
vortexing (20 mL, 100 mM). After incubating at 0 °C for 30 min, the cells were 
centrifuged (J6-MC, rotor 4.2, 1500 rpm, 5 min, 4 °C), the supernatant removed and 
the pellet gently resuspended in ice-cold CaCl2 (1 mL, 100 mM). Further incubation 
at 0 °C (30 min) gave a suspension of competent cells for immediate use or 
cryogenic storage.  
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2.1.7 Cryogenic storage of competent cells 
 
Competent cells were stored after addition of 25 µL 50% glycerol to 100 µL cells. 
Aliquots were flash-frozen and stored at -80 °C.  
 
 
2.1.8 Transformation of competent cells 
 
Competent E. coli DH5α or BL21 CodonPlus cells (200 µL) were added to a 15 mL 
centrifuge tube. Ligation mixture (10 µL) or plasmid DNA (1 µg) was added and the 
mixture incubated on ice (30 min) before heat-shocking at 42 °C (45 s) and returning 
to ice (2 min). SOC medium (0.8 mL) was added and the culture incubated at 37 °C, 
210 rpm (1 h). Transformed cells were grown by spreading on LB-agar plates 
containing the relevant antibiotic (see Appendix  C for specific plasmid antibiotic 
resistance) and incubating at 37 °C (16 h). Cultures were grown at two 
concentrations: 100 µL of transformation culture (low concentration) or 900 µL of 
transformation culture pelleted and resuspended in a small volume (100 µL) of 
culture medium (high concentration).  
 
 
2.1.9 Cryogenic storage of transformed bacteria 
 
Glycerol stocks of transformed bacteria were prepared by addition of glycerol 
(400 µL of 50% aq. solution) to bacteria culture (600 µL). Stocks were then stored 
at -80°C.  
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2.1.10 Isolation of plasmid D*A 
 
Transformed E. coli DH5α cells were cultured in LB plus the appropriate antibiotic 
(37 °C, 210 rpm, 16 h). Small scale preparation of DNA was performed using a 
Qiagen miniprep kit according to the manufacturer’s instructions and eluting into 
40 µL nuclease-free water. Large scale preparation was achieved using a Promega 
PureYield Midi Prep kit according to the manufacturer’s instructions. DNA 
concentration was measured by diluting DNA (1 µL) with nuclease-free water 
(199 µL) and measuring the absorbance at 260 nm. The absorbance multiplied by a 
factor of 10 gives the DNA concentration in µg µL-1.  
 
 
2.1.11 D*A sequencing 
 
DNA sequencing was performed by DNA Sequencing & Services (MRCPPU, 
College of Life Sciences, University of Dundee, Scotland, www.dnaseq.co.uk) using 
Applied Biosystems Big-Dye Ver 3.1 chemistry on an Applied Biosystems model 
3730 automated capillary DNA sequencer. 
 
 
2.2 Protein expression and purification 
 
2.2.1 Human His-ABAD expression and purification (small scale) 
 
The pEHISTEV-ABAD DNA plasmid (provided by K. Forfar159) was transformed 
into and expressed in E. coli BL21 CodonPlus cells. Overnight cultures in Terrific 
broth (TB; Sigma; 2 × 5 mL) containing kanamycin (50 µL mL-1) were incubated at 
37 °C, 210 rpm (16 h). Cultures were combined, transferred to fresh TB (500 mL) 
and incubated at 37 °C (100 min) until Abs595 nm ~0.4 was obtained. Protein 
expression was induced by addition of isopropyl β-D-1-thiogalactopyranoside (IPTG; 
1 mM), followed by incubation at 25 °C (5 h) and centrifuged at 5 °C (15 min, 6000 
rpm). Resulting pellets were rinsed with distilled water and resuspended in lysis 
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solution (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0; 10 mL) 
containing amastatin (1 mM), LEU peptin (10 mM), bestatin (5 mg mL-1), pepstatin 
(0.1 mM) and aprotinin (7.7 mM). The suspension was sonicated (6 × 10 s), followed 
by addition of Triton X-100 [0.1% (v/v)] and freeze-thawed in liquid N2 (3 times). 
The suspension was centrifuged at 4 °C (J2-MC, 13.1 rotor, 6000 rpm, 45 min) to 
remove cellular debris. Ni-NTA His-bind beads (1 mL, Qiagen) were added to the 
supernatant and mixed at 4 °C (3 h) before loading onto column. The column was 
washed with 10 mM imidazole buffer (10 mM imidazole, 50 mM NaH2PO4, 300 mM 
NaCl, pH 8.0; 10 mL), and 20 mM imidazole buffer (20 mM imidazole, 50 mM 
NaH2PO4, 300 mM NaCl, pH 8.0; 8 mL) before elution with 250 mM imidazole 
buffer (250 mM imidazole, 50 mM NaH2PO4, 300 mM NaCl, pH 8.0; 12 mL) into 6 
× 2 mL fractions. The purification was confirmed by gel electrophoresis. Staining 
with Coomassie Blue (30 min) revealed a single protein band at ~30 kDa. Protein 
was stored with an equal volume of cryopreservation solution [50% (v/v) glycerol, 
10 mM NADH, 1% NaN3, 1 mM benzamide, 50 mM NaH2PO4, 300 mM NaCl, 
adjusted to pH 7.4] at -80 °C. 
 
 
2.2.2 Human ABAD and His-ABAD expression and purification (large scale) 
 
The pEHISTEV-ABAD DNA plasmid159 was transformed into and expressed in E. 
coli BL21 CodonPlus cells. An overnight culture in LB (50 mL) containing 
kanamycin (50 µL mL-1) was incubated at 37° C, 210 rpm (18 h). This culture 
(5 mL) was used to inoculate an LB culture (5 L), incubated at 37 °C, 210 rpm until 
Abs600 nm ~0.8 (3 h). Protein expression was induced by addition of IPTG (1 mM), 
followed by incubated at 25 °C, 180 rpm (18 h). The culture was then centrifuged at 
4 °C (Beckman Avanti J-20XP, rotor JLA-8.1, 6000 rpm, 20 min). The resulting 
pellet (24 g) was resuspended in lysis buffer [20 mM sodium phosphate, 500 mM 
NaCl, 30 mM imidazole, 10% (v/v) glycerol] containing protease inhibitors 
(Complete EDTA-free, Roche), lysozyme (1 mg mL-1), DNAase 1 (20 µg mL-1) and 
Triton X-100 [0.5% (v/v)] at 4 °C, 30 min. The suspension was lysed using a cell 
disrupter at 30,000 psi and centrifuged (Sorvall Evolution RC, rotor S5-34 55-34 
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angle, 20500 rpm, 30 min, 4 °C) to remove cell debris. Initial purification was 
performed using a nickel affinity column. Ni-NTA His-bind beads (5 mL, Qiagen) 
were equilibrated with lysis buffer (3 × 3 mL) before incubation with protein 
supernatant (4 °C, 30 min). Using a gravity column, the beads were washed with 
30 mM imidazole buffer (30 mM imidazole, 20 mM sodium phosphate, 500 mM 
NaCl, 10% glycerol, pH 7.4; 4 × 15 mL) then eluted with 300 mM imidazole buffer 
(300 mM imidazole, 20 mM sodium phosphate, 500 mM NaCl, 10% glycerol, pH 
7.4; 6 × 7.5 mL). Fractions containing ABAD, as determined by SDS-PAGE, were 
desalted (HiPrep 26/10 desalting column, GE Healthcare) and eluted into desalt 
buffer (20 mM Tris, 500 mM NaCl, 30 mM imidazole, 10% glycerol, pH 7.5) to 
yield ~180 mg protein. Fractions were combined and EDTA (1 mM) and DTT 
(1 mM) added to aid solubility. At this point, optional His-tag cleavage could be 
performed (see Section  2.2.2.1) 
 
The flow-through, containing ABAD, was concentrated to ~7 mL before final 
purification using gel filtration to remove the imidazole (Hi-Load 16/60 Sephadex 75 
prep grade column, GE Healthcare, flow rate 1.5 mL min-1). Protein was eluted into 
gel filtration buffer (10 mM Tris, 150 mM NaCl, 10% glycerol, pH 7.5) before 
concentrating to 25 mg mL-1 (~2.5 mL), flash-freezing in liquid N2 and storing 
at -80 °C. 
 
2.2.2.1 Optional His-tag removal 
The histidine tag was removed after desalting by cleaving with TEV protease 
(0.04 mg mL-1) at room temperature. SDS-PAGE showed complete cleavage after 
16 h. The protein solution was concentrated using a Vivaspin column (10 kDa 
MWCO, GE Healthcare) to ~60 mL and the cleaved His tag removed using a 
His-trap column. The final gel filtration was then performed as described above. 
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2.2.3 Measurement of protein concentration 
 
Protein concentration was measured using a Nanodrop (ThermoScientific) according 
to manufacturer’s instructions.  
 
Alternatively, protein concentration was measured using the Bradford assay. Samples 
were diluted into to a final volume of 500 µL MQ water, to which 500 µL Bradford 
reagent (Sigma-Aldrich) was added. The samples were incubated in the dark for 
5 min before measuring their absorbance at 595 nm. Protein concentration was 
calculated by comparison to a standard curve determined by measurement of bovine 
serum albumin (BSA) solutions of known concentrations (0, 2, 4, 6 µg mL-1). 
 
 
2.3 Preparation of Aβ monomers 
 
Aβ monomers were prepared as described by a literature procedure.160 Amyloid 
(1 mg) was dissolved in hexafluoroisopropanol (HFIP; 1 mL), aliquoted into 10 × 
0.1 mL, incubated at room temperature for 1 h before allowing evaporation of HFIP 
overnight. Traces of HFIP were removed under reduced pressure and the desiccated 
peptide stored at -20 °C.  
 
 




Culture flasks and dishes were from Nunc (VWR) unless otherwise stated. Cells 
were cultured in T75 flask at 37 °C in a humidified atmosphere with 5% CO2. 
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2.4.2 Routine cell culture 
 
Human embryonic kidney (HEK293) cells were cultured in minimum essential 
medium (MEM) supplemented with 10% (v/v) foetal calf serum (FCS; Sera 
Laboratories International), 1% (v/v) minimum non-essential amino acids (Sigma), 
2 mM L-glutamine (Sigma), 100 units mL-1 penicillin (Sigma) and 0.1 mg mL-1 
streptomycin (Sigma). 
 
SK-N-SH cells were cultured in Dulbecco’s modified medium (DMEM) 
supplemented with 2 mM L-glutamine (Sigma), 100 units mL-1 penicillin (Sigma) 
and 0.1 mg mL-1 streptomycin (Sigma). 
 
Mouse primary cortical neurons were cultured in dishes pre-coated with 0.01% (w/v) 
polylysine. After preparation of a single cell suspension (G. Doherty), cells were 
seeded and grown in cortical serum medium [MEM supplemented with 10% (v/v) 
FCS and 10% (v/v) horse serum]. After 24 h, medium was changed to serum-free 
medium [MEM, supplemented with SR2 (Sigma) and 80 µM 5-fluorodeoxyuridine]. 
 
 
2.4.3 Passage of cells 
 
Cells were cultured to ~80% confluency and washed briefly (10 s) with trypsin-
EDTA (1.5 mL; Gibco) to remove dead cells. Cells were then agitated gently with 
fresh trypsin-EDTA (1.5 mL) until cells detached. Culture medium (15 mL) was 
added to the detached cells and seeded into flasks/dishes at appropriate densities. 
 
 
2.4.4 Cryogenic storage/rescue of cell lines 
 
Frozen stocks of cells were prepared by trypsinisation of a confluent T75 flask and 
removal into 10 mL culture medium. The cells were centrifuged (1000 rpm, 4 °C, 
5 min) and the pellet resuspended in 1 mL fresh medium, 400 µL FCS and 100 µL 
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DMSO. The suspension was transferred into a cryotube and brought slowly to -80 °C 
using a “Mr Frosty” cryo 1 °C freezing container (Nalgene) in a -80 °C for 24 h 
before transfer to liquid nitrogen for long term storage.  
 
Frozen cell cultures were rescued by thawing at 37 °C and suspending into 15 mL 
cold culture medium in a T75 flask. Cells were incubated at 37 °C for 24 h before 
replacing medium with fresh culture medium to remove DMSO.  
 
 
2.4.5 Transfection of cells 
 
2.4.5.1 HEK293 cells 
HEK293 cells were transfected using GeneJammer reagent (Stratagene) according to 
the manufacturer’s instructions. An appropriate volume of GeneJammer (3 µL per 
1 µg DNA) was incubated at room temperature in Optimem medium (Gibco; 100 µL 
per 1 µg DNA) for 5 min before addition of DNA and incubation for a further 
20 min. The transfection mixture (100 µL per 35 mm dish) was added drop-wise to a 
dish of cultured cells at 70% confluency and incubated for 24–48 h as required. 
 
2.4.5.2 SK-0-SH cells 
SK-N-SH cells were transfected using BioIngenio electroporation solution (Mirus) 
and a nucleofector electroporator (Amaxa). A confluent T75 flask was trypsinised 
and suspended in 15 mL culture medium and split into 3 mL aliquots. Cells were 
centrifuged (1000 × g, 5 min) and the resulting pellet resuspended in 110 µL 
BioIngenio solution. Plasmid DNA (1–2 µg) was added, transferred to an Amaxa 
nucleofector cuvette and electroporated using the nucleofector programme X-04. The 
treated cells were transferred immediately to a dish containing 2 mL warmed culture 
medium and incubated as described above.  
 
2.4.5.3 0eurons 
Primary cortical mouse neurons were transfected using the Amaxa nucleofector 
system (Mouse Neuron Nucleofector kit). A suspension of E14 cortical neurons 
(5 embryos) was centrifuged (300 × g, 5 min) and resuspended in 400 µL 
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nucleofection solution and split into four aliquots. Appropriate DNA was added and 
the cells tranferred to the Amaxa cuvette before electroporating using the 
nucleofector programme O-05. The treated cells were transferred immediately to a 
dish containing 2 mL warmed cortical serum medium, which was replaced with fresh 




2.5 Western blotting 
 
2.5.1 Preparation of samples for SDS-PAGE 
 
Cells were cultured in 35 or 60 mm dishes as appropriate. Cells were washed in 
phosphate buffered saline (PBS, 2 × 3 min), harvested in lysis solution (50 µL for 
35 mm dish, 100 µL for 60 mm dish) containing protease inhibitor cocktail (1 ×, 
Sigma), 8 M urea, 4.7% (w/v) 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS), 1% (w/v) dithiothreitol (DTT) and 1.5 µM 
phenylmethylsulfonyl fluoride (PMSF), and sonicated (60 Hz, 3 × 3 s). After cooling 
on ice (15 min), samples were centrifuged (13,000 × g, 5 min) to remove debris, the 
supernatant added to an equal volume of 2 × protein sample buffer [2% (w/v) sodium 
dodecyl sulfate (SDS), 20% (v/v) glycerol, 20 mM Tris, 20 mM 
ethylenediaminetetraacetic acid (EDTA), 0.24 M β-mercaptoethanol, 1 µg mL–1 
bromophenol blue] and boiled for 10 min. 
 
 
2.5.2 SDS-polyacrylomide gel electrophoresis (SDS-PAGE) 
 
Samples were run on 10- or 15-well NuPAGE 4–12% Bis-Tris gels (Invitrogen) or 
15-well Precise 8–16% Bis-Tris gels (Pierce, ThermoScientific) in 
2-(0-morpholino)ethanesulfonic acid (MES) buffer at constant voltage (45 min, 
200 V). SeeBlue Plus2 pre-stained standard (Invitrogen) was used as a molecular 
weight marker.  
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2.5.3 Western blotting 
 
The SDS-PAGE resolved proteins were then transferred onto a nitrocellulose 
membrane (Whatman) at 30 V for 1 h using NuPAGE transfer buffer (Invitrogen). 
Protein transfer was confirmed by staining with Ponceau S solution [0.1% (w/v) 
Ponceau S, 5% acetic acid]. Ponceau stain was removed by washing with 
Tris-buffered saline (TBS). 
 
 
2.5.4 Detection of proteins 
 
Membranes were blocked in 5% (w/v) low-fat milk in TBS containing 0.1% 
Tween 20 (TBS-T; 1 h). The membrane was then incubated with anti-ABAD (rabbit 
polyclonal, 1:6000 dilution, Sigma) in 3% milk in TBS containing 0.1% Tween20 
(TBS-T, 4 °C, 16 h). The membrane was washed with TBT-T (3 × 5 min) before 
incubating with anti-rabbit horseradish peroxidase (HRP) (goat, 1:20,000 dilution, 
Abcam) in 3% milk in TBS-T (5 mL, 30 min). The membrane was then washed with 
TBS-T (1 × 15 min, 2 × 5 min) and TBS (1 × 5 min) before incubating with 
SuperSignal West Pico enhanced chemiluminescence reagent (ECL; 4 mL, 5 min; 
Sigma) and detected using a chemiluminescence detector. 
 
β-Actin was detected after stripping the membrane (10% acetic acid, 4 × 10 min) and 
blocking in 5% milk (1 h). The membrane was then incubated with anti-β-actin 
(mouse, 1:20,000 dilution, Sigma) in 3% milk in TBS-T (1 h). The membrane was 
washed with TBT-T (3 × 5 min) before incubating with anti-mouse HRP (goat, 
1:20,000 dilution, Abcam) in TBS-T or 3% milk in TBS-T (5 mL, 30 min). The 
membrane was then washed with TBS-T (1 × 15 min, 2 × 5 min) and TBS 
(1 × 5 min) before incubating with ECL reagent (4 mL, 5 min) and detected using a 
chemiluminescence detector. 
 
ABAD:β-actin ratios were calculated using Image J software. 
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2.6 Microscopy  
 
2.6.1 Fixing cells for fluorescence microscopy 
 
Cells were cultured on glass coverslips (VWR) in 35 mm dishes, as appropriate. 
Cells were washed with ice-cold PBS (3 × 3 min), fixed with neutral buffered 
formalin [NBF; 10% (v/v) formalin, 0.4% (w/v) NaH2PO4.H2O, 0.65% (w/v) 
Na2HPO4] for 10 min at room temperature and washed again with ice-cold PBS 
(3 × 3 min) before performing immunocytochemistry or directly mounting onto glass 
slides (VWR) with Mowiol [10% (w/v) Mowiol 488 (Calbiochem) containing 





Coverslips were incubated for 1 h with primary antibody [anti-ABAD(110-116), 
rabbit, Sigma; 1–2 µg mL-1 in PBS containing 0.2% Triton X-100 and 3% (w/v) 
BSA], washed with PBS (3 × 3 min) and incubated with secondary antibody 
conjugated with a fluorescent tag [Alexa 568 goat anti-rabbit, 1:5000 in PBS 
containing 5% (w/v) goat serum; FITC sheep anti-rabbit, 1:160 in PBS containing 
5% (w/v) goat serum]. After a final wash with PBS (3 × 3 min), coverslips were 
mounted with Mowiol/DAPI as described above (Section  2.6.1). 
 
 
2.6.3 Fluorescence microscopy 
 
Confocal fluorescence microscopy was performed on a Leica TCS SL or Leica SP 
MP microscope (Leica), equipped with a Leica DM IRE2 inverted microscope with a 
63 × or 40 × oil objective. Excitation of fluorescence was achieved with a diode 
(405 nm), Ar (488 nm) or HeNe (633 nm) laser, as appropriate. 
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2.7  (–)-CHA.A-studies 
 
2.7.1 ABAD enzyme activity assay 
 
Assay buffer: 0.1 M K2PO4, pH 9.0 
ABAD: (–)-CHANA (2–50 µM final concentration) and NAD+ (500 µM, from 
25 mM in assay buffer) was added to assay buffer to a final volume of 1 mL and 
mixed (10 s). ABAD (diluted to final concentration of 5 mg L-1) was added, mixed 
(10 s) and absorbance at 340 nm measured. (Shimadzu UV-1601 spectrophotometer 
with UVProbe software; T = 30°C, controlled by thermostatic cell; λ = 340 nm; cycle 
time = 2 s; mode = kinetics); measured for 20 min. Initial rate of reaction was 
calculated using ε (NADH) = 6220 L mol-1 cm-1. 
His-ABAD: (–)-CHANA (2–50 µM final concentration) and NAD+ (500 µM, from 
25 mM in assay buffer was added to assay buffer to a final volume of 1 mL and 
mixed (10 s). His-ABAD (diluted to final concentration of 5 mg L-1) was added, 





HEK293 cells were grown on coverslips and transfected with MTS-ABAD for 48 h 
(Section  2.4.5). Cells were then treated with 20 µM (–)-CHANA in phenol red-free 
medium [DMEM plus 4.5 g L-1 glucose, minus phenol red (Gibco), supplemented 
with charcoal-stripped FCS [1% (v/v)], penicillin (100 units mL-1), streptomycin 
(0.1 mg mL-1) and glutamine (2 mM)] for the desired time period, before placing 
samples on ice prior to measurement. 
 
Coverslips were removed from the dishes and the fluorescence was measured using a 
Fluoromax fluorimeter. Samples were excited at 405 nm and the emission spectra 
over 470–600 nm recorded. 
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2.7.3 Live cell imaging 
 
Cells were cultured on 35 mm glass-bottomed dishes (World Precision Instruments) 
and transfected as appropriate with pcDNA3, MTS-ABAD, mAPP or 
MTS-ABAD/mAPP using GeneJammer (Section  2.4.5.1) or electroporation (Section 
 2.4.5.2) for 24–48 h. Prior to imaging, medium was changed to phenol red-free 
medium [DMEM plus 4.5 g L-1 glucose, minus phenol red (Gibco), supplemented 
with 1% v/v charcoal-stripped foetal calf serum, penicillin (100 units mL-1), 
streptomycin (0.1 mg mL-1) and glutamine (2 mM)]  and incubated with 2 µM (–)-
CHANA (from 1 mM stock in DMSO) with images taken every 15 min over a period 
of 1 h. Fluorescence imaging was carried out as described in Section  2.6.3 using a 
heated stage (37 °C). Samples were excited at 405 nm and the emission collected at 
500–520 nm (HEK293) or 470–540 nm (SK-N-SH) with a 40 × oil objective at 
200 Hz, averaged over 8 images. Three images per dish were recorded and three 
dishes were measured in separate experiments. Mean fluorescence intensities were 
calculated using ImageJ (National Institutes of Health), with a threshold set to 
remove non-cell regions of the image from calculations. Errors are reported as SEM. 
Statistical analysis was performed using the Student’s t-test.  
 
 
2.7.4 MitoTracker staining 
 
Cells were cultured in 35 mm glass-bottomed tissue culture dishes. Mitochondrial 
staining was performed using MitoTracker Deep Red (25–100 nM in DMEM, from 
1 mM stock in DMSO, Invitrogen) at 37 °C for 20–40 min. Medium was changed to 
2 µM (–)-CHANA for 1 hour before imaging using a 63 × oil objective. MitoTracker 
staining was observed by excitation at 633 nm and emission 640–700 nm;                
(–)-CHANA excitation 405 nm and emission 470–540 nm. 
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2.7.5 Knock-down studies 
 
Knockdown of ABAD in HEK293 cells was achieved by transfection of siRNA 
using GeneEraser (Stratagene) according to the manufacturer’s instructions. siRNA 
oligomers AAGAAGUUAGGAAACAACUGCGUUU and 
AAACGCAGUUGUUUCCUAACUUCUU (Invitrogen, HSD17B10HSS179169), 
were used at a final concentration of 15 nM for 72 h. Non-targeted siRNA controls 
were performed using non-targeted siRNA (Thermoscientific non-targeting 
siRNA #2). Knockdown was confirmed by Western blotting, as described in 
Section  2.5. 
 
 
2.7.6 Amyloid inhibition studies 
 
Monomerised Aβ42 was prepared as described in Section  2.3. Monomerised Aβ42 
(0.1 mg) was dissolved in DMSO (10 µL), sonicated in an ultrasonic bath (10 min) 
before dilution with culture medium to the appropriate concentration. Cells were 
treated with 0 or 22 µM Aβ42 for 24 h before imaging with (–)-CHANA as described 
above. Statistical analysis was performed using the Student’s t-test. 
 
 
2.8 In vitro assays 
 
2.8.1 ABAD activity assay 
 
Assay buffer: 50 mM NaH2PO4, 300 mM NaCl, adjusted to pH 7.41. Buffer was 
warmed to 30 °C prior to use. 
 
2.8.1.1 Variation of substrate 
Cortisone (100 µM, from 10 mM stock in EtOH), ethyl acetoacetate (4000 µM, from 
200 mM stock in assay buffer) or acetoacetate (4000 µM, from 200 mM stock in 
assay buffer) was added to assay buffer to a final volume of 1 mL. His-ABAD (in 
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preservation solution containing 5 mM NADH; diluted to final concentration of 
4.2 mg L-1 His-ABAD and 100 µM NADH) was added, mixed (10 s) and the 
absorbance at 340 nm measured over a period of 2–3 h (Shimadzu UV-1601 
spectrophotometer with UVProbe software; T = 30 °C, controlled by thermostatic 
cell; λ = 340 nm; cycle time = 30–120 s; mode = kinetics). Initial rate of reaction 
calculated using ε (NADH) = 6220 L mol-1 cm-1.  
S-acetoacetate-CoA was measured using 40 µM substrate, as described below 
(Section  2.8.1.2). 
 
2.8.1.2 Determination of enzymatic parameters 
ABAD: S-acetoacetyl-coenzyme A (4–240 µM final concentration, from 2 mM stock 
in assay buffer) and NADH (250 µM final concentration, from 25 mM stock in assay 
buffer) was added to assay buffer to a final volume of 1 mL and mixed (10 s). ABAD 
(diluted to give a final concentration of 5 mg L-1) was added, mixed (10 s) and 
absorbance at 340 nm measured. (Shimadzu UV-1601 spectrophotometer with 
UVProbe software; T = 30°C, controlled by thermostatic cell; λ = 340 nm; cycle time 
= 1 s; mode = kinetics); measured for 30–100 s. Initial rate of reaction over the first 
10 seconds was calculated using ε (NADH) = 6220 L mol-1 cm-1. 
 
His-ABAD: S-acetoacetyl-coenzyme A (4–80 µM final concentration) was added to 
assay buffer to a final volume of 1 mL and mixed (10 s). His-ABAD (in preservation 
solution containing 5 mM NADH; diluted to final concentration of 4.2 mg L-1 
His-ABAD and 100 µM NADH) was added, mixed (10 s) and absorbance at 340 nm 
measured as described above.  
 
2.8.1.3 Amyloid inhibition assay 
Aβ was monomerised as described above (Section  2.3). His-ABAD (20 µL of 
210 µg L-1) was mixed with Aβ40 (10 µL of 185 µM solution in DMSO or MilliQ 
water) or Aβ42 (10 µL of 185 µM solution in DMSO or 1% aq. NH4OH) and 
incubated on ice for 0–24 h. DMSO/1% aq. NH4OH/water, as appropriate, was used 
in place of Aβ for control samples. 
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S-acetoacetyl-coenzyme A (40 µM) was added to assay buffer (950 µL) and mixed 
(10 s). Incubated ABAD/Aβ mixture (30 µL) was added, mixed (10 s) and the rate of 
reaction calculated as described above (Section  2.8.1.2).  
 
2.8.1.4 Small molecule inhibition assay 
Assays buffer contained 50 mM NaH2PO4 and 300 mM NaCl, adjusted to pH 7.4. 
Stock solutions of acetoacetyl-CoA (3.2 mM) and NADH (10 mM) were prepared in 
assay buffer. Stocks of test compounds (2, 0.2, 0.02 M) in DMSO were prepared and 
diluted to 400, 40 and 4 mM using assay buffer. ABAD was diluted to 0.2 mg mL-1 
in assay buffer. 
Assays were performed in cuvettes (VWR; final volume 1 mL) or 96 well plates 
(Corning; final volume 160 µL). Acetoacetyl-CoA (80 µM), NADH (250 µM) and 
test compound (10, 1 or 0.1 mM; final DMSO 0.5%) were added to assay buffer 
(final volume 1 mL or 160 µL, as appropriate) and mixed before addition of ABAD 
(5 mg L-1). Control samples contained 0.5% DMSO and no test compound. The 
samples were mixed by pipetting up and down 3 times before measuring absorption 
at 340 nm every 0.5 s over 60 s (Shimadzu UV-1601 spectrophotometer with 
UVProbe software or NOVOstar fluorescence plate reader, BMG Labtech Ltd. with 
NOVOstar software V1.10-0; T = 30°C). Enzyme activity was calculated using 
ε = 6220 L mol-1 cm-1 for NADH, the rate of consumption of which is equal to the 
rate of reduction of acetoacetyl-CoA. All assays were performed in triplicate and the 
error reported as ± SEM. 
 
 
2.8.2 Thermal shift assay 
 
Solutions of Maybridge Ro3 fragment library compounds (200 mM in DMSO; 
Thermo Fisher Scientific Inc.) were diluted to 20 mM in buffer (20 mM sodium 
phosphate, pH 7.4). Protein master mix containing ABAD (19.8 µM) and Sypro 
Orange (1:500, Invitrogen) was prepared. Ninety-six (Greiner) or forty-eight well 
plates (Axygen) were then prepared by mixing 30 µL protein master mix with 30 µL 
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library compound (total volume 60 µL; final [ABAD] 9.9 µM; [fragment] 10 mM; 
[DMSO] 5%).  
 
Assays were performed using a Stratagene Mx3005P qPCR machine (Sybr filter, 
ex. 492 nm, em. 516 nm) or BioRad MiniOpticon qPCR machine (FAM filter). 
Initial temperature was set to 25 °C, increasing in increments of 0.5 °C every 60 s for 
120 cycles (25–85 °C). Readings were taken in triplicate at each temperature point. 
The negative reciprocal was plotted and the protein unfolding temperature (Tm) taken 
as the lowest point of the curve obtained. The change in unfolding temperature (∆Tm) 
was then calculated as the shift from the Tm when no fragment was present. Controls 
with no fragment, no Sypro Orange or no ABAD were also run.  
2.8.3 Isothermal titration calorimetry 
 
ABAD (25 mg mL-1) was provided in gel filtration buffer (10 mM Tris, 150 mM 
NaCl, 10% glycerol, pH 7.5); small molecule fragments were provided as 2 M 
solutions in DMSO. Cell (ABAD) and syringe (ligand) solutions were prepared in 
phosphate buffer (10 mM sodium phosphate, pH 7.4), matching protein, ligand and 
buffer solutions with DMSO and gel filtration buffer as appropriate. The pH of all 
solutions were adjusted to pH 7.40 ± 0.01. All solutions were degassed by sonication 
at 20 °C for 15 min before use. ABAD concentrations are given in monomer 
concentrations. 
 
Calorimetric titrations were carried out at 25°C using a VP-ITC instrument (Microcal 
LLC). The instrument was operated in high feedback mode, applying a reference 
power of 5 µcal s-1 and stirring the cell contents at 307 rpm. The cell volume was 
1.4 mL and the injector volume was 290 µL. Unless otherwise stated, the cell 
solution contained ABAD (49.3 µM monomer concentration), while the syringe 
contained 15 mM small molecule fragment. The cell and syringe were first washed 
with buffer (5 ×) and degassed buffer (1 ×) before filling. The ligand solution was 
injected into the cell in a series of 20 injections (initial injection 3 µL, subsequent 
injections 7 µL, injection rate 0.5 µL s-1) every 360 s. In order to account for heat of 
dilution, the cell solution was then replaced with buffer and the ligand injection 
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repeated. The heat of dilution was then subtracted from the main experiment. Raw 
data was processed using MicroCal Origin software. Baseline adjustment and 
integrations were carried out manually.  
 
2.8.3.1 0ADH binding 
As above except cell contained 9.9 µM ABAD and syringe contained 210 µM 
NADH. DMSO was not required for NADH solubility.  
 
 
2.8.4 Surface plasmon resonance (SPR) 
 
2.8.4.1 General 
His-ABAD was prepared in stock solution of 1.3 mg mL-1 (see Section  2.2.1). 
Untagged ABAD (utABAD) was prepared in stock solution 20 mg mL-1 (see Section 
 2.2.2). Aβ40 (Innovagen) and Aβ42 (R-Peptide) were monomerised by treatment 
with HFIP (see Section  2.3).160  
 
Truncated peptides were synthesised by Peptide Synthetics. Pep[XX]–[XX] refers to 







All experiments were carried out on a Biacore T100 using NTA (nickel affinity 
immobilisation) or CM5 (covalent immobilisation) sensor chips. Running buffer was 
either HEPES buffered saline (HBS; 10 mM HEPES, 150 mM NaCl, pH 7.4) with 
50 µM EDTA and 0.05% Tween20 (polyoxyethylenesorbitan laurate) or HBS with 
1 mM EDTA and 0.005% Tween20.  
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2.8.4.2 Immobilisation of ABAD onto an 0TA chip 
An NTA chip was activated with NiCl2 (500 µM, 10 µL min
-1, 60 s), followed by 
immobilisation of His-ABAD (500 nM, 10 µL min-1, 60 s), ~400 response units (RU) 
were immobilised. The chip surface was regenerated by EDTA (0.35 M, 10 µL min-1, 
60 s). 
 
2.8.4.3 Immobilisation of ABAD onto a CM5 chip 
His-ABAD (2 µM in 10 mM sodium acetate, pH 4.0) or ABAD (2 µM in 10 mM 
sodium acetate, pH 5.5) were immobilised by amine coupling according to standard 
methods: the chip surface was activated with 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC) and 0-hydroxysuccinimide (NHS); ABAD was 
immobilised at 5 µL min-1 until desired immobilisation level was obtained; unreacted 
sites were blocked with ethanolamine. 
 
2.8.4.4 Immobilisation of amyloid onto a CM5 chip 
Aβ40 (solubilised in 0.1% trifluoroacetic acid, then 10 µM in 10 mM sodium acetate, 
pH 4.0) or Aβ42 (solubilised in DMSO, then 10 µM in 10 mM sodium acetate, pH 
5.5) were immobilised by amine coupling according to standard methods: the chip 
surface was activated with EDC and NHS; Aβ was immobilised at 5 µL min-1 until 
desired immobilisation level was obtained (Aβ40, 5700 RU; Aβ42, 6300 RU), then 
ethanolamine was used to block unreacted sites. 
 
2.8.4.5 Binding of 0ADH to ABAD 
NAD (serial dilutions 500–3.9 µM) was bound to ABAD immobilised on a CM5 
chip (contact time 60 s, dissociation time 180 s, flow rate 30 µL min-1). Data was 
fitted to a steady state affinity model. 
 
2.8.4.6 Binding of ABAD to Aβ 
His-ABAD (serial dilutions 12.5–0.098 µM) or ABAD (25–0.0015 µM) were bound 
to Aβ40 or Aβ42 immobilised on a CM5 chip (contact time 45 s, dissociation time 
300 s, flow rate 30 µL min-1; regeneration by 4 M guanidine hydrochloride, pH 7.7, 
10 s, 30 µL min-1, stabilisation period 200 s). Samples were run in triplicate.  
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2.8.4.7 Binding of peptides to Aβ 
Peptides (serial dilutions Pep92–120, Pep120–92:  250–0.0076 µM; Pep100–110, 
Pep98–102, Pep107–111 2000–0.0076 µM) were bound to Aβ40 or Aβ42 
immobilised on a CM5 chip (contact time 45 s, dissociation time 300 s, flow rate 
30 µL min-1; regeneration by 4 M guanidine hydrochloride, pH 7.7, 10 s, 







ABAD protein was produced as described in Section  2.2.2, with the His tag removed 
by TEV protease cleavage. 
 
Commercially available crystallisation screens were used to screen initial conditions 
of crystallization, such as JCSG+, Classics and PEGS (Qiagen). A nano-drop 
crystallization robot Cartesian HoneyBee, Genomic Solutions), as part of the 
Hamilton-ThermoRhombix system, was used for preparing 96 well plates. 
 
Using 10–30% (v/v) glycerol in the crystallization buffer, the crystals of target 
proteins were cryoprotected. A suitable protein crystal was picked out from the drops 
with a crystal loop and transferred to 5 µL cryoprotectant drop. Then the crystal was 
re-looped and mounted onto X-ray at 100K in-house using a Rigaku/MSC 
MicroMax-007HF rotating anode equipped with a Saturn 944+ CCD detector at 
wavelength 1.54178 Å. 
 
 
2.9.2 ABAD-fragment co-crystallisation 
 
Protein solutions were prepared as shown in Table  2.1. Fragments were provided as 
2 M stocks in DSMO. Crystal trial were set up in 96 well plates (sitting drop): drop 
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size, 200 nL; 1:1 ratio of protein solution:crystallisation buffer; reservoir volume, 
70 µL. Plates were incubated at 20 °C. 
 
Table  2.1: Protein solutions for ABAD-fragment co-crystallisation 
 .AD absent .AD present 
ABAD 25 mg mL-1 20 mg mL-1 
DTT 1 mM 1 mM 
NAD - 5 mM 
Fragment 10 mM 10 mM 
 
 
2.9.3 ABAD-Aβ20 co-crystallisation 
 
Aβ20 (DAEFRHDSGYEVHHQKLVFF; R-Peptide or Genscript) was added to 
ABAD protein solutions (10 or 20 mg mL-1) in 2, 5 or 20 molar excess in the 
presence and absence of 5 mM NAD+ and 1 mM DTT. 
 
Crystal trial were set up in 96 well plates (sitting drop): drop size, 150 nL; 1:1 or 2:1 
ratio of protein solution:crystallisation buffer; reservoir volume, 70 µL. Plates were 
incubated at 20 °C. Additional trial were set up in 24 well plate (hanging drop): drop 
size, 1 µL; 1:1, 1:2 or 2:1 ratio of protein solution:crystallisation buffer; reservoir 
volume, 400 µL. Plates were incubated at 4 or 20 °C. 
 
 
2.10 ABAD docking studies 
 
Docking studies were carried out using ICM Pro 3.7-2a software (Molsoft). The 
ABAD protein structure, as determined by Kissinger et al.119 (protein data bank 
accession number 1U7T), was used to dock in the ligand, 116. A single protein 
monomer (subunit B) was used in order to minimise calculation time and weakly 
bound water molecules were removed. Docking was performed in the presence and 
absence of NAD+, starting with the ligand in space.  
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2.11 Synthesis of organic compounds 
 
2.11.1 General experimental 
 
Chemicals were purchased from Acros UK, Sigma-Aldrich UK, Alfa Aesar UK, 
Fisher UK, Fluka UK, Fluorochem, Merck and TCI-Europe. Suzuki couplings were 
performed in 25 mL reaction tubes on a Radleys carousel reactor under an 
atmosphere of argon and solvents were degassed by freeze-pump-thaw (6 cycles) 
prior to use. Where appropriate, and if not otherwise stated, all other non-aqueous 
reactions were performed under an inert atmosphere of nitrogen using a double 
vacuum manifold with the inert gas passing through a bed of activated 4 Å molecular 
sieves and self-indicating silica gel. 
 
Analytical thin layer chromatography (TLC) was carried out on Merck silica gel 
60 F254 aluminium-supported thin layer chromatography sheets or 60 RP-18 F254S 
aluminum-supported thin layer chromatography sheets. Visualisation was by 
absorption of UV light (λmax 254 or 365 nm) or thermal development after dipping an 
aqueous solution of potassium permanganate, potassium carbonate and sodium 
hydroxide. 
 
Flash column chromatography was carried out on Merck silica gel 60 (240-400 
mesh), eluting with solvents under a positive pressure of compressed air.  
 
Reverse phase chromatography was carried out on Fluka Ltd silica gel 100 C18-
reversed phase under a positive pressure of compressed air. 
 
Strong cation exchange (SCX) chromatography was carried out on a Biotage 
SCX-2 column (5 g/25 mL) under a positive pressure of nitrogen. 
 
1
H .MR spectra were recorded on Bruker DPX400 (400 MHz), Bruker AV400 
(400 MHz) or Bruker DRX500 (500 MHz) using deuterated chloroform, methanol, 
dimethylsulfoxide or deuterium oxide (as stated) as a reference for internal deuterium 
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lock. Chemical shift data are given as δH in parts per million (ppm) relative to 
tetramethylsilane (TMS) where δ (TMS) = 0.00 ppm. The multiplicity of each signal 
is indicated by: s (singlet); d (doublet); t (triplet); q (quartet); dd (doublet of 
doublets); ddd (doublet of doublets of doublets); or m (multiplet). The number of 
protons, n, for a certain resonance signal is given as nH. Coupling constants, J, were 
determined by analysis using Bruker TopSpin software and are quoted in Hz to the 
nearest 0.1 Hz. Identical proton coupling constants were averaged in each spectrum 
and reported to the nearest 0.1 Hz.  
 
13
C .MR spectra were recorded on a Bruker AV500 (126 MHz), Bruker DRX500 
(126 MHz) or Bruker AV400 (100 MHz) spectrometer with broadband proton 
decoupling and internal deuterium lock. The chemical shift data for each signal are 
given as δ in units of parts per million (ppm) relative to tetramethylsilane (TMS) 
where δC (TMS) = 0.00 ppm. Where appropriate, coupling constants (J) are quoted 
in Hz and are recorded to the nearest 0.1 Hz. 
 
1H and 13C spectra were assigned using 2D NMR experiments including COSY, 
HSQC and HMBC. 
 
19
F .MR spectra were recorded on a Bruker AV400 (376 Hz) using a deuterium 
internal lock. The chemical shift data for each signal are given as δF in parts per 
million (ppm) relative to trichlorofluoromethane, where δF = 0.00 ppm. 
 
Mass spectra were acquired on a Micromass LCT Premier or Bruker MicroTOF 
spectrometer using electrospray ionisation or field ionisation, operating in positive or 
negative mode, from solutions in methanol. m/z values are reported in Daltons and 
followed by their percentage abundance in parentheses. 
 
Melting points were determined using a Kofler hot stage microscope and are 
uncorrected. 
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Microanalyses were obtained from the Elemental Analysis Service, London 
Metropolitan University, London. 
 
Infrared spectra were obtained as a thin film on sodium chloride discs or as 
potassium bromide discs, as indicated. The spectra were recorded on a Bruker Tensor 
27 spectrometer. Absorption maxima are reported in wavenumbers (cm-1) as assigned 
as strong (s), medium (m) or weak (w). 
 
In vacuo refers to the use of a rotary evaporator attached to a diaphragm pump. 
Brine refers to a saturated aqueous solution of sodium chloride. Hexane refers to a 










Palladium(II) chloride (503 mg, 2.84 mmol) and triphenylphosphine (3.72 g, 
14.2 mmol) were added to DMSO (34 mL) and heated at 140 ˚C under N2 for 
30 min. The reaction mixture was cooled to 125 ˚C and hydrazine monohydrate 
(565 mg, 550 µL, 11.28 mmol) added dropwise with stirring, during which time the 
reaction mixture changed from orange to yellow. The reaction mixture was cooled to 
room temperature and the resulting yellow precipitate filtered then washed with ethyl 
acetate (15 mL) and diethyl ether (15 mL) to afford tetrakis(triphenylphosphine)-
palladium (2.98 g, 91% yield) as a bright yellow solid.161 
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4-Pyridinylboronic acid (94 mg, 0.76 mmol), 1-fluoro-4-iodobenzene (202 mg, 
105 µL, 0.91 mmol) and sodium carbonate (237 mg, 2.23 mmol) were added to the 
reaction tube. Toluene (7.5 mL), ethanol (2.5 mL) and water (0.75 mL) were 
transferred to the reaction tube via cannula under a positive pressure of Ar, followed 
by the addition of Pd(PPh3)4 (42 mg, 0.036 mmol). The reaction mixture was heated 
under reflux for 16 h, after which time the solvent was removed in vacuo and the 
resulting residue partitioned between water (5 mL) and CH2Cl2 (10 mL). The organic 
layer was washed with brine (3 × 5 mL) and the combined aqueous layers 
backwashed with CH2Cl2 (10 mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. The crude product (146 mg) was purified 
by flash column chromatography, eluting with ethyl acetate/petroleum ether (1:2) to 
yield 4-(4-fluorophenyl)pyridine 95a (63 mg, 48%) as an off-white solid: Rf 0.16 
(ethyl acetate/petroleum ether 1:2); mp 45–46 ºC (from hexane) [lit.162 47–48.5 °C 
(hexane)]; 1H NMR (400 MHz; CDCl3): δ 8.67 (2H, d, J 4.8, H-2), 7.65–7.60 (2H, 
m, H-6), 7.47 (2H, dd, J 4.8, 1.7, H-3) and 7.22–7.16 (2H, m, H-7); 13C NMR (100 
MHz; CDCl3): δ 163.4 (d, J 248, CH-8), 150.3 (CH-2), 147.2 (C-4), 134.2 (d, J 4.0, 
C-5), 128.7 (d, J 9.1, CH-6), 121.4 (CH-3) and 116.1 (d, J 22.1, CH-7); 19F NMR 
(376 MHz; CDCl3): δ -112.6 ppm (m); m/z (ESI
+) 174.07 ([M+H]+, 100%). Data are 
in good agreement with literature values162 
 
In addition, 4-phenylpyridine 96 (3% yield) was isolated as a side product from the 
reaction. 
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Rf 0.16 (ethyl acetate/petroleum ether 1:2); mp 51–66 ºC (pentane) [lit.
163 77–78°C]; 
1H NMR (400 MHz; CDCl3): δ 8.67 (2H, d, J 5.8, H-2), 7.68–7.62 (2H, m, H-3) and 
7.53–7.45 (5H, m, H-5, H-6 and H-7); 13C NMR (100 MHz; CDCl3): δ 150.2 (CH-2), 
148.3 (C-4), 138.1 (C-5), 129.1 (CH), 129.0 (CH), 127.0 (CH-6) and 121.6 (CH-3); 








4-Pyridinylboronic acid (92 mg, 0.75 mmol), 3-bromo-0-methylbenzylamine 
(180 mg, 123 µL, 0.90 mmol) and sodium carbonate (239 mg, 2.25 mmol) were 
added to the reaction tube. Toluene (7.5 mL), ethanol (2.5 mL) and water (0.75 mL) 
were transferred to the reaction tube via cannula under a positive pressure of Ar, 
followed by the addition of Pd(PPh3)4 (43 mg, 0.037 mmol). The reaction mixture 
was heated under reflux for 20 h, after which time solvent was removed in vacuo and 
the resulting residue partitioned between water (5 mL) and ethyl acetate (5 mL). The 
organic layer was washed with brine (3 × 5 mL) and the combined aqueous layers 
backwashed with ethyl acetate (5 mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. The crude product (128 mg) was purified 
by flash column chromatography, eluting with methanol/triethylamine/ethyl acetate 
(2.5:5:92.5) to yield 0-methyl-0-(3-(pyridin-4-yl)benzyl)amine 73 (108 mg, 73%) as 
a yellow-orange oil: Rf 0.14 (methanol/triethylamine/ethyl acetate 2.5:5:92.5); vmax 
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(NaCl plates)/cm-1: 3304 (w, N–H stretch), 3030 (w, Ar–H stretch). 2920 (w, C–H 
stretch), 2830 (w, C–H stretch), 1597 (s, Ar), 1548 (m, N–H bend), 1479 (m), 1408 
(m), 831 (m, p-subst. Ar), 790 (s, m-subst. Ar), 700 (m), 616 (m); 1H NMR 
(400 MHz; CDCl3): δ 8.65 (2H, d, J 6.2, H-2), 7.63 (1H, s, H-10), 7.57–7.50 (3H, m, 
H-3, H-6), 7.50–7.38 (2H, m, H-7, H-8), 3.85 (2H, s, H-11) and 2.50 (3H, s, H-13); 
13C NMR (100 MHz; CDCl3): δ 150.2 (CH-2), 148.2 (C-4), 140.8 (C), 138.2 (C), 
129.2 (CH), 128.9 (CH), 126.8 (CH), 125.7 (CH), 121.6 (CH-3), 55.8 (CH2-11) and 
35.9 (CH3-13); HRMS m/z (ESI
+) [Found: (M+H)+ 199.1229. C13H15N2 requires M
+, 
199.1230]; m/z (ESI+) 199.11 ([M+H]+, 47%), 322.13 ([M+C5H4N+2Na]
+, 98%), 
520.24 ([2M+C5H4N+2Na]
+, 100%), 643.26 ([3M+NHCH3+H3O]
+, 98%); Anal. 








3-Pyridinylboronic acid (92 mg, 0.76 mmol), 3-bromo-0-methylbenzylamide 
(108 mg, 123 µL, 0.90 mmol) and sodium carbonate (239 mg, 2.25 mmol) were 
added to the reaction tube. Toluene (7.5 mL), ethanol (2.5 mL) and water (0.75 mL) 
were transferred to the reaction tube via cannula under a positive pressure of Ar, 
followed by the addition of Pd(PPh3)4 (43 mg, 0.037 mmol). The reaction mixture 
was heated under reflux for 20 h, after which time solvent was removed in vacuo and 
the resulting residue partitioned between water (5 mL) and ethyl acetate (5 mL) 
before filtering to remove insoluble denatured catalyst. The organic layer was 
washed with brine (3 × 5 mL) and the combined aqueous layers backwashed with 
ethyl acetate (5 mL). The combined organic layers were dried over MgSO4, filtered 
and concentrated in vacuo. The crude product (88 mg) was purified by flash column 
chromatography, eluting with methanol/triethylamine/ethyl acetate (1:1:18) to yield 
0-methyl-0-(3-(pyridin-3-yl)benzyl)amine 74 (106 mg, 71%) as a yellow-orange oil: 
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Rf 0.16 (methanol/triethylamine/ethyl acetate 1:1:18); vmax (NaCl plates)/cm
-1: 3306 
(m, N–H stretch), 3030 (m, Ar–H stretch), 2920 (m, C–H stretch), 2830 (m, C–H 
stretch), 1022 (m), 1471 (s, Ar), 788 (s, m-subst. Ar), 711 (s); 1H NMR (400 MHz; 
CDCl3): δ 8.84 (1H, d, J 1.8, H-2), 8.57 (1H, d, J 4.8, H-6), 7.87 (1H, dt, J 7.9, 1.7, 
H-4), 7.55 (1H, s, H-12), 7.49–7.39 (2H, m, H-8 and H-9), 7.39–7.30 (2H, m, H-5 
and H-10), 3.83 (2H, s, CH2-13) and 2.49 (3H, s, CH3-15); 
13C NMR (100 MHz; 
CDCl3): δ 148.4 (CH-6), 148.3 (CH-2), 140.7 (C), 138.0 (C), 136.5 (C), 134.4 (CH-
4), 129.1 (CH), 128.0 (CH), 127.0 (CH), 125.9 (CH), 123.5 (CH-5), 55.8 (CH2-13), 
35.9 (CH3-15); HRMS m/z (ESI
+) [Found: (M+H)+ 199.1229. C13H15N2 requires M
+, 
199.1230]; m/z (ESI+) 199.11 ([M+H]+,17%), 322.12 ([M+C5H4N+2Na–H]
+, 99%), 
520.23 ([2M+ C5H4N+2Na–H]
+, 100%), 643. 24 ([3M+NHCH3+H3O]
+, 99%); Anal. 







4-Pyridinylboronic acid (92 mg, 0.76 mmol), 2-bromo-0-methylbenzylamine 
(180 mg, 133 µL, 0.76 mmol) and sodium carbonate (239 mg, 2.25 mmol) were 
added to a reaction tube. Toluene (7.5 mL), ethanol (2.5 mL) and water (0.75 mL) 
were transferred to the reaction tube via cannula under a positive pressure of Ar, 
followed by the addition of Pd(PPh3)4 (43 mg, 0.037 mmol). The reaction mixture 
was heated to 110 ºC under reflux for 48 h before a second addition of Pd(PPh3)4 
(23 mg, 0.020 mmol) and heating under reflux for a further 5 days, after which time 
solvent was removed in vacuo. The resulting solid was taken up in water (5 mL) and 
CHCl2 (5 mL) before filtering to remove insoluble denatured catalyst and residual 
starting material. The organic layer was washed with brine (3 × 5 mL) and the 
combined backaqueous layers washed with CHCl2 (5 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated in vacuo. The crude product 
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(72 mg) was purified by flash column chromatography, eluting with 
methanol/triethylamine/ethyl acetate (2.5:5:92.5) to yield 0-methyl-0-(2-(pyridin-4-
yl)benzyl)amine 100 (16 mg, 11%) as a yellow-orange oil. The product was not 
successfully obtained in high purity. Rf 0.17 (methanol/triethylamine/ethyl acetate 
2.5:5:92.5); vmax (NaCl plates)/cm
-1: 3399 (b, N–H stretch), 2922 (s), 1642 (s), 1407 
(s), 767 (s, o-subst. Ar); 1H NMR (400 MHz; CDCl3): δ 8.66 (2H, d, J 5.1, H-2), 
7.52–7.23 (6H, m, H-3, H-6, H-7, H-8 and H-9), 3.67 (2H, s, CH2-11) and 2.37 (3H, 
s, CH3-13); 
13C NMR (400 MHz; CDCl3): δ 149.6 (CH-2), 149.1 (C-4), 139.1 (C), 
137.0 (C), 129.5 (CH), 129.4 (CH), 128.6 (CH), 127.3 (CH), 124.2 (CH-3), 53.1 
(CH2-11) and 36.0 (CH3-13); HRMS m/z (ESI
+) [Found: (M+H)+ 199.1230. 
C13H15N2 requires M
+, 199.1230]; m/z (ESI+) 118.12 ([M–80]+, 100%), 199.12 
([M+H]+, 53%), 235.27 ([M+2H2O+H]







3-Pyridinylboronic acid (92 mg, 0.76 mmol), 2-bromo-0-methylbenzylamine 
(180 mg, 133 µL, 0.76 mmol) and sodium carbonate (239 mg, 2.25 mmol) were 
added to a reaction tube. Toluene (7.5 mL), ethanol (2.5 mL) and water (0.75 mL) 
were transferred to the reaction tube via cannula under a positive pressure of Ar, 
followed by the addition of Pd(PPh3)4 (43 mg, 0.037 mmol). The reaction mixture 
was heated to 110ºC under reflux for 48 h before a second addition of Pd(PPh3)4 
(23 mg, 0.020 mmol) and heated under reflux for a further 5 days, after which time 
solvent was removed in vacuo. The resulting solid was taken up in water (5 mL) and 
CH2Cl2 (5 mL). The organic layer was washed with brine (2 × 5 mL) and the 
combined aqueous layers backwashed with CH2Cl2 (5 mL). The combined organic 
layers were dried over MgSO4, filtered and concentrated in vacuo. The crude product 
(67 mg) was purified by flash column chromatography, eluting with 
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methanol/triethylamine/ethyl acetate (2.5:5:92.5) to yield 0-methyl-0-(2-(pyridin-3-
yl)benzyl)amine 101 (28 mg, 19%) as a yellow-orange oil: Rf 0.19 
(methanol/triethylamine/ethyl acetate 2.5:5:92.5); vmax (NaCl plates)/cm
-1: 3305, (w, 
N–H stretch), 3027 (m, Ar–H stretch), 2930 (m, C–H stretch), 2848 (m, C–H 
stretch), 1565 (s, N–H bend), 813 (s, m-subst. Ar), 760 (s, o-subst. Ar); 1H NMR 
(400 MHz; CDCl3): δ 8.64 (H, d, J 1.8, H-2), 8.62 (1H, dd, J 4.6, 1.9, H-6), 7.76 (1H, 
ddd, J 7.8, 1.9, 1.8, H-4), 7.52 (1H, dd, J 7.5, 1.0, H-11), 7.42–7.33 (3H, m, H-5, H-9 
and H-10), 7.26 (1H, dd, J 7.5, 1.5, H-8), 3.67 (2H, s, CH2-13) and 2.36 (3H, s, CH3-
15); 13C NMR (400 MHz; CDCl3): δ 149.8 (CH-2), 148.4 (CH-6), 138.0 (C), 137.7 
(C), 136.8 (C), 136.5 (CH-4), 130.2 (CH-11), 129.3 (CH-8), 128.3 (CH), 127.2 (CH), 
123.0 (CH-5), 53.2 (CH2-13) and 36.1 (CH3-15); HRMS m/z (ESI
+) [Found: (M+H)+ 
199.1231. C13H15N2 requires M
+, 199.1230]; m/z (ESI+) 199.12 ([M+H]+, 100%); 








4-Pyridinylboronic acid (92 mg, 0.76 mmol), 4-bromo-0-methylbenzylamine 
(180 mg, 180 µL, 0.90 mmol) and sodium carbonate (239 mg, 2.25 mmol) were 
added to a reaction tube. Toluene (7.5 mL), ethanol (2.5 mL) and water (0.75 mL) 
were transferred to the reaction tube via cannula under a positive pressure of Ar, 
followed by the addition of Pd(PPh3)4 (43 mg, 0.037 mmol). The reaction mixture 
was heated under reflux for 20 h, after which time solvent was removed in vacuo and 
the resulting residue partitioned between water (5 mL) and CH2Cl2 (5 mL). The 
organic layer was washed with brine (3 × 5 mL) and the combined aqueous layers 
backwashed with CH2Cl2 (10 mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. The crude product (209 mg) was purified 
by flash column chromatography, eluting with methanol/triethylamine/ethyl acetate 
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(2.5:5:92.5) to yield 0-methyl-0-(4-(pyridin-4-yl)benzyl)amine 102 (124 mg, 83%) 
as a yellow-orange oil: Rf 0.15 (methanol/triethylamine/ethyl acetate 2.5:5:92.5); vmax 
(NaCl plates)/cm-1: 3306 (m, N–H stretch), 3030 (w, Ar–H stretch), 2850 (m, C–H 
stretch), 2780 (m, C–H stretch), 1599 (s, Ar), 1542 (w, N–H bend), 1489 (m), 1404 
(m), 803 (s, p-subst, Ar); 1H NMR (400 MHz; CDCl3): δ 8.62 (2H, d, J 4.9, H-2), 
7.62 (2H, d, J 7.9, H-6), 7.48 (2H, d, J 4.9, H-3), 7.43 (2H, d, J 7.9, H-7), 3.85 (2H, 
s, CH2-9) and 2.50 (3H, s, CH3-11); 
13C NMR (100 MHz; CDCl3): δ 150.2 (CH-2), 
148.0 (C-4), 141.1 (C), 136.8 (C), 128.9 (CH), 127.0 (CH), 121.5 (CH), 55.5 (CH2-9) 
and 35.9 (CH3-11); HRMS m/z (ESI
+) [Found: (M+H)+ 199.1230. C13H15N2 requires 
M+, 199.1230]; m/z (ESI+) 199.14 ([M+H]+,15%), 322.14 ([M+C5H4H+2Na]
+, 95%), 
520.26 ([2M+ C5H4H+2Na], 100%); Anal. Calcd for C13H14N2: C, 78.75; H, 7.12; N, 







3-Pyridinylboronic acid (92 mg, 0.75 mmol), 4-bromo-0-methylbenzylamine 
(180 mg, 180 µL, 0.90 mmol) and sodium carbonate (239 mg, 2.25 mmol) were 
added to a reaction tube. Toluene (7.5 mL), ethanol (2.5 mL) and water (0.75 mL) 
were transferred to the reaction tube via cannula under a positive pressure of Ar, 
followed by the addition of Pd(PPh3)4 (43 mg, 0.037 mmol). The reaction mixture 
was heated under reflux for 20 h, after which time solvent was removed in vacuo and 
the resulting solid dissolved in water (5 mL) and ethyl acetate (5 mL). The organic 
layer was washed with brine (3 × 5 mL) and the combined aqueous layers 
backwashed with ethyl acetate (5 mL). The combined organic layers were dried over 
MgSO4, filtered and concentrated in vacuo. The crude product (159 mg) was purified 
by flash column chromatography, eluting with methanol/triethylamine/ethyl acetate 
(1:1:18) to yield 0-methyl-0-(4-(pyridin-3-yl)benzyl)amine 103 (107 mg, 73%) as a 
yellow-orange viscous oil: Rf 0.15 (methanol/triethylamine/ethyl acetate 1:1:18); vmax 
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(NaCl plates)/cm-1: 3310 (m, N–H stretch), 3030 (m, Ar–H stretch), 2934 (w, C–H 
stretch), 2848 (w, C–H stretch), 1561 (w, N–H bend), 1449 (s), 849 (m, p-subst. Ar), 
798 (s, m-subst. Ar), 712 (s); 1H NMR (400 MHz; CDCl3): δ 8.81 (1H, s, H-2), 8.55 
(1H, d, J 5.0, H-6), 7.86–7.80 (1H, m, H-4), 7.52 (2H, d, J 7.7, H-8), 7.41 (2H, d, J 
7.7, H-9), 7.32 (1H, dd, J 7.7 and 5.0, H-5), 3.79 (2H, s, CH2-11) and 2.46 (3H, s, 
CH3-13); 
13C NMR (100 MHz; CDCl3): δ 148.3 (CH-6), 148.2 (C-2), 140.0 (C), 
136.5 (C), 136.3 (C), 134.2 (CH-4), 128.9 (CH-9), 127.1 (CH-8), 123.5 (CH-5), 55.5 
(CH2-11) and 35.9 (CH3-13); HRMS m/z (ESI
+) [Found: (M+H)+ 199.1230. 
C13H15N2 requires M
+, 199.1230]; m/z (ESI+) Found: 199.11 ([M+H]+, 10%), 322.13 
([M+ C5H4H+2Na–H]
+, 99%), 520.24 ([2M+C5H4H+2Na–H]
+, 100%), 643.28 
([3M+NHCH3+H3O], 72%); Anal. Calcd for C13H14N2: C, 78.75; H, 7.12; N, 14.13. 
Found: C, 75.89; H, 6.99; N, 14.22.  
 
 



















0-Methyl-0-(3-(pyridin-4-yl)benzyl)amine (73) (51 mg, 0.26 mmol) was dissolved 
in formic acid (1 mL). Formaldehyde (36.5% aq. solution, 40 µL, 0.51 mmol) was 
added and the reaction mixture heated under reflux for 2 h. After cooling to room 
temperature, the reaction mixture was transferred to a separating funnel, the pH 
adjusted to >11 by the addition of 4 M NaOH (5 mL) and extracted into CH2Cl2 (6 × 
10 mL). The organic phases were dried over MgSO4, filtered, concentrated in vacuo 
and combined to afford the crude product, which was purified by flash column 
chromatography, eluting with methanol/triethylamine/ethyl acetate (1:1:48) to yield 
0,0-dimethyl-0-(3-(pyridin-4-yl)benzyl)amine 104 (39 mg, 72%) as a pale brown oil: 
Rf 0.21 (methanol/triethylamine/ethyl acetate 1:1:48); vmax (NaCl plates)/cm
-1: 3025 
(w, Ar–H stretch), 2944 (m), 2816 (m, NC–H stretch), 2772 (m) 1595 (s, Ar), 1407 
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(m), 1030 (m), 830.0 (m, p-subst. Ar), 787 (s, m-subst. Ar), 700 (m), 615 (m); 1H 
NMR (400 MHz; CDCl3): δ 8.63 (2H, dd, J 4.5,1.7, H-2), 7.61 (1H, s, H-10), 7.58–
7.51 (3H, m, H-3 and H-6), 7.50–7.37 (2H, m, H-7 and H-8), 3.51 (2H, s, CH2-11) 
and 2.28 (6H, s, CH3-13); 
13C NMR (100 MHz; CDCl3): δ 150.2 (CH-2), 148.2 (C), 
139.6 (C), 138.2 (C), 129.8 (CH), 129.1 (CH), 127.6 (CH), 125.8 (CH), 121.7 (CH-
3), 64.1 (CH2-11), 45.3 (CH3) and 45.2 (CH3); HRMS m/z (ESI
+) [Found: (M+H)+ 
213.1384. C14H17N2 requires M
+, 213.1386]; m/z (ESI+) 213.12 ([M+H]+, 73%), 
336.14 ([M+C5H4H+2Na]
+, 95%), 358.14 ([M+C5H4N–2H+3Na]
+, 87%), 548.23 
([2M+C5H4H+2Na], 100%), 693.26 ([3M+H2O+K]
+, 100%); Anal. Calcd for 







0-Methyl-0-(3-(pyridin-3-yl)benzyl)amine (74) (51 mg, 0.26 mmol) was dissolved 
in formic acid (1 mL). Formaldehyde (36.5% aq. solution, 40 µL, 0.51 mmol) was 
added and the reaction mixture heated under reflux for 2.5 h. After cooling to room 
temperature, the reaction mixture was transferred to a separating funnel, the pH 
adjusted to >11 by the addition of 4 M NaOH (5 mL) and extracted into ethyl acetate 
(2 × 8 mL) and CH2Cl2 (3 × 10 mL). The organic phases were dried over MgSO4, 
filtered, concentrated in vacuo and combined to afford the crude product, which was 
purified by flash column chromatography, eluting with methanol/triethylamine/ethyl 
acetate (1:1:48) to yield 0,0-dimethyl-0-(3-(pyridin-3-yl)benzyl)amine 105 (42 mg, 
77%) as a pale brown oil: Rf 0.19 (methanol/triethylamine/ethyl acetate 1:1:48); vmax 
(NaCl plates)/cm-1: 3040 (w, Ar–H stretch), 2808 (m, NC–H stretch), 2772 (s), 785 
(s, m-subst. Ar), 712 (s); 1H NMR (400 MHz; CDCl3): δ 8.85 (1H, s, H-2), 8.56 (1H, 
d, J 4.6, H-6), 7.87 (1H, d, J 7.9, H-4), 7.53 (1H, s, H-12), 7.49–7.38 (2H, m, H-8 
and H-9), 7.36–7.30 (2H, m, H-5 and H-10), 3.49 (2H, s, CH2-13) and 2.27 (6H, s, 
CH3-15); 
13C NMR (100 MHz; CDCl3): δ 148.4 (CH-6), 148.3 (CH-2), 139.8 (C), 
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137.8 (C), 136.5 (C), 129.0 (CH), 128.8 (CH), 127.8 (CH), 125.9 (CH), 123.4 (CH-
5), 64.2 (CH2-13), 45.4 (CH3) and 45.3 (CH3); HRMS m/z (ESI
+) [Found: (M+H)+ 
123.1384. C14H17N2 requires M
+, 213.1386]; m/z (ESI+) 213.25 ([M+H]+, 100%); 








0-Methyl-0-(4-(pyridin-4-yl)benzyl)amine (102) (53 mg, 0.27 mmol) was dissolved 
in formic acid (1 mL). Formaldehyde (36.5% aq. solution, 40 µL, 0.51 mmol) was 
added and the reaction mixture heated under reflux for 3 h. After cooling to room 
temperature, the reaction mixture was transferred to a separating funnel, the pH 
adjusted to >11 by the addition of 4 M NaOH (5 mL) and extracted into CH2Cl2 (6 × 
7 mL). The organic phases were combined, dried over MgSO4, filtered and 
concentrated in vacuo to give the crude product, which was purified by flash column 
chromatography, eluting with methanol/triethylamine/ethyl acetate (1:1:48) to yield 
0,0-dimethyl-0-(4-(pyridin-4-yl)benzyl)amine 106 (30 mg, 55%) as a pale brown-
orange oil: Rf 0.26 (methanol/triethylamine/ethyl acetate 1:1:48); vmax (NaCl 
plates)/cm-1: 3025 (w, Ar–H stretch), 2745 (m), 1580 (s), 801 (s, p-subst. Ar); 
1H NMR (400 MHz; CDCl3): δ 8.66 (2H, d, J 4.6, H-2), 7.62 (2H, d, J 8.3, H-6), 
7.52 (2H, d, J 4.6, H-3), 7.44 (2H, d, J 8.3, H-7), 3.49 (2H, s, CH2-9) and 2.28 (6H, s, 
CH3-11); 
13C NMR (100 MHz; CDCl3): δ 150.2 (CH-2), 148.1 (C), 140.0 (C), 136.8 
(C), 129.8 (CH), 126.6 (CH), 121.5 (CH-3), 63.9 (CH2-9) and 45.4 (CH3-11); HRMS 
m/z (ESI+) [Found: (M+H)+ 213.1385. C14H17N2 requires M
+, 213.1386]; m/z (ESI+) 




+, 100%), 693.31 ([3M+H2O+K]
+, 17%); Anal. Calcd for 
C14H16N2: C, 79.21; H, 7.60; N, 13.20. Found: C, 79.32; H, 7.49; N, 13.10.  






0-Methyl-0-(4-(pyridin-3-yl)benzyl)amine (103) (51 mg, 0.26 mmol) was dissolved 
in formic acid (1 mL). Formaldehyde (36.5% aq. solution, 40 µL, 0.51 mmol) was 
added and the reaction mixture heated under reflux for 2 h. After cooling to room 
temperature, the reaction mixture was transferred to a separating funnel, the pH 
adjusted to >11 by the addition of 4 M NaOH (5 mL) and extracted into CH2Cl2 (6 × 
7 mL). The organic phases were combined, dried over MgSO4, filtered and 
concentrated in vacuo to give the crude product, which was purified by flash column 
chromatography, eluting with methanol/triethylamine/ethyl acetate (1:1:48) to yield 
0,0-dimethyl-0-(4-(pyridin-3-yl)benzyl)amine 107 (42 mg, 77%) as a pale brown oil: 
Rf 0.23 (methanol/triethylamine/ethyl acetate 1:1:48); vmax (NaCl plates)/cm
-1: 3020 
(w, Ar–H stretch), 2815 (m, CN–H stretch), 2774 (m), 1473 (m), 1363 (m), 1021 
(m), 961 (m, p-subst. Ar), 796 (s, m-subst. Ar), 712 (m); 1H NMR (400 MHz; 
CDCl3): δ 8.86–8.81 (1H, m, H-2), 8.56 (1H, d, J 4.5, H-6), 7.86 (1H, ddd, J 7.9, 1.4, 
1.4, H-4), 7.53 (2H, d, J 8.1, H-8), 7.41 (2H, d, J 8.1, H-9), 7.36 (1H, dd, J 7.9, 4.5, 
H-5), 3.49 (2H, s, CH2-11) and 2.29 (6H, s, CH3-13); 
13C NMR (100 MHz; CDCl3): 
δ 148.3 (CH-6), 148.2 (CH-2), 138.8 (C), 136.6 (C), 136.4 (C), 134.2 (CH), 129.8 
(CH), 127.0 (CH), 123.5 (CH-5), 63.9 (CH2-11) and 45.3 (CH3-13); HRMS m/z 
(ESI+) [Found; (M+H)+ 213.1388. C14H17N2 requires M
+, 213.1386]; m/z (ESI+) 
213.13 ([M+H]+, 56%), 336.16 ([M+C5H4H+2Na]
+, 66%), 358 ([M+C5H4N–
2H+3Na]+, 55%), 453.15 ([2M+C2H5])
+, 42%), 548.29 ([2M+C5H4H+2Na]
+, 100%), 
693.30 ([3M+H2O+K]
+, 80%); Anal. Calcd for C14H16N2: C, 79.21; H, 7.60; N, 
13.20. Found: C, 79.16; H, 7.46; N, 13.06.  
 
 






3-Bromobenzyl alcohol (468 mg, 300 µL, 2.50 mmol) was stirred in THF (6 mL) and 
heated to 30 °C under an atmosphere of Ar. Potassium hydroxide (423 mg, 
7.54 mmol) and dimethyl sulfate (480 mg, 360 µL, 3.80 mmol) were added with 
stirring and the reaction mixture heated under reflux for 16 h, after which time 
solvent was removed in vacuo and the residue partitioned between water (10 mL) 
and Et2O (10 mL). The organic layer was washed with brine (2 × 5 mL) and the 
combined aqueous layers backwashed with Et2O. The combined organic layers were 
dried over MgSO4, filtered and concentrated in vacuo. Purification by flash column 
chromatography, eluting with ethyl acetate/petroleum ether (1:70), afforded 1-
bromo-3-(methoxymethyl)benzene 113 (339 mg, 67%) as a colourless oil: Rf 0.68 
(ethyl acetate/petroleum ether 1:9); 1H NMR (400 MHz; CDCl3): δ 7.52–7.52 (1H, 
m, H-2), 7.43 (1H, ddd, J 7.6, 1.6, 1.6, H-4), 7.27-7.20 (2H, m, H-5 and H-6), 4.43 
(2H, s, CH2-7) and 3.40 (3H, s, CH3-9); 
13C NMR (100 MHz; CDCl3): δ 140.6 (C-1), 
130.7 (CH), 130.6 (CH), 130.0 (CH), 126.0 (CH-6), 122.5 (CBr-3), 73.8 (CH2-7) and 
58.3 (CH3-9); m/z (FI
+) 199.98 (M+ [79Br], 100%), 201.98 (M+ [81Br], 93%). These 







4-Pyridinylboronic acid (92 mg, 0.75 mmol), 1-bromo-3-(methoxymethyl)benzene 
(113) (151 mg, 0.75 mmol) and sodium carbonate (239 mg, 2.25 mmol) were added 
to a reaction tube. Toluene (7 mL), ethanol (2 mL) and water (0.75 mL) were 
transferred to the reaction tube via cannula under a positive pressure of Ar, followed 
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by the addition of Pd(PPh3)4 (43 mg, 0.037 mmol). The reaction mixture was heated 
under reflux for 20 h, after which time solvent was removed in vacuo and the 
resulting residue partitioned between water (5 mL) and CH2Cl2 (5 mL) The organic 
layer was washed with brine (2 × 5 mL) and the combined aqueous layers washed 
with CH2Cl2 (10 mL). The combined organic layers were dried over MgSO4, filtered 
and concentrated in vacuo. The crude product (161 mg) was purified by flash column 
chromatography, eluting with ethyl acetate/petroleum ether (1:2) to yield 4-(3-
(methoxymethyl)phenyl)pyridine 108 (99 mg, 66%) as a pale yellow oil: Rf 0.16 
(ethyl acetate/petroleum ether 1:2); vmax (NaCl plates)/cm
-1: 2927 (m), 2822 (m, C–
O–CH3, C–H stretch), 1596 (s), 1408 (m), 1194 (m), 1103 (s, C–O–C stretch), 789 
(s); 1H NMR (400 MHz; CDCl3): δ 8.66 (2H, d, J 5.3, H-2), 7.63 (1H, s, H-10), 
7.58–7.53 (3H, m, H-3 and H-6), 7.48 (1H, dd, J 7.6, 7.6, H-7), 7.41 (1H, d, J 7.6, 
H-8), 4.54 (2H, s, CH2-11) and 3.45 (3H, s, CH3-13); 
13C NMR (100 MHz; CDCl3): 
δ 150.2 (CH-2), 148.2 (C-4), 139.3 (C), 138.3 (C), 129.2 (CH), 128.3 (CH), 126.3 
(CH), 126.2 (CH), 121.7 (CH-3), 74.4 (CH2-11) and 58.3 (CH3-13); HRMS m/z 
(ESI+) [Found: (M+H)+ 200.1071. C13H14NO requires M
+, 200.1070]; m/z (ESI+) 
200.11 ([M+H]+, 100 %); Anal. Calcd for C13H13NO: C, 78.36; H, 6.58; N, 7.03. 







3-Pyridinylboronic acid (92 mg, 0.75 mmol), 1-bromo-3-(methoxymethyl)benzene 
113 (151 mg, 0.75 mmol) and sodium carbonate (239 mg, 2.25 mmol) were added to 
a reaction tube. Toluene (7 mL), ethanol (2 mL) and water (0.75 mL) were 
transferred to the reaction tube via cannula under a positive pressure of Ar, followed 
by the addition of Pd(PPh3)4 (43 mg, 0.037 mmol). The reaction mixture was heated 
to 110ºC and heated under reflux for 20 h, after which time solvent was removed in 
vacuo and the resulting solid taken up in water (5 mL) and CH2Cl2 (5 mL). The 
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organic layer was washed with brine (2 × 5 mL) and the combined aqueous layers 
washed with CH2Cl2 (10 mL). The combined organic layers were dried over MgSO4, 
filtered and concentrated in vacuo. The crude product (157 mg) was purified by flash 
column chromatography, eluting with ethyl acetate/petroleum ether (2:5) to yield 3-
(3-(methoxymethyl)phenyl)pyridine 109 (90 mg, 60%) as a pale yellow oil: Rf 0.21 
(ethyl acetate/petroleum ether 2:5); vmax (NaCl plates)/cm
-1: 2890 (m), 2821 (m, C–
O–CH3, C–H stretch), 1470 (m), 1403 (m), 1188 (s), 1105 (C–O–C stretch), 815 (s), 
739 (s); 1H NMR (400 MHz; CDCl3): δ 8.86 (1H, d, J 2.0, H-2), 8.60 (1H, dd, J 4.8, 
2.0, H-6), 7.89 (1H, ddd, J 7.9, 2.0, 2.0, H-4), 7.59–7.56 (1H, m, H-12), 7.52 (1H, 
ddd, J 7.6, 1.4, 1.4, H-8), 7.47 (1H, dd, J 7.6, 7.6, H-9), 7.39–7.35 (2H, m, H-5 and 
H-10), 4.54 (2H, s, CH2-13) and 3.44 (3H, s, CH3-15); 
13C NMR (100 MHz; CDCl3): 
δ 148.5 (CH-6), 148.3 (CH-2), 139.2 (C), 138.0 (C), 136.5 (C), 134.4 (CH), 129.1 
(CH), 127.3 (CH), 126.4 (CH), 126.4 (CH), 123.5 (CH-5), 74.5 (CH2-13) and 58.3 
(CH3-15); HRMS m/z (ESI
+) [Found: (M+H)+ 200.1069. C13H14NO requires M
+, 
200.1070]; m/z (ESI+) 200.11 ([M+H]+, 100%); Anal. Calcd for C13H13NO: C, 78.36; 





















Phenylboronic acid (91 mg, 0.75 mmol), 3-bromo-0-methylbenzylamine (180 mg, 
123 µL, 0.90 mmol) and sodium carbonate (239 mg, 2.25 mmol) were added to a 
reaction tube. Toluene (7 mL), ethanol (2 mL) and water (0.75 mL) were transferred 
to the reaction tube via cannula under a positive pressure of Ar, followed by the 
addition of Pd(PPh3)4 (43 mg, 0.037 mmol). The reaction mixture was heated under 
reflux for 20 h, after which time solvent was removed in vacuo and the resulting 
residue partitioned between water (5 mL) and CH2Cl2 (5 mL). The organic layer was 
washed with brine (2 × 5 mL) and the combined aqueous layers washed with CH2Cl2 
(10 mL). The combined organic layers were dried over MgSO4, filtered and 
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concentrated in vacuo. The crude product (180 mg) was purified by flash column 
chromatography, eluting with methanol/triethylamine/ethyl acetate (1:1:48) to yield 
0-methyl-0-(3-phenylbenzyl)amine 110 (122 mg, 82%) as a pale yellow oil: Rf 0.19 
(methanol/triethylamine/ethyl acetate 1:1:48); vmax (NaCl plates)/cm
-1 3307 (w, N–H 
stretch), 3032 (m, Ar–H stretch), 2790 (m), 1599 (m, Ar), 1479 (s) 798 (m, m-subst. 
Ar), 756 (s, mono-subst. Ar), 700 (s, mono-subst. Ar); 1H NMR (400 MHz; CDCl3): 
δ 7.63–7.60 (2H, m, H-3), 7.56 (1H, s, H-10), 7.51–7.31 (6H, m, H-1, H-2, H-6, H-7 
and H-8), 3.83 (2H, s, CH2-11) and 2.50 (3H, s, CH3-13); 
13C NMR (100 MHz; 
CDCl3): δ 141.4 (C), 141.1 (C), 140.6 (C), 128.8 (CH), 128.7 (CH), 127.3 (CH), 
127.2 (CH), 127.1 (CH), 127.0 (CH), 125.8 (CH), 56.1 (CH2-11) and 36.1 (CH3-13); 
HRMS m/z (ESI+) [Found: (M+H)+ 198.1278. C14H16N requires M
+, 198.1277]; m/z 
(ESI+) 198.12 ([M+H]+, 100 %); Anal. Calcd for C14H15N: C, 85.24; H, 7.66; N, 



















Phenylboronic acid (91 mg, 0.75 mmol), 4-bromo-0-methylbenzylamine (150 mg, 
150 µL, 0.75 mmol), sodium carbonate (239 mg, 2.25 mmol) and Pd(PPh3)4 (43 mg, 
0.037 mmol) were added to a reaction tube. Toluene (7 mL), ethanol (2 mL) and 
water (0.75 mL) were transferred to the reaction tube via cannula under a positive 
pressure of Ar. The reaction mixture was heated under reflux for 19 h, after which 
time solvent was removed in vacuo and the resulting residue partitioned between 
water (5 mL) and CH2Cl2 (5 mL). The organic layer was washed with brine (2 × 
5 mL) and the combined aqueous layers backwashed with CH2Cl2 (10 mL). The 
combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. 
The crude product (179 mg) was purified by flash column chromatography, eluting 
with methanol/triethylamine/ethyl acetate (1:1:48) to yield 0-methyl-0-(4-
phenylbenzyl)amine 111 (113 mg, 76%) as a pale yellow oil. Proton NMR indicated 
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purity of ~95%, with the presence of ~5% starting alkylbromide, which could not be 
separated from the product using chromatography. NMR peaks assigned below are 
for the product only. Rf 0.43 (methanol/triethylamine/ethyl acetate 1:1:18); vmax 
(NaCl plates)/cm-1 3323 (m, N–H stretch), 3028 (m, Ar–H stretch), 2932 (m, HC–H 
stretch), 2790 (m, NC–H stretch), 1600 (w, Ar), 1487 (s, Ar), 819 (m, p-subst. Ar), 
760 (s), 736 (m, mono-subst. Ar), 697 (s, mono-subst. Ar); 1H NMR (400 MHz; 
CDCl3): δ 7.64–7.54 (4H, m, H-3 and H-6), 7.48–7.32 (5H, m, H-1, H-2 and H-7), 
3.81 (2H, s, CH2-9) and 2.50 (3H, s, CH3-11); 
13C NMR (100 MHz; CDCl3): δ 141.0 
(C), 139.9 (C), 139.2 (C), 128.7 (CH), 128.6 (CH), 127.2 (CH), 127.1 (CH), 127.1 
(CH), 55.7 (CH2-9), 36.1 (CH3-13); HRMS m/z (ESI
+) [Found: (M+Na)+ 198.1278. 
C14H16N requires M
+, 198.1277]; m/z (ESI+) 167.08 ([M–NHCH3]
+, 100%), 198.15 
([M+H]+, 76%); Anal. Calcd for C14H15N: C, 85.24; H, 7.66; N, 7.10. Found: C, 
85.25; H, 7.68; N, 7.03.  
 
 






3,5-Dimethylisoxazole-4-boronic acid (105 mg, 0.75 mmol), 3-bromo-0-
methylbenzylamine (253 mg, 180 µL, 1.26 mmol), sodium carbonate (239 mg, 
2.25 mmol) and Pd(PPh3)4 (43 mg, 0.037 mmol) were added to a reaction tube. 
Toluene (7 mL), ethanol (2 mL) and water (0.75 mL) were transferred via cannula 
under positive pressure of Ar. The reaction mixture was heated under reflux for 19 h, 
after which time solvent was removed in vacuo and the resulting residue partitioned 
between water (5 mL) and CH2Cl2 (5 mL). The organic layer was washed with brine 
(2 × 5 mL) and dried over MgSO4, filtered and concentrated in vacuo. The crude 
product (220 mg) was purified by flash column chromatography, eluting with 
methanol/triethylamine/ethyl acetate (2:2.5:95.5) to yield 0-methyl-0-(3-(3,5-
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dimethylisoxazol-4-yl)benzyl)amine 115 (85 mg, 52%) as a pale yellow oil: Rf 0.32 
(methanol/triethylamine/ethyl acetate 3:3:94); vmax (NaCl plates)/cm
-1: 3317 (w, N–H 
stretch). 2929 (m, H2C–H stretch), 2851 (m, H2C–H stretch), 1632 (s), 1584 (w, Ar), 
1295 (s), 1244 (s), 798 (s, m-subst. Ar), 708 (s); 1H NMR (400 MHz; CDCl3): δ 7.41 
(1H, dd, J 7.6 and 7.6, H-8), 7.32 (1H, d, J 7.6, H-7), 7.22 (1H, s, H-11), 7.15 (1H, d, 
J 7.6, H-9), 3.80 (2H, s, CH2-12), 2.49 (3H, s, CH3), 2.41 (3H, s, CH3) and 2.30 (3H, 
s, CH3); 
13C NMR (100 MHz; CDCl3): δ 165.1 (C), 158.7 (C), 140.7 (C), 130.5 (C), 
128.3 (CH-8), 128.3 (CH-11), 127.7 (CH-7), 127.4 (CH-9), 116.6 (C), 55.8 
(CH2-12), 36.0 (CH3-14), 11.6 (CH3) and 10.8 (CH3); HRMS m/z (ESI
+) [Found: 
(M+H)+ 217.1136. C13H17N2O requires M
+, 217.1135]; m/z (ESI+) 217.14 ([M+H]+, 
100%); Anal. Calcd for C13H16N2O: C, 72.19; H, 7.46; N, 12.95. Found: C, 72.03; H, 







Pyrimidine-5-boronic acid hemihydrate (100 mg, 0.75 mmol), 3-bromo-0-
methylbenzylamine (253 mg, 180 µL, 1.26 mmol), sodium carbonate (239 mg, 
2.25 mmol) and Pd(PPh3)4 (43 mg, 0.037 mmol) were added to a reaction tube. 
Toluene (7 mL), ethanol (2 mL) and water (0.75 mL) were transferred via cannula 
under positive pressure of Ar. The reaction mixture was heated under reflux for 19 h, 
after which time solvent was removed in vacuo and the resulting residue partitioned 
between water (5 mL) and CH2Cl2 (5 mL). The organic layer was washed with brine 
(2 × 5 mL) and dried over MgSO4, filtered and concentrated in vacuo. The crude 
product (262 mg) was purified by flash column chromatography, eluting with 
methanol/triethylamine/ethyl acetate (1:1:18) to yield 0-methyl-0-(3-(pyrimidin-5-
yl)benzyl)amine 116 (110 mg, 74%) as a pale yellow oil: Rf 0.39 
(methanol/triethylamine/ethyl acetate 1:1:18); vmax (NaCl plates)/cm
-1: 3039 (m, Ar–
H stretch), 1557 (s), 1417 (s), 796 (s, m-subst. Ar), 725 (s), 703 (s); 1H NMR 
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(400 MHz; CDCl3): δ 9.21 (1H, s, H-1), 8.97 (2H, s, H-3), 7.57 (1H, s, H-10), 7.50–
7.42 (3H, m, H-6, H-7 and H-8), 3.86 (2H, s, CH2-11) and 2.51 (3H, s, CH3-13); 
13C NMR (100 MHz; CDCl3): δ 157.4 (CH-1), 154.9 (CH-3), 141.4 (C), 134.4 (C), 
134.3 (C), 129.5 (CH), 128.8 (CH), 126.8 (CH-10), 125.7 (CH), 55.7 (CH2-11) and 
36.0 (CH3-15); HRMS m/z (ESI
+) [Found: (M+H)+ 200.1182. C12H14N3 requires M
+, 
200.1182]; m/z (ESI+) 200.13 ([M+H]+, 42%), 322.16 ([M+123]+, 100%), 299.29 
([2M+H]+, 25%); Anal. Calcd for C12H13N3: C, 72.33; H, 6.58, N, 21.09. Found: C, 







1H-Pyrazole-4-boronic acid pinacol ester (146 mg, 0.75 mmol), 3-bromo-0-
methylbenzylamine (150 mg, 103 µL, 0.75 mmol), sodium carbonate (239 mg, 
2.25 mmol) and Pd(PPh3)4 (43 mg, 0.037 mmol) were added to a reaction tube. 
Dioxane (6 mL) and water (2 mL) were transferred via cannula under positive 
pressure of Ar. The reaction mixture was heated under reflux for 20 h, after which 
time solvent was removed in vacuo and the resulting residue partitioned between 
water (5 mL) and CH2Cl2 (5 mL). The organic layer was washed with brine 
(2 × 5 mL) and dried over MgSO4, filtered and concentrated in vacuo. The crude 
product (157 mg) was purified by flash column chromatography, eluting with 
methanol/triethylamine/ethyl acetate (1:1:18) to yield 0-methyl-3-(1H-pyrazol-4-
yl)benzyl)amine 117 (58 mg) as a pale yellow oil. Purification of this compound 
proved to be difficult by standard techniques due to insolubility and for this reason 
was not taken further. Rf 0.05 (methanol/triethylamine/ethyl acetate 1:1:18); 
1H NMR (400 MHz; CDCl3): δ 8.04–7.92 (2H, m, H-3 and H-5), 7.63 (1H, s, H-11), 
7.56 (1H, d, J 7.7, H-7), 7.39 (1H, dd, J 7.7, 7.7, H-8), 7.24 (1H, d, J 7.7, H-9), 3.88 
(2H, s, CH2-12) and 2.51 (3H, s, CH3-14); m/z (ESI
+) 188.13 ([M+H]+, 82%), 189.11 
([M+2]+, 100%). 






4-Pyridinylboronic acid (91 mg, 0.74 mmol), 3-bromo-0-methylaniline (140 mg, 
95 µL, 0.75 mmol), sodium carbonate (239 mg, 2.25 mmol) and Pd(PPh3)4 (39 mg, 
0.034 mmol) were added to a reaction tube. Toluene (7 mL), ethanol (2 mL) and 
water (0.75 mL) were transferred to the reaction tube via cannula under a positive 
pressure of Ar. The reaction mixture was heated under reflux for 17 h, after which 
time solvent was removed in vacuo and the resulting residue partitioned between 
water (5 mL) and CH2Cl2 (5 mL) The organic layer was washed with brine (2 × 
5 mL) and dried over MgSO4, filtered and concentrated in vacuo. The crude product 
(152 mg) was purified by flash column chromatography, eluting with ethyl 
acetate/petroleum ether (1:1) to yield 0-methyl-0-(3-(pyridin-4-yl)phenyl)amine 118 
(81 mg, 58%) as a pale yellow solid: Rf 0.22 (ethyl acetate/petroleum ether 1:1); mp 
105–107ºC (ethyl acetate); vmax (NaCl plates)/cm
-1: 3287 (s, N–H stretch), 3041 (w, 
Ar–H stretch), 1607 (s, Ar), 1593 (s, Ar), 845 (m, p-subst. Ar), 827 (m, m-subst. Ar); 
1H NMR (400 MHz; CDCl3): δ 8.64 (2H, d, J 4.9, H-2), 7.50 (1H, d, J 4.9, H-3), 
7.30 (1H, dd, J 7.8, 7.8, H-7), 6.97 (1H, ddd, J 7.8, 1.9, 0.8, H-6), 6.83 (1H, dd, J 
2.2, 1.9, H-10), 6.69 (1H, ddd, J 7.8, 2.2, 0.8, H-8), 3.91 (1H, bs, NH-11) and 2.91 
(3H, s, CH3-12); 
13C NMR (100 MHz; CDCl3): δ 150.1 (CH-2), 149.9 (C), 149.0 (C), 
139.2 (CH-5), 129.9 (CH-7), 121.7 (CH-3), 115.9 (CH-6), 113.1 (CH-8), 110.5 (CH-
10) and 30.7 (CH3-12); HRMS m/z (ESI
+) [Found: (M+H)+ 185.1073. C12H13N2 
requires M+, 185.1073]; m/z (ESI+) 185.11 ([M+H]+, 100 %); Anal. Calcd for 
C12H12N2: C, 78.21; H, 6.57; N, 15.21. Found: C, 78.34; H, 6.63; N, 15.27.  
 
 






3-Pyridinylboronic acid (93 mg, 0.76 mmol), 3-bromo-0-methylaniline (140 mg, 
95 µL, 0.75 mmol), sodium carbonate (239 mg, 2.25 mmol) and Pd(PPh3)4 (43 mg, 
0.037 mmol) were added to a reaction tube. Toluene (7 mL), ethanol (2 mL) and 
water (0.75 mL) were transferred to the reaction tube via cannula under a positive 
pressure of Ar. The reaction mixture was heated under reflux for 17 h, after which 
time solvent was removed in vacuo and the resulting residue partitioned between 
water (5 mL) and CH2Cl2 (5 mL) The organic layer was washed with brine (2 × 
5 mL) and dried over MgSO4, filtered and concentrated in vacuo. The crude product 
(145 mg) was purified by flash column chromatography, eluting with ethyl 
acetate/petroleum ether (1:2) to yield 0-methyl-0-(3-(pyridin-3-yl)phenyl)amine 119 
(68 mg, 49%) as a pale yellow oil: Rf 0.22 (ethyl acetate/petroleum ether 1:2); vmax 
(NaCl plates)/cm-1: 3314 (m, N–H stretch), 3032 (w, Ar-H), 1607 (s, Ar), 1590 (m, 
Ar), 810 (s, m-subst. Ar), 775 (s, m-subst. Ar); 1H NMR (400 MHz; CDCl3): δ 8.84 
(1H, d, J 2.3, H-2), 8.58 (1H, dd, J 4.8, 1.7, H-6), 7.87 (1H, ddd, J 7.9, 2.3, 1.7, H-4), 
7.35 (1H, dd, J 7.9, 4.8, H-5), 7.30 (1H, dd, J 7.8, 7.8, H-9), 6.92 (1H, ddd, J 7.8, 
2.0, 0.8, H-8), 6.79 (1H, dd, J 2.0, 2.0,  H-12), 6.67 (ddd, J 7.8, 2.0, 0.8, H-10), 3.91 
(1H, bs, NH-13) and 2.91 (3H, s, CH3-14); 
13C NMR (100 MHz; CDCl3): δ 149.9 
(C), 148.3 (CH-2), 148.3 (CH-6), 139.9 (C), 137.3 (C), 134.4 (CH-4), 129.9 (CH-9), 
123.4 (CH-5), 116.2 (CH-8), 112.2 (CH-10), 110.9 (CH-12) and 30.7 (CH3-14); 
HRMS m/z (ESI+) [Found: (M+H)+ 185.1074. C12H13N2 requires M
+, 185.1073]; m/z 
(ESI+) 185.11 ([M+H]+, 100%); Anal. Calcd for C12H12N2: C, 78.21; H, 6.57; N, 
15.21. Found: C, 78.31; H, 6.67; N, 15.16.  
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1,2,3,4-Tetrahydroisoquinoline (468 mg, 440 µL, 3.51 mmol) was added drop-wise 
with stirring to ice-cold sulfuric acid (5 mL). Potassium nitrate (390 mg, 3.86 mmol) 
was added portion-wise while cooling the reaction mixture on ice. The reaction 
mixture was then warmed to room temperature and stirred overnight before adding 
drop-wise to ice-cold conc. ammonia solution (22 mL), ensuring pH >11. The 
product was extracted with CHCl3 (4 × 20 mL), the combined organic phases washed 
with brine (30 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude 
product was dissolved in ethanol (2.5 mL) and precipitated out as the hydrochloride 
salt by addition of conc. hydrochloric acid. The salt was then filtered and washed 
with ethanol before crystallising from methanol to yield 7-nitro-1,2,3,4-
tetrahydroisoquinoline hydrochloride 129 (210 mg, 28%) as a colourless solid: mp 
190–204 ºC (deg., from methanol) [lit.166 260–262 °C (acetone)]; 1H NMR 
(400 MHz; DMSO): δ 9.78 (2H, bs, +NH2), 8.22 (1H, d, J 2.3, H-8), 8.11 (1H, dd, 
J 8.5, 2.3, H-6), 7.53 (1H, d, J 8.5, H-5), 4.39 (2H, s, CH2-1), 3.41–3.37 (2H, m, 
CH2-3) and 3.15 (2H, t, J 6.2, CH2-4); m/z (ESI
+) Found 179.09 ([M+H]+, 100%). 
These data are in good agreement with the literature values.166 
 
 




7-Nitro-1,2,3,4-tetrahydroisoquinoline hydrochloride (129) (853 mg, 3.97 mmol) 
was dissolved in water (32 mL). Tin (II) chloride (2.10 g, 11.1 mmol) was added, 
followed by conc. aqueous HCl solution (12 mL). The reaction mixture was heated 
under reflux for 18 h before addition of a further 1 eq. of SnCl2 (760 mg) and further 
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heating under reflux until TLC analysis showed consumption of starting material (2.5 
h). The pH of the reaction mixture was adjusted to pH >11 with 4 M NaOH solution 
(45 mL) and extracted with CHCl3 (5 × 50 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The crude product was purified by flash column 
chromatography, eluting with methanol/ triethylamine/ethyl acetate (1:1:18): 1H 
NMR (400 MHz; DMSO): δ 6.70 (1H, d, J 8.0, H-5), 6.34 (1H, dd, J 8.0, 1.9, H-6), 
6.21–6.17 (1H, m, H-8), 4.74 (2H, br s, NH2), 3.69 (2H, s, CH2-1) 2.87 (2H, t, J 5.8, 
CH2-3) and 2.53–2.48 (2H, m, CH2-4 [under solvent peak]); m/z (ESI
+) 149.10 ([M + 
H]+, 100%); m/z (ESI+) 149.10 ([M + H]+, 100%). The crude material was further 
purified by dissolving in ethanol and precipitated as the dihydrochloride salt to yield 
7-amino-1,2,3,4-tetrahydroisoquinoline dihydrochloride 130 (406 mg, 46%) as a 
beige coloured solid: mp 195–200ºC (dec., from methanol) [lit.166 290°C, dec., 
(acetone)]; 1H NMR (400 MHz; MeOD): δ 7.47 (1H, d, J 8.2, H-5), 7.38–7.33 (2H, 
m, H-6 and H-8), 4.47 (2H, s, CH2-1), 3.56 (2H, t, J 6.4, CH2-3) and 3.29 (2H, t, J 
6.4, CH2-4); m/z (ESI
+) 149.10 ([M+H]+, 100%). These data are in good agreement 







7-Amino-1,2,3,4-tetrahydroisoquinoline dihydrochloride (130) (384 mg, 1.74 mmol) 
was added to an ice-cold solution of HBr (48% aq. solution, 1.8 mL) in water (6 
mL). A solution of sodium nitrite (133 mg, 1.93 mmol) in water (3.3 mL) was added 
dropwise on ice, after which a positive starch-iodide test indicated excess HNO2, 
which was removed by addition of urea (40 mg). A solution of CuBr (750 mg, 5.23 
mmol, purified according to the literature procedure167) in HBr (48% aq. solution, 
6 mL) and water (9 mL) was warmed to 35°C and the diazotised solution added 
drop-wise with stirring. The reaction mixture was heated at 75°C for 1.5 h, during 
which time bubbles of gas were evoloved and the reaction mixture turned from 
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yellow-orange to red-brown. The pH of the reaction mixture was adjusted to pH >11 
with 4 M NaOH solution (12 mL), extracted with CH2Cl2 (3 × 20 mL), filtered and 
washed with saturated NaHCO3 solution (30 mL). The organic phase was dried over 
MgSO4, filtered and concentrated in vacuo to give the crude product, which was 
purified by flash column chromatography, eluting with methanol/triethylamine/ethyl 
acetate (2.5:2.5:95) to afford 7-bromo-1,2,3,4-tetrahydroisoquinoline 126 (155 mg, 
42%) as a viscous yellow oil: Rf 0.28 (methanol/triethylamine/ethyl acetate 
2.5:2.5:95); 1H NMR (400 MHz; CDCl3): δ 7.25 (1H, dd, J 8.2, 1.9, H-6), 7.17–7.15 
(1H, m, H-8), 6.96 (1H, d, J 8.2, H-5), 3.98 (2H, s, CH2-1), 3.12 (2H, t, J 5.9, CH2-3) 
and 2.73 (2H, t, J 5.9, CH2-4); m/z (ESI
+) 212.02 ([M+H]+, 79Br, 100%), 214.02 
([M+H]+, 81Br, 98%). These data are in good agreement with the literature values.168 
 
 
2.11.2.4 Fourth generation compounds 
 




1,2,3,4-Tetrahydroisoquinoline (106.4 mg, 100 µL, 0.80 mmol) was stirred in 
CH2Cl2 (2 mL) and 0-bromosuccinimide (157 mg, 0.88 mmol) added portion-wise 
over 5 min. The reaction mixture was stirred at room temperature until TLC analysis 
showed the complete consumption of starting material (2 h). Sodium hydroxide (4 M 
aq. solution, 0.5 mL) was added and the reaction mixture stirred for a further 1 h. 
The organic phase was separated, washed with water (1 mL) and extracted into acid 
(1 M HCl, 3 × 1 mL). The acid phase was washed with CH2Cl2 (1 mL), the pH 
adjusted to >11 with conc. ammonia solution and the product extracted back into 
CH2Cl2 (3 × 2 mL). The combined organic extracts were dried over MgSO4, filtered 
and concentrated in vacuo to give the crude product, which was purified by flash 
column chromatography, eluting with ethyl acetate/petroleum ether (1:1) to yield 
3,4-dihydroisoquinoline 128 (64 mg, 61%) as a pale yellow oil: Rf 0.23 (ethyl 
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acetate/petroleum ether 1:1); 1H NMR (400 MHz; CDCl3): δ 8.38–8.830 (1H, m, 
H-1), 7.39–7.27 (3H, m, H-6, H-7 and H-8), 7.17 (1H, d, J 7.2, H-5), 3.79 (2H, dt, J 
7.7, 2.0, CH2-3) and 2.77 (2H, t, 7.7, CH2-4); m/z (ESI
+) 132.07 ([M+H]+, 65%), 







To a stirred suspension of sodium chlorite (223 mg, 2.46 mmol) in THF (2 mL) was 
added NaH2PO4 (1 M aq. solution, 0.75 mL), resulting in the formation of a pale 
yellow solution. A solution of imine 128 (64 mg, 0.49 mmol) in THF (0.5 mL, plus 
2 × 0.2 mL washings) was added drop-wise over 5 min. After 2 h at room 
temperature, TLC analysis indicated the consumption of all starting material. The 
reaction mixture was diluted with ethyl acetate (15 mL) and washed with water 
(5 mL) before stirring with sodium thiosulfate (10% aq. solution, 15 mL) for 20 min. 
The organic phase was washed with brine (5 mL), dried over MgSO4 and 
concentrated in vacuo to give the crude product, which was purified by flash column 
chromatography, eluting with ethyl acetate/petroleum ether (3:2) to yield 3,4-
dihydroisoquinolin-1(2H)-one 136 (36 mg, 50%) as a colourless oil: Rf 0.22 (ethyl 
acetate/petroleum ether 1:1); 1H NMR (400 MHz; CDCl3): δ 8.06 (1H, d, J 7.5, H-8), 
7.44 (1H, ddd, J 7.5, 7.5, 1.2, H-6), 7.35 (1H, dd, J 7.5, 7.5, H-7), 7.21 (2H, m, H-5 
and NH-2), 3.57 (2H, 2 × t, J 6.6, CH2-3) and 2.99 (2H, t, J 6.6, CH2-4); 
13C NMR 
(100 MHz; CDCl3): δ 166.7 (O=C-1), 138.9 (C), 132.1 (CH), 129.0 (C), 127.9 (CH-
8), 127.2 (CH), 127.0 (CH), 40.1 (CH2-3) and 28.3 (CH2-4); m/z (ESI
+) 148.08 
([M+H]+, 59%), 170.06 ([M+Na]+, 100%), 317.15 ([2M+Na]+, 79%). The data are in 










7-Bromo-1,2,3,4-tetrahydroisoquinoline (598 mg, 2.18 mmol) was dissolved in 
CH2Cl2 (18 mL). 0-Bromosuccinimide (748 mg, 4.20 mmol) was added portion-wise 
over 15 min. The reaction mixture was stirred at room temperature for 10 min then 
heated at 35°C for 30 min, during which time a yellow precipitate formed. The 
reaction mixture was then stirred at room temperature for 1 h with 15% NaOH 
solution (5 mL), during which time the precipitate dissolved. The organic layer was 
separated, washed with water (2 × 10 mL), dried over MgSO4, filtered and 
concentrated in vacuo to yield the crude product, which was purified by flash column 
chromatography, eluting with ethyl acetate/petroleum ether (1:2) to afford 7-bromo-
3,4-dihydroisoquinoline 137 (395 mg, 67%) as a yellow gum: Rf 0.30 (ethyl 
acetate/petroleum ether 1:1); vmax (NaCl plates)/cm
-1 2938 (s), 2896 (m), 2850 (m), 
1625 (s), 1562 (m), 1481 (s), 1191 (s) 1051 (m), 828 (s), 818 (s); 1H NMR 
(400 MHz; CDCl3): δ 8.29 (1H, dd, J 2.0, 2.0, H-1), 7.48 (1H, dd, J 8.0, 2.0, H-6), 
7.42 (1H, d, J 2.0, H-8), 7.05 (1H, d, J 8.0, H-5), 3.81–3.76 (2H, m, CH2-3) and 2.70 
(2H, t, J 7.7, CH2-4); 
13C NMR (100 MHz; CDCl3): δ 158.9 (CH-1), 135.1 (C), 133.8 
(CH-6), 130.0 (CH-8), 129.9 (C), 129.1 (CH-5), 120.4 (CBr-7), 47.3 (CH2-3), 24.4 
(CH2-4); HRMS m/z (ESI
+) [Found: (M+H)+ 209.9908/11.9890. C9H9BrN requires 
M+, 209.9913/211.9893]; m/z (ESI+) 210.01/212.01 ([M+H]+, 100/97%). NMR data 
are in good agreement with literature values.171 
 






To a stirred suspension of sodium chlorite (733 mg, 8.10 mmol) in THF (12 mL) was 
added NaH2PO4 (1 M aq. solution, 2.4 mL), resulting in the formation of a pale 
yellow solution. A solution of imine 137 (314 mg, 1.49 mmol) in THF (6 mL) was 
added drop-wise over 7 min. After 1 h at room temperature, TLC analysis indicated 
the consumption of all starting material. The reaction mixture was diluted with ethyl 
acetate (15 mL) and washed with water (15 mL) before stirring with sodium 
thiosulfate (10% aq. solution, 15 mL) for 5 min, after which time TLC analysis 
indicated the conversion of intermediate (Rf 0.76 [ethyl acetate/petroleum ether 1:1]) 
to product (Rf 0.19). The organic phase was washed with brine (2 × 15 mL), dried 
over MgSO4 and concentrated in vacuo to give the crude product, which was purified 
by flash column chromatography, eluting with ethyl acetate/petroleum ether (3:2) to 
yield 7-bromo-3,4-dihydroisoquinolin-1(2H)-one 138 (186 mg, 51%) as a white 
solid: Rf 0.27 (ethyl acetate/petroleum ether 3:2); mp 118–123 ºC (dec., from ethyl 
acetate); vmax (NaCl plates)/cm
-1: 3092.6 (w, lactam N–H stretch), 1687 (s, lactam 
C=O stretch), 1656 (s), 1475 (s), 1426 (s), 1325 (s), 816 (s, p-subst. Ar), 778 (s); 
1H NMR (400 MHz; CDCl3): δ 8.18 (1H, d, J 2.2, H-8), 7.55 (1H, dd, J 8.1, 2.2, 
H-6), 7.25 (1H, bs, NH-2), 7.11 (1H, d, J 8.1, H-5), 3.57 (2H, 2 × t, J 6.6, CH2-3) 
and 2.94 (2H, d, J 6.6, H-4); 13C NMR (100 MHz; CDCl3): δ 165.3 (O=C-1), 137.6 
(C-9), 135.0 (CH-6), 130.8 (CH-8), 130.7 (C-10), 129.0 (CH-5), 120.9 (CBr-7), 39.9 
(CH2-3) and 27.8 (CH2-4); HRMS m/z (ESI
+) [Found: (M+H)+ 225.9862 (79Br), 
227.9840 (81Br). C9H9BrNO requires M
+, 225.9862 (79Br), 277.9842 (81Br)]; m/z 
(ESI+) 226.02 ([M+H]+, 79Br, 18%), 228.02 ([M+H]+, 81Br, 16%), 248.00 ([M+Na]+, 
79Br, 57%), 249.99 ([M+Na]+, 81Br, 56%), 473.00 ([2M+Na]+, 79Br/79Br 57%),  
474.99 ([2M+Na]+, 79Br/81Br 100%),  476.99 ([2M+Na]+, 81Br/81Br, 49%); Anal. 
Calcd for C9H8BrNO: C, 47.82; H, 3.57; N, 6.20. Found: C, 47.97; H, 3.44; N, 6.11. 
NMR data is in good agreement with literature values.172,173 
 






Pyrimidine-5-boronic acid hemi-hydrate (50 mg, 0.38 mmol), 138 (110 mg, 
0.45 mmol), sodium carbonate (239 mg, 2.25 mmol) and Pd(PPh3)4 (43 mg, 
0.037 mmol) were added to a reaction tube. Toluene (7 mL), ethanol (2 mL) and 
water (2 mL) were transferred via cannula under positive pressure of Ar. The 
reaction mixture was heated under reflux for 16 h, after which time solvent was 
removed in vacuo and the resulting residue partitioned between water (5 mL) and 
CH2Cl2 (5 mL). The organic layer was washed with brine (2 × 5 mL) then the 
aqueous phases backwashed with CH2Cl2 (10 mL). The combined organic phases 
were dried over MgSO4, filtered and concentrated in vacuo. The crude product was 
purified using flash column chromatography, eluting with 
methanol/triethylamine/ethyl acetate (1:1:48) to yield 7-(pyrimidin-5-yl)-3,4-
dihydroisoquinolin-1(2H)-one 132 (58 mg, 68%) as a white solid: Rf 0.39 
(methanol/triethylamine/ethyl acetate 1:1:18); mp 193–209ºC (dec., precipitate); vmax 
(NaCl plates)/cm-1 3195 (s, lactam N–H stretch), 3049 (m, Ar–H stretch), 2941 (m, 
HC–H stretch), 1683 (s, lactam C=O stretch), 1614 (m, Ar), 1574 (m, Ar), 1483 (m, 
Ar), 1411 (s), 810 (m, p-subst. Ar); 1H NMR (400 MHz; CDCl3): δ 9.22 (1H, s, H-1), 
9.00 (2H, s, H-3), 8.32 (1H, d, J 1.9, H-14), 7.68 (1H, dd, J 7.8, 1.9, H-6), 7.40 (1H, 
d, J 7.8, H-7), 7.03 (1H, bs, NH-11), 3.64 (2H, 2 × t, J 6.6, H-10) and 3.08 (2H, t, J 
6.6, H-9); 13C NMR (100 MHz; CDCl3): δ 165.8 (O=C-12), 157.7 (CH-1), 154.8 
(CH-3), 139.7 (C), 133.4 (C), 133.3 (C), 130.3 (CH-6), 130.0 (C), 128.6 (CH-7), 
126.4 (CH-14), 40.0 (CH2-10) and 28.0 (CH2-9); HRMS m/z (ESI
+) [Found: (M+H)+ 
226.0978. C13H12N3O requires M
+, 226.0975]; m/z (ESI+) 226.13 ([M+H]+, 48%), 
248.11 ([M+Na]+, 100%), 280.14 ([M+Na+MeOH]+, 69%), 473.22 ([2M+Na]+, 
50%); Anal. Calcd for C13H11N3O: C, 69.32; H, 4.92; N, 18.66. Found: C, 69.53; H, 
4.84; N, 18.48.  
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Pyrimidine-5-boronic acid hemi-hydrate (100 mg, 0.75 mmol), 2-bromo-4-
fluorobenzylamine hydrochloride (216 mg, 0.90 mmol), sodium carbonate (245 mg, 
2.30 mmol) and Pd(PPh3)4 (48 mg, 0.042 mmol) were added to a reaction tube. 
Toluene (7 mL), ethanol (2 mL) and water (2 mL) were transferred via cannula under 
positive pressure of Ar. The reaction mixture was heated under reflux for 16 h, after 
which time solvent was removed in vacuo and the resulting residue partitioned 
between water (5 mL) and CH2Cl2 (5 mL). The organic layer was washed with brine 
(2 × 5 mL), then the aqueous phases backwashed with CH2Cl2 (10 mL). The 
combined organic phases were dried over MgSO4, filtered and concentrated in vacuo. 
The crude product was purified by flash column chromatography, eluting with 
methanol/triethylamine/ethyl acetate (1:1:18, Rf 0.12) and subsequently precipitated 
from CH2Cl2 using HCl (2 M in Et2O) to yield the hydrochloride salt 0-(3-
(pyrimidin-5-yl)-4-fluoro-benzyl)amine hydrochloride 134 (64 mg, 36%) as a brown 
hygroscopic solid: mp 176–184ºC (precipitate); vmax (KBr disc)/cm
-1: 3070 (w, +NH3 
N–H stretch), 2916 (sat. C–H stretch), 1594 (s,+NH3 N–H bend), 1499 (s, 
+NH3 N–H 
bend), 1413 (s), 898 (s), 842 (s, p-subst. Ar), 696 (s, C–F); 1H NMR (400 MHz; 
D2O:MeOD [2:1]): δ 8.96 (1H, s, H-1), 8.89 (1H, s, H-3), 7.46 (1H, d, J 6.0, H-10), 
7.42–7.33 (1H, m, H-8), 7.16 (1H, dd, J 9.2, 9.2, H-7) and 4.01 (2H, s, CH2-11); all 
peaks are broad due to compound being a salt. 13C NMR (100 MHz; D2O:MeOD 
[2:1]): δ 159.3 (CH-1), 156.9 (CH-3), 155.7 (CF-6), 133.1 (CH-8), 133.1 (C), 131.7 
(CH-10), 130.4 (C), 117.8 (C-5), 117.6 (CH-7) and 42.7 (CH2-11); 
19F NMR 
(376 MHz, D2O:MeOD 2:1): δ -118.0; HRMS m/z (ESI
+) [Found: M+ 204.0933. 
C13H11FN3 requires M
+, 204.0932]; m/z (ESI+) 204.08 ([M+H]+, 84%), 340.19 
([M+C6H4CH2NH2+MeOH]
+, 100%); Anal. Calcd for C11H11ClFN3: C, 55.12; H, 
4.63; N, 17.53. Found: C, 54.96; H, 4.54; N, 17.41.  
 






Aluminium(III) chloride (75 mg, 0.56 mmol), 3-bromo-0-methylbenzylamine 
(100 mg, 68 µL,0.50 mmol) and acetyl chloride (39 mg, 36 µL, 0.50 mmol) were 
added to anhydrous CH2Cl2 (5 mL) and stirred at room temperature (24 h). The 
reaction mixture was then heated under reflux for 5 h before the addition of further 
AlCl3 (100 mg, 0.75 mmol) and heated under reflux for a further 66 h, after which 
time TLC analysis indicated the complete consumption of starting material. The 
reaction mixture was washed with water (5 mL) and brine (2 × 5 mL) and the organic 
phase dried over MgSO4, filtered and concentrated in vacuo to yield the crude 
product, which was purified by flash column chromatography, eluting with ethyl 
acetate/petroleum ether (1:1) to afford 0-(3-bromobenzyl)-0-methylacetamide 141 
(25 mg, 21%) as a colourless oil: Rf 0.69 (methanol/triethylamine/ethyl acetate 
1:1:48); vmax (NaCl plates)/cm
-1 1639 (s, 3° amide C=O stretch); 1H NMR (500 MHz; 
DMSO; 373K): δ 7.46 (1H, d, J 7.3, H-4), 7.42 (1H, s, H-2), 7.31 (1H, dd, J 7.3, 7.3, 
H-5), 7.24 (1H, d, J 7.3, H-6), 4.52 (2H, s, CH2-7), 2.93 (3H, s, CH3-11) and 2.07 
(3H, s, CH3-9); 
13C NMR (126 MHz; DMSO; 373K): δ 170.9 (O=C-10), 141.7 (C-1), 
131.4 (CH-5), 130.8 (CH-2), 130.8 (CH-4), 127.4 (CH-6), 122.7 (CBr-3), 50.5 (CH2-
7), 29.7 (CH3-11) and 22.0 (CH3-9); HRMS m/z (ESI
+) [Found: (M+H)+ 
242.0175/244.0157. C10H13BrNO requires M
+, 242.0175/244.0155]; m/z (ESI+) 
242.04 ([M+H]+, 79Br, 63%),  244.04 ([M+H]+, 81Br, 62%), 264.02 ([M+Na]+, 79Br, 
100%), 266.02 ([M+Na]+, 81Br, 98%), 505.06 ([2M+Na]+, 79Br/79Br, 49%), 507.05 
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In order to progress the understanding of ABAD and how it interacts with its 
intracellular binding partners, such as β-amyloid (Aβ), small molecule probes of the 
enzyme that are capable of inhibiting or enhancing its activity will be useful tools in 
its study. 
 
Over the years, a number of screening methods have been employed to identify lead 
compounds for drug development and the methods used are also applicable to the 
identification of molecular probes. For example, high-throughput screening (HTS) 
has been used in the past to screen “drug-like” molecules for lead identification. 
High-throughput screening libraries typically comprise compounds that are highly 
functionalised with a molecular weight (MW) in the range of ~250–600 Da. 
However, in order to optimise hits, additional functionality and hence additional 
molecular weight is often added, to the detriment of the compounds’ characteristics 
as drugs. For a compound to be considered “drug-like”, Lipinski’s “Rule of 5” is 
often used as the distinguishing criterion (Table  3.1);174 compounds that fall outwith 
these criteria tend to be poorly absorbed by the body and hence are unsuitable as 
orally available drugs. 
 
Recently, fragment-based screening methods have become more popular as an 
approach for designing lead compounds for drug discovery (reviewed by Carr,175 
Congreve176 and Schultz177). Using a range of techniques, such as nuclear magnetic 
resonance (NMR) spectroscopy, thermal shift analysis (TSA), surface plasmon 
resonance (SPR) and X-ray crystallography, small molecules (MW 100–300 Da) that 
bind to the protein of interest are identified. From this small molecular fragment a 
lead compound can be developed, either by linking together several fragments found 
to bind in close proximity or by growing out the fragment to fill the surrounding 
space within the binding site (Figure  3.1).177,178 
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Figure  3.1: Fragment-based lead optimisation. Small molecular fragments that bind to a receptor 
are identified before optimisation by A) linking together several molecular fragments that bind in 
close proximity or B) extending the fragment structure into the surrounding binding site.177 
 
In contrast to HTS, the use of a fragment-based approach starts with small 
(MW 100–250 Da) compounds with limited functionality, which conform to the 
“Rule of 3” criteria176 (Table  3.1).  
 
Table  3.1: Comparison of criteria for “drug-like” and “fragment-like” compounds, known as 
Lipinski’s Rule of 5 and the Rule of 3, respectively. 
 
Lipinski’s 
‘Rule of 5’ 
Fragment screening 
‘Rule of 3’ 
MW < 500 Da < 300 Da 
H-bond donors ≤ 5 ≤ 3 
H-bonds acceptors ≤ 5 ≤ 3 
logP ≤ 5 ≤ 3 
 
Although fragments tend to have lower binding affinities than HTS hits due to the 
smaller number of interactions possible, these interactions are thought to be of higher 
quality as they utilise more of the compound. This phenomenon can be expressed in 
terms of a compound’s ligand efficiency, which is a measure of the free energy of 
ligand binding per heavy (non-hydrogen) atom. (Equation 1).179,180 
 
Equation 1: Calculation of ligand efficiency 
L.E. = ∆G/Nnon-hydrogen atoms = -RT.lnKd/Nnon-hydrogen atoms ≈ -RT.ln(IC50)/Nnon-hydrogen atoms 
 
Kuntz et al. calculated that the maximum free energy contribution by a non-hydrogen 
atom is ~ 1.5 kcal mol-1, for up to 15 non-hydrogen atoms per molecule.180 For 
molecules above this size, free energy increases little with increasing MW. 
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Therefore, smaller ligands are more “efficient” than larger ones. By expressing the 
affinity as a function of MW in this way, affinity can be “normalised”, allowing the 
identification of hits which have the largest ligand efficiency, rather than the 
strongest affinity, for further development. This strategy enables high affinity 
compounds to be developed while minimising the increase in molecular weight to 
avoid violation of Lipinski’s Rule of 5.  
 
A further advantage of fragment-based screening is that the library size is relatively 
small: typically only ~1000 compounds are screened, in contrast to up to 106 
compounds for HTS. The reason for this difference can be related to the idea of 
“chemical space”.181 As the number of atoms in a molecule (i.e. its molecular 
weight) increases, there is an exponential increase in the number of theoretical 
permutations of compounds and hence the number of compounds required to include 
all different structure types is enormous. By limiting the molecular weight for a 
fragment-based approach, the number of compounds required to cover a proportion 
of the available chemical space is greatly reduced. In addition, the lower complexity 
of fragments increases the probability of a complementary binding site being found 




3.1.1 Thermal shift analysis as a fragment-based screening approach 
 
Thermal shift analysis (TSA), also known as ThermoFluor®, is one of the many 
available techniques for fragment based screening.182-184 The technique is a relatively 
simple one, and involves measuring the unfolding temperature (Tm) of the protein as 
an indicator of protein stability. A fluorescent dye, commonly Sypro Orange 
(SyproO), is added to a solution of protein but the fluorescence is quenched under 
aqueous conditions. As the protein is heated up it becomes denatured and its 
hydrophobic core is exposed. The dye binds to the hydrophobic region of the protein 
and as a result, the fluorescence of the dye is no longer quenched, resulting in a 
fluorescent emission. The appearance of fluorescence can therefore be used to 
Chapter 3. Results and Discussion: Small molecule inhibitors of ABAD 
 102
determine the Tm of the protein (Figure  3.2A). When a binding partner (for example, 
a small molecule) is present, the stability of the folded protein changes and hence the 
Tm of the protein is altered (Figure  3.2B). This method can therefore be used to 
identify small molecules capable of binding to proteins. This change in Tm (∆Tm) can 
be positive or negative, depending on whether the small molecule stabilises (positive 
∆Tm) or destabilises (negative ∆Tm). One potential downfall of the technique is 
identifying the protein conformation to which the small molecule binds. A situation 
can be imagined where two conformations of the protein exists in equilibrium and 
the molecule binds preferentially to one; however, use of this technique as a 
preliminary screen then supplemented with complementary techniques to verify hits 
accounts for this issue.  
 
 
Figure  3.2: Thermal shift analysis as a method for studying protein unfolding temperature (an 
indicator of protein stability). A) Sypro Orange (SyproO) is used as a fluorescent binding probe. 
When a protein unfolds, SyproO binds to the newly exposed hydrophobic core and fluoresces. This 
change in fluorescence is monitored and the unfolding temperature (Tm) of the protein calculated. B) 
If a small molecule is bound to a protein, the temperature at which unfolding occurs is altered 
depending on its stabilising/destabilising effect. 
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3.2 Chapter aims 
 
Using TSA as a starting point, the first aim of the following work was to identify low 
MW compounds capable of binding to ABAD. The subsequent aim was to then 
identify and develop inhibitors of the enzyme using a medicinal chemistry approach. 
This involved modifying the structures of hits from the fragment screen in order to 
determine the compounds’ structure-activity relationship (SAR) and optimise its 
interactions with ABAD in order to increase its efficacy.  This work was done with 
the intention of developing small molecular probes to assist the future study of 
ABAD activity and function. 
 
 
3.3 The identification of small molecule binding partners of ABAD 
 
The Maybridge Ro3 molecular fragment library (Thermo Fisher Scientific Inc.) was 
selected for screening against ABAD by thermal shift analysis. This library consisted 
of 672 compounds with a molecular weight range of 94–206 Da, which conform to 
the “Rule of Three” criteria for fragment-based drug discovery.  
 
Before proceeding with the fragment screen, it was first necessary to confirm that 
TSA would give the expected output upon the binding of a molecule to ABAD. A 
positive control was employed, whereby the effect of a known binder of ABAD, the 
enzyme co-factor NADH, was examined. The dissociation curve (Figure  3.3) plots 
the negative reciprocal of fluorescence as a function of temperature; the unfolding 
temperature (Tm) therefore occurs at the lowest point of the curve. Incubating 
11.7 µM ABAD with 10 mM NADH resulted in a shift in Tm from 41.5 °C to 60 °C, 
demonstrating the ability of thermal shift to identify binding partners of ABAD 
(Figure  3.3). 
 





























Figure  3.3: Thermal shift analysis of ABAD in the absence (blue) and presence (red) of .ADH. 
The unfolding temperature, Tm, is given as the bottom of the curve. Assay conditions: 11.7 µM ABAD, 
10 mM 0ADH, 1 × Sypro Orange, 5% DMSO in 10 mM sodium phosphate, pH 7.4. 
 
Figure  3.4 shows a sample dissociation curve obtained from the screening of ABAD 
(11.7 µM) and fragments (10 mM). It can be seen that the baseline Tm of ABAD at 
41 °C, shown by dark blue circles, was altered in the presence of some of the 
fragments tested and that the change in unfolding temperature (∆Tm) could be 
positive or negative.  
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Figure  3.4: Sample dissociation curve showing a shift in unfolding temperature in the presence 
of selected molecular fragments. 0-Methyl-0-(3-pyridin-4-ylbenzyl)amine 73 (khaki squares); 
0-methyl-0-(3-pyridin-3-ylbenzyl)amine 74 (turquoise triangles); control sample, no fragment present 
(dark blue circles). Assay conditions: 11.7 µM ABAD, 10 mM fragment, 1 × Sypro Orange, 5% DMSO 
in 10 mM sodium phosphate, pH 7.4. 
 
Of particular interest are the compounds that showed a positive ∆Tm, as this 
demonstrates the stabilisation of the protein in the presence of the molecular 
fragment and hence indicates that binding between the two is occurring. In some 
cases, a negative Tm was observed, which may be caused by the molecular fragment 
stabilising the unfolded form of the protein, i.e. it binds preferentially to the 
denatured protein,185 or by the fragment inducing a conformational change within the 
protein, resulting in a more disordered structure.186 
 
Of the initial 672 compounds screened, 84 were identified as giving positive ∆T of 
≥2 °C. The structures of these compounds (4–87) can be found in Appendix  A. 
Rescreening of these 84 compounds gave inconsistent results in some instances; this 
inconsistency was subsequently identified as being due to the compounds being 
unstable in aqueous solution. Repeating the screen with compound solutions freshly 
73 
74 
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prepared from DMSO stocks led to an increase in reproducibility, although some 
variability was still seen (Figure  3.5).  
 
























































Figure  3.5: Unfolding ∆T values of initial thermal shift hits. Graphs show the results of the initial 
screen (blue), the rescreen of those fragments (red, yellow) and the rescreen using freshly prepared 
samples (green). Tm values for ABAD in the presence of fragments were subtracted from that of 
native ABAD to give the change in unfolding temperature, ∆Tm. Assay conditions: 11.7 µM ABAD, 
10 mM fragment, 1 × Sypro Orange, 5% DMSO in 10 mM sodium phosphate, pH 7.4. 
 
From these screens, nineteen compounds were identified as giving consistent ∆T 
values of >2 °C. Of these, three were excluded as false positives, giving responses in 
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the absence of either ABAD or Sypro Orange, leaving a short list of 16 compounds 
for further investigation (Table  3.2). 
 
Table  3.2: .ames and structures of short-listed ABAD-binding compounds. Compounds were 
identified from the Maybridge Ro3 library as being binding partners of ABAD in a thermal shift 
assay. Assay conditions: 11.7 µM ABAD, 10 mM fragment, 1 × Sypro Orange, 5% DMSO in 10 mM 
sodium phosphate, pH 7.4. 








































































3.4 Identification of ABAD inhibitors 
 
Having identified a series of molecular fragments that were capable of binding to 
ABAD, the next step was to investigate the effect of the compounds on the 
enzymatic activity ABAD. As well as identifying compounds that were inhibitors of 
ABAD, this would also give some indication of the compound binding site. The 
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enzymatic activity of purified ABAD can be easily measured using a UV-Vis 
spectrometer by following the oxidation of NADH, which absorbs at 340 nm, to 
NAD+, which has negligible absorbance at this wavelength, during the reduction of 
S-acetoacetyl-coenzyme A (AcAcCoA, 88) (Scheme  3.1). For further details on the 
development of this assay, see Section  5.3.1, detailed experimental procedure can be 
found in Materials and Methods, Section  2.8.1. 
 
 
Scheme  3.1: Reduction of S-acetoacetyl-CoA by ABAD. The rate of reaction can be calculated by 
monitoring the rate of change of NADH absorption at 340 nm. 
 
The fragments were added to the assay at concentrations of 0.1, 1 or 10 mM and the 
resulting enzyme activity measured to see if any inhibition or activation resulted 
(Figure  3.6). Control samples containing no fragment were also included. To avoid 
competition/displacement issues, the substrate, co-factor and fragment were mixed 










































Figure  3.6: ABAD activity in the presence of short-listed fragments. The fragment (0.1, 1, 
10 mM), S-acetoacetyl-CoA (80 µM) and NADH (250 µM) were mixed before the addition of ABAD 
(5 µg mL-1) and the absorption at 340 nm monitored over 30 s. The final DMSO content was 
0.5% (v/v). Reaction rates were calculated from the change in NADH absorbance. Control samples 
(0.5% DMSO) containing no fragment are shown in blue and were run at the beginning and end of 
each session (~8 h, as indicated by the red dashed lines), revealing a decrease in ABAD activity over 
the course of each session. Measurements were performed in triplicate and the error reported as 
±SEM. 
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Fragments 16 and 69 were only tested at 0.1 mM due to high absorbance (> 3) of 
these compounds at 340 nm at high concentrations. The activity assays were run over 
the course of two days, with a control (no fragment present) performed at the start 
and end of each session. It was noted that the baseline activity of ABAD decreased 
by around 40% over the course of the session (approximately 8 h), despite all 
components being kept at 0 °C for the duration. For this reason, quantitative 
inhibition values could not be accurately determined. However, qualitative analysis 
of the results indicated that fragments 10, 11, 17, 54, 64, 73 and 74 all exhibited 
some degree of inhibition. The 0.1 mM data could not be easily analysed, due the 
problems associated with decreasing baseline described above. However, comparison 
of the 1 and 10 mM data with the 0.1 mM data (in effect using the 0.1 mM data as a 
control) indicated that these seven fragments showed inhibition at 10 mM and that 17 
also showed a high level of inhibition at 1 mM compared to that seen at 0.1 mM.  
 
Compounds that had shown binding through TSA but did not exhibit inhibition of 
ABAD activity can therefore be predicted to bind to a site other than the enzyme 
active site. These compounds may therefore be useful in other applications, such as 
finding compounds that prevent the formation of the ABAD-Aβ complex (see 
Chapter  5). 
 
On the basis of the TSA and ABAD activity assay results, four fragments were 
selected for further analysis and potential synthetic derivation: 11, 17, 73 and 74 




Figure  3.7: Hits selected for future development. Selection was made on the basis of the results of 
thermal shift and ABAD activity assays. 
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3.5 Determining the interaction of hits with ABAD 
 
3.5.1 Isothermal titration calorimetry 
 
Although thermal shift analysis has been reported as a quantitative method for 
calculating binding affinities, with the change in folding temperature being 
proportional to the binding affinity,183,185 more established techniques for calculating 
binding affinities are available. Isothermal titration calorimetry (ITC) has long been 
used for determining the binding affinities of protein-ligand complexes, although it is 
only more recently that the technique has been employed for weak (mM) 
interactions, such as those found in small molecule fragment screening.187 
 
In order to confirm ITC as a method for measuring a ligand binding to ABAD, 
NADH was again used as a positive control. Using a cell solution of 9.9 µM ABAD 
and syringe concentration of 210 µM NADH, the titration curve shown in Figure  3.8 
was obtained. Fitting to a one site model, which assumes only a single binding site 
per protein monomer, gave a Kd of 2.1 µM.  













































Figure  3.8: Isothermal titration calorimetery curve showing the binding of .ADH to ABAD. 
NADH (210 µM) was injected into an ABAD (9.9 µM) solution in 7 µL injections. Dilution controls 
were provided by injection of NADH into a buffer solution and subtracted from the experimental data. 
Data was fitted to a one site model. 
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Binding experiments were then repeated using compounds 11, 73 and 74, using 
49.3 µM ABAD and 15 mM fragment in order to push the equilibrium towards the 
formation of the complex and hence maximise the signal observed. Due to solubility 
issues, compound 17 was not investigated at this time. As the solutions used for 
fragment binding contained DMSO, which was not present in the NADH control, the 
buffer matching between syringe and cell solutions was checked to ensure that errors 
in pipetting reproducibility were not leading to DMSO mismatch and hence 
interfering with the results obtained. Buffer mismatch would result in an extra heat of 
dilution being present during injections. However, it can be seen in Figure  3.9 that 
buffer mismatch was not contributing in this way, with little or no signal being 
detected. 
 



















Figure  3.9: DMSO matching between ligand and protein solutions. Injection of blank ligand 
solution (containing identical buffer composition but no fragment) into a blank cell solution 
(containing no ABAD) indicated that pipetting errors would not lead to heats of dilution due to buffer 
mismatch. 
 
Data obtained from these preliminary experiments did not show fitting to a one-site 
binding model, as had been the case with NADH (Figure  3.10). This result may be 
due to the binding being too weak to observe or simply that further optimisation is 
required. One interesting point to note is that the period required for the baseline to 
return after each injection was very long (360 s). This phenomenon may be 
indicative of a very slow conformational change occurring upon binding to ABAD 
(if indeed binding is occurring). 
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Figure  3.10: Isothermal titration calorimetery curve of the injection of small molecular 
fragments into an ABAD solution. Compounds 11 (left), 73 (centre) and 74 (right) (15 mM) was 
injected into an ABAD (49.3 µM) solution in 7 µL injections. Dilution controls were provided by 




3.5.2 Crystallography studies 
 
It was also hoped to obtain some structural information on the physical interactions 
occurring between ABAD and the fragments. If a co-crystal structure could be 
obtained, this would provide a wealth of knowledge about the binding, including the 
binding location (e.g. the enzyme active site or an allosteric binding site), as well as 
information on the specific functional groups involved, for example H-bonding 
groups, and how their interactions could be optimised. This information would prove 
invaluable for aiding the rational design of extended and functionalised analogues. 
 
Attempts at co-crystallising ABAD and the fragments were unsuccessful; further 
details of the experiments can be found in Appendix  B. 
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An alternative to co-crystallisation is the soaking-in method, where the protein is first 
crystallised and then bathed in a solution containing the ligand of interest. While 
crystallisation conditions for ABAD have been previously reported,84,118,119 this 
method presents its own problems, namely that much larger crystals of protein are 
required to soak compared with that needed for straight analysis. It is therefore hoped 
that this work may be returned to in the future.  
 
 
3.6 Design and synthesis of analogues of small molecule inhibitors of ABAD  
 
Having identified four small molecule fragments capable of binding to and inhibiting 
the activity of ABAD, it was proposed to synthesise a series of analogues in order to 
determine the structure-activity relationship (SAR) of the compounds and improve 
their affinity for ABAD.  
 
Due to the structural similarity between 73 and 74, these two compounds were 
initially selected for modification. Proposed structural modifications to the structure 
of 73 can be seen in Figure  3.11 and were also applicable to 74. Potential strategies 
for determining the SAR included determining the role of the heteroatoms by 
removal or replacement with other heteroatoms; removing the H-bond donor ability 
of the amine; altering the chain length of the side chain, which may have steric or 
electronic consequences; and optimising the position of the side chain on the 
aromatic ring.  
 
 
Figure  3.11: Potential structural modifications of 73 to determine the structure-activity 
relationship. 
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Scheme  3.2 shows the retrosynthetic analysis of 73 to 4-pyridinylboronic acid (89) 
and 3-bromo-0-methylbenzylamine (90). A similar approach was possible for the 
synthesis of 74.  
 
 
Scheme  3.2: Retrosynthetic analysis of 73 for the development of analogues of 73 and 74. 
 
This strategy (Scheme  3.2) allowed the synthesis of analogues (91) from 
commercially available aryl boronic acids (92) and aryl halides (93) via the Suzuki 
coupling,188 which is outlined in Scheme  3.3. In brief, Pd(0) inserts into the Ar-halide 
bond by oxidative insertion to form a Pd(II) complex. Reaction of the boronic acid 
with a negatively charged base forms the “ate” complex, increasing its 
nucleophilicity and hence promoting the transmetallation reaction with the Pd(II) 
aryl halide. Trans to cis isomerisation, followed by reductive elimination results in 
the formation of the diaryl product and reduction of the palladium catalyst back to 
Pd(0). For an in-depth review of this reaction, see Miyaura & Suzuki.189 
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Scheme  3.3: Catalytic cycle for the Suzuki coupling.
190
 Pd(0) inserts into Ar–X bond by oxidative 
addition; boronic acid reacts with base to form the “ate” complex, which undergoes transmetallation 




3.6.1 Synthesis of first generation compounds 
 
The reaction conditions for the Suzuki coupling were first optimised using 4-
fluoroiodobenzene (94a) and 4-methyliodobenzene (94b) as the aryl halides in 




Scheme  3.4: Suzuki coupling of 4-pyridinylboronic acid with substituted iodobenzenes. Reaction 
conditions: i) Pd(PPh3)4 (0.05 eq.), aq. 0a2CO3, toluene/EtOH, 110 °C, 16 h, R = F, 48%; H, 2.5%; 
Me, not isolated. 
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The key to the success of these reactions was found to be thorough degassing of the 
solvents prior to use. Degassing by simple purging of the reaction mixture with N2 
prior to catalyst addition, as reported by Wang et al.,191 was not found to be 
sufficient and resulted in a low yields, most likely due to deactivation of the catalyst 
by oxygen. Instead, a freeze-pump-thaw method of degassing solvents, combined 
with an Ar atmosphere, was found to be more effective and gave yields of up to 48%  
for 95a (Table  3.3).  
 
TLC analysis of the reaction mixtures indicated the presence of several side products. 
During the purification of 95a, the non-substituted 4-phenylpyridine 96 was also 
isolated in 2.5% yield. It was assumed that this resulted from reaction with the 
catalyst as the same product was also shown by 1H NMR to be present in the reaction 
with 95b. Due to very similar polarities of 95b and 96, 95b could not be isolated by 
flash column chromatography, although NMR and MS showed the product to be 
present. 
 
With a suitable procedure in hand, the synthesis of 73 and 74 analogues was carried 
out (Scheme  3.5).  
 
 
Scheme  3.5: Synthesis of 73 and 74 and their analogues. Reaction conditions: i) pyridinylboronic 
acid (1 eq.), aryl bromide (1.2 eq.), Pd(PPh3)4 (0.05 eq.), aq. 0a2CO3 (3 eq.), toluene/EtOH, 110 °C, 
16  h – 7 d. 
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This first series of compounds included the resynthesis of the original screening hits, 
73 and 74, and variation of the amine side chain on the phenyl ring to discover if the 
position of the amine group in space within the binding pocket could be optimised to 
increase its binding ability. Yields of the 2-substituted compounds 100 and 101 were 
significantly lower that of the 3- and 4-substituted analogues (73, 74, 102, 103), even 
after extended reaction times of up to 7 days and increased catalyst loading of up to 
14 mol% (Table  3.3). The rate determining step of the Suzuki coupling is the 
oxidative insertion of Pd into the aryl–Br bond,189 implying that steric effect are 
possibly coming into play in this instance. Purification of 100 and 101 also proved 
problematic. It was noted in all cases that degradation did occur over time, 
particularly in solution, however, the 2-substituted compounds did not give 
completely clean 1H NMR spectra directly after purification by flash column 
chromatography. This impurity may have been due to the small yields obtained 
making purification more difficult or that the long reaction time generated 
degradation products that could not be separated easily by chromatography. Further 
purification was attempted by strong cation exchange (SCX) chromatography, 
however, this method also proved unsuccessful. From 1H NMR and elemental 
analysis results, it was decided to proceed with biological testing, but to minimise 
any degradation by storing the compounds at -20 °C, away from light and only in 
solution when required.  
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3.6.2 Biological testing of first generation compounds 
 
The ABAD activity assay described above (Section  3.4, Scheme  3.1) was used to 
determine the effect of the compounds synthesised for the first generation library on 
ABAD activity in vitro. This evaluation was carried out using a different set up to 
previous assays: assays were performed in a 96 well plate (final volume 140 µL) 
rather than in a 1 mL cuvette. Due to the change in set up, controls were repeated to 
ensure the baseline measurements were comparable. In these controls, assays were 
performed in the absence of each component (AcAcCoA, NADH, ABAD, DMSO). 
It can be seen in Figure  3.12 that in the absence of substrate, co-factor or enzyme, 
negligible activity was recorded compared with the baseline rate of 
7.7 µM min-1 mg-1. The presence of 0.5% (v/v) DMSO, required to aid the solubility 




































Figure  3.12: Controls for ABAD activity assay. ABAD activity was determined by measuring the 
rate of oxidation of NADH (ε = 6220 L mol-1 cm-1 at 340 nm) during the reduction of S-acetoacetyl-
CoA (AcAcCoA; substrate) in the presence of NADH (co-factor), ABAD and DMSO, then repeated 
in the absence of NADH, S-acetoacetyl-CoA, ABAD or DMSO. Reaction rates are shown as specific 
activities. Assays were performed in triplicate and errors expressed as ± SEM. Statistical analysis was 
performed using a pairwise Student’s t-test. Assay conditions: 5 µg mL-1 ABAD, 80 µM S-acetoacetyl-
CoA, 250 µM 0ADH and 0.5% DMSO in buffer containing 50 mM sodium phosphate, 300 mM 
sodium chloride, pH 7.4 at 30 °C.  
 
*** *** *** 
*** p < 0.00006 
p = 0.98 
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In contrast to previous activity assays, the baseline activity of ABAD was not seen to 
diminish over the time period required to run the assays. Baseline measurements 
were taken at approximately 0, 3, 4 and 7 h and no statistically significant change in 
activity was observed (Figure  3.13), although it appeared that the specific activity 
measured in this case was at the low end of the scale in comparison to previous 








































Figure  3.13: Time course study of baseline ABAD activity. ABAD activity was determined by 
measuring the rate of oxidation of NADH (ε = 6220 L mol-1 cm-1 at 340 nm) during the reduction of 
S-acetoacetyl-CoA (AcAcCoA; substrate) in the presence of NADH (co-factor), and ABAD. Assays 
were performed at set time points after the component solutions had been prepared. Reaction rates are 
shown as specific activities. Assays were performed in triplicate and errors expressed as ± SEM. 
Statistical analysis was performed using a pairwise Student’s t-test. Assay conditions: 5 µg mL-1 
ABAD, 80 µM S-acetoacetyl-CoA, 250 µM 0ADH and 0.5% DMSO in buffer containing 50 mM 
sodium phosphate, 300 mM sodium chloride, pH 7.4 at 30 °C.  
 
 
Assays were then run in the presence of the test compounds at concentrations of 0.1, 
1 or 10 mM. Comparison of the data obtained from the library compounds with the 
synthesised versions showed good agreement, validating 73 and 74 as hits and also 
confirming that the new assay set up was satisfactory (Figure  3.14).  As the baseline 
activity was constant, the percentage inhibition caused by each compound at a given 
concentration could be calculated (Figure  3.15).  
 
















































Figure  3.14: Comparison of ABAD activity in the presence of the original hits and their 
resynthesised counterparts.  Assay conditions: 5 µg mL
-1
 ABAD, 80 µM S-acetoacetyl-CoA, 250 µM 
0ADH, 0.1, 1 or 10 mM test compound and 0.5% DMSO in buffer containing 50 mM sodium 
phosphate, 300 mM sodium chloride, pH 7.4 at 30 °C. 
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Figure  3.15: Inhibitory effect of first generation compounds on ABAD activity. A) Structures of 
first generation compounds. B) The rate of ABAD activity was measured by determining the rate of 
oxidation of NADH (ε = 6220 L mol-1 cm-1 at 340 nm) during the reduction of S-acetoacetyl-CoA and 
expressed as a percentage inhibition of baseline ABAD activity. Assays were performed in triplicate 
and errors expressed as ± SEM. Statistical analysis was performed using a pairwise Student’s t-test. 
Baseline measurements (containing no test compound) were performed before, during and after the 
assays (four measurements in triplicate) and showed no significant change in the baseline ABAD 
activity over the course of the experiment (p = 0.74). Assay conditions: 5 µg mL-1 ABAD, 80 µM 
S-acetoacetyl-CoA, 250 µM 0ADH, 0.1, 1 or 10 mM test compound (96 was only tested at 0.1 and 
1 mM) and 0.5% DMSO in buffer containing 50 mM sodium phosphate, 300 mM sodium chloride, pH 
7.4 at 30 °C. 
 
It can be seen that replacement of the amine side chain with a hydrogen atom (96) or 
fluorine atom (95a) resulted in loss of all inhibition of ABAD at the concentrations 
tested. The remaining six compounds all exhibited a significant inhibitory effect of 
50–100% at 10 mM (p < 0.001). Compounds 100, 101 and 102 also showed 
significant inhibition, of ~20%, at 1 mM. The position of the pyridinyl-0 atom did 

























**   p < 0.01 vs control 









**    *** 
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firm conclusion about the optimal position of the amine side chain was drawn, other 
than its presence being important. This result is not unexpected: due to the low level 
of functionalisation of the fragments, it was anticipated that those functional groups 
present would prove critical.  
 
 
3.6.3 Synthesis of second generation compounds 
 
One of the features of fragment-based drug discovery is that the initial fragment is 
not highly functionalised and that the initial fragment framework is generally 
maintained throughout development to the final compound. In this case, the two 
functional groups present are the pyridine ring and the secondary amine. It was 
desirable to determine the role of the fragment heteroatoms in binding with ABAD, 
for example, if the amine interacted through its N–H bond (H-bond donor) or 
through its lone pair (H-bond acceptor) and with this in mind, a second generation of 
compounds was proposed (Figure  3.16).   
 
 
Figure  3.16: Second generation target compounds. 
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Conversion of the secondary amine to a tertiary amine, to eliminate H-bond donor 
ability, was achieved by reductive amination of 73, 74, 102 and 103 using 
formaldehyde in formic acid (Eschweiler-Clarke reaction).192 Under these conditions, 
compounds 104–107 were obtained in 55–77% yield (Scheme  3.6, Table  3.4). 
 
 
Scheme  3.6: Reductive amination of secondary amines. Methylation of 73. Reaction conditions: 
i) formaldehyde (2 eq.), formic acid, 100 °C, 2 h, 71%. 
 
Table  3.4: Reaction yields for reductive aminations of secondary amines. Reaction conditions: 
formaldehyde (2 eq.), formic acid, 100 °C, 2 h 













The conversion of secondary to tertiary amine was confirmed by 1H NMR, where 
integration of the methyl group doubled from 3H to 6H. The loss of the N–H stretch 
between 3300–3100 cm-1 was also observed by IR spectroscopy.  
 
Compounds 108 and 109 were synthesised as shown in Scheme  3.7. Methylation of 
3-bromobenzyl alcohol (112)165 afforded 113, which was then coupled to 
pyridinylboronic acids 89 and 97 to afford 108 and 109 (Table  3.5).  
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Scheme  3.7: Preparation of 108 and 109. Reaction conditions: i) KOH (3 eq.), Me2SO4 (1.5 eq.), 
THF, 65 °C, 16 h, 67%; ii) pyridinylboronic acid 89 or 97 (1 eq.), aq. 0a2CO3 (3 eq.), Pd(PPh3)4 
(0.05 eq.), toluene/EtOH, 110 °C, 20 h. 
 
Compounds 110 and 111 were prepared by coupling aryl bromides 90 and 99 to 
phenylboronic acid 114 (Table  3.5). Purification of 111 proved difficult as the 
product had the same Rf as the starting aryl bromide and 
1H NMR indicated a 9:1 
ratio of product:starting material. The mixture was still subjected to biological 
testing, with the view to reinvestigating purification methods if results looked 
promising.  
 
Table  3.5: Reaction yields for second generation Suzuki couplings. 
Boronic acid Aryl halide Product Yield (%) 
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3.6.4 Biological testing of second generation compounds 
 
The second generation compounds were evaluated using the ABAD activity, as 
previously described. Since no significant ABAD inhibition had been seen by any 
compounds at 0.1 mM during the first series of testing, compound concentrations 
were changed to 1, 5 and 10 mM in this series of assays, in order to try and 
distinguish better the effects at low mM concentrations. The results of these assays 
are summarised in Figure  3.17. 
 
Figure  3.17: Inhibitory effect of second generation compounds on ABAD activity. A) Structures 
of second generation compounds. B) The rate of ABAD activity was measured by determining the rate 
of oxidation of NADH (ε = 6220 L mol-1 cm-1 at 340 nm) during the reduction of S-acetoacetyl-CoA 
and expressed as a percentage inhibition of baseline ABAD activity. Assays were performed in 
triplicate and errors are expressed as ± SEM. Statistical analysis was performed using a pairwise 
Student’s t-test. Baseline measurements (containing no test compound) were performed before, during 
and after the assays (four measurements in triplicate) and showed no significant change in the baseline 
ABAD activity over the course of the experiment (p > 0.38). Assay conditions: 5 µg mL-1 ABAD, 
80 µM S-acetoacetyl-CoA, 250 µM 0ADH, 1, 5 or 10 mM test compound and 0.5% DMSO in buffer 





























  ** ** 
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 * 
*    p < 0.05 vs control 
**   p < 0.01 vs control 
*** p < 0.001 vs control 
Chapter 3. Results and Discussion: Small molecule inhibitors of ABAD 
 127 
 
Replacement of the pyridine ring with a phenyl ring (110 and 111) resulted in loss of 
all ABAD inhibition at the concentrations measured, indicating that the interactions 
of the pyridine-0 atom within the binding site is vital for activity of the compound. 
Removal of the N–H bond, either by methylation (104–107) or by replacement with 
an oxygen atom (108 and 109) resulted in a decrease in ABAD inhibition, with 
activity at 10 mM now in the range of 15–30%, rather than 50–100%. No significant 
ABAD inhibition was seen at 1 mM concentrations of any compounds. This loss of 
inhibitory effect upon removal of the N–H bond implies that the H-bond donor 
ability of the amine plays a role in its action. Had the interaction come purely from 
the nitrogen lone pair, it would have been expected that there would have been little 
or no change from the previous compounds and that replacement of the methylamine 
with a methoxy group, containing two lone pairs, would have strengthened its 
interactions.  
 
These results confirm the earlier anticipation that the functional groups present in the 
original fragment hit are essential for its activity. For this reason, these functional 
groups were retained in the third generation of compounds described below.  
 
 
3.6.5 Synthesis of third generation compounds 
 
Having satisfactorily shown that removal of any of the functional groups present in 
the original hits resulted in a negative effect on its inhibitory properties, the next aim 
was to try and increase the performance of the compounds. The proposed compounds 
for this third generation synthesis are shown in Figure  3.18. 
 






































Figure  3.18: Third generation target compounds. 
 
The first subset of compounds in the third generation was designed to increase the 
number of potential interactions within the molecule by increasing the heteroatom 
content of the heteroaromatic ring. This aim was achieved by coupling commercially 
available boronic acids or boronic acid pinacol esters (122–124) with 90 as before. 
The syntheses of 115 and 116 were straight-forward and proceeded in yields of 52% 
and 74%, respectively, after purification by flash column chromatography. The 
synthesis of 117 required some modification of the standard reaction conditions, 
which yielded very little product. As this was the only Suzuki coupling to be carried 
out using the pinacol ester of the boronic acid rather than the free acid, it was thought 
that this may have played a role in the poor yield obtained. The solvent system was 
switched from toluene/ethanol/water to dioxane/water (3:1 ratio),193 which resulted 
in a much cleaner TLC of the reaction with a definite product spot apparent. Due to 
the presence of an additional secondary amino group, 117 was more polar and ran 
close to the baseline of normal phase TLC in 5% MeOH/5% NEt3 in ethyl acetate. 
Despite eluting from a normal phase column under these conditions, the sample 
obtained was not of high purity. A further attempt was made to purify 117 by SCX 
column, which proved unsuccessful, despite eluting as a single spot by TLC, and 
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further efforts to purify were hampered by the insolubility of the product. For this 
reason, work on compound 117 was discontinued. 
 
Compounds 118 and 119 have a shortened amino side chain. This shortening has two 
potential effects: the first is a change in the physical position of the amino group in 
relation the rest of the molecule due to the loss of a CH2 group; the second is 
electronic as the nitrogen lone pair can now delocalise into the aromatic ring system, 
making the nitrogen less basic and the proton more acidic. This alteration also 
reduces the compounds’ H-bond acceptor ability, while retaining H-bond donor 
ability, which is the converse to the compounds in the second generation. 
Compounds 118 and 119 were prepared in one step from the relevant 
pyridinylboronic acid (89 and 97) and 3-bromo-0-methylaniline 125 in good yield 
(Table  3.6). 
 
The final pair of compounds in this series, 120 and 121, possess ring constrained 
amino groups. This approach reduces the entropy of the molecule through restriction 
of the number of conformations in which it can exist. Upon binding to the enzyme, 
the ∆Sbinding will be less negative as there is less decrease in entropy associated with 
binding and therefore binding is more thermodynamically favourable. In addition, 
constrained structures may also exhibit enhanced selectivity.194 
 
It was planned to achieve this side chain constrainment by the preparation of 126, 
which could then be coupled to the pyridinylboronic acid as before. Direct 
bromination of 1,2,3,4-tetrahydroisoquinoline (127) with 0-bromosuccinimide 
proved unsuccessful, instead producing the elimination product 
3,4-tetrahydroisoquinoline,  128 (Scheme  3.8). 
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Scheme  3.8: Reaction of 1,2,3,4-tetrahydroisoquinoline (127) with *-bromosuccinimide. 
Reaction conditions: 0BS (1.1 eq.), DMF, 1 h, 35%. 
 
Grunewald et al.166 previously reported the synthesis of 130 from 1,2,3,4-
tetrahydrosioquinoline (127) via 129 (Scheme  3.9). Following this route, synthesis of 
129 proved to be straight forward and produced only the desired mono-substituted 
product. Use of 2D-NMR spectroscopy confirmed that the nitro group was on the 
desired 7-position. The reported conditions for reduction of the nitro group to an 
amino group (130) involved the use of high pressure hydrogenation. As an 
alternative, reduction using an H-cube hydrogenation was investigated. Using 10% 
Pd/C, 80 bar H2, 1 mL min
-1 at 30 °C showed reduction of the nitro group, seen by 
mass spectrometry and TLC, but in very low yield (< 30%). Instead, chemical 
reduction by SnCl2/HCl proved more successful, resulting in 46% yield after 
precipitation of the amine as its hydrochloride salt. The conversion of 130 to the 
desired alkyl bromide 126 via the diazomium ion intermediate using the Sandmeyer 




Scheme  3.9: Synthesis of 120 and 121. Reaction conditions: i) K0O3 (1.1 eq), conc. H2SO4, 0 °C–
r.t., 16 h; ii) EtOH/HCl, 28%; iii) SnCl2 (3.8 eq.), conc. HCl, water, 100 °C, 20 h; iv) EtOH/HCl, 
46%; v) 0a0O2 (1.1 eq.), aq. HBr, 0 °C,  30 min; vi) CuBr (3 eq.), aq HBr, 75 °C, 1.5 h, 42%).  
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Scheme  3.10: Mechanism of the Sandmeyer reaction. Reaction of nitrite with acid forms the 
nitronium ion in situ. Attack by the amine lone pair results in formation of a diazomium ion, which 
then reacts with CuBr to form the aryl bromide, with release of N2.  
 
The final step in the synthesis of 120 and 121 was the coupling to pyridinylboronic 
acids 89 and 97. Despite reasonable yields of 54 and 55%, respectively, it became 
apparent upon purification that the compounds were not stable. Despite purification 
by flash column chromatography, which eluted the product as a single spot by TLC, 
1H NMR analysis showed a large number of unidentified peaks in addition to the 
product and further TLC analysis of aged samples indicated that degradation was 
occurring. Analysis by mass spectrometry suggested the presence of the imine 131 
(Scheme  3.11).  
 
 
Scheme  3.11: Proposed breakdown of 120 
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Table  3.6: Reaction yields for third generation Suzuki couplings 
Boronic acid Aryl halide Product Yield (%) 
   
52 





   
58 








* Not obtained in high purity 
 
Compound 111 (Section  3.6.3) was resynthesised and achieved this time in 95% 
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3.6.6 Biological testing of third generation compounds 
 
The ability of this third group of compounds to inhibit ABAD activity was then 
determined as before (Figure  3.19).  
 
 
Figure  3.19: Inhibitory effect of third generation compounds on ABAD activity. A) Structures of 
third generation compounds. B) The rate of ABAD activity was measured by determining the rate of 
oxidation of NADH (ε = 6220 L mol-1 cm-1 at 340 nm) during the reduction of S-acetoacetyl-CoA and 
expressed as a percentage inhibition of baseline ABAD activity. Assays were performed in triplicate 
and errors are expressed as ± SEM. Statistical analysis was performed using a pairwise Student’s 
t-test. Baseline measurements (containing no test compound) were performed before, during and after 
the assays (four measurements in triplicate) and showed no significant change in the baseline ABAD 
activity over the course of the experiment (p > 0.38). Assay conditions: 5 µg mL-1 ABAD, 80 µM 
S-acetoacetyl-CoA, 250 µM 0ADH, 1, 5 or 10 mM test compound and 0.5% DMSO in buffer 
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    *** 
    *** 
*    p < 0.05 vs control 
**   p < 0.01 vs control 
*** p < 0.001 vs control 
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The shortening of the amino side chain (118 and 119) led to a decrease in the 
inhibitory effect of the compounds from >70% to <20% at 10 mM. As has been 
previously discussed, this may be as the result of one of two effects: either a steric 
effect because of the change in position of the amino group in relation to the rest of 
the molecule, or an electronic effect due to the delocalisation of the nitrogen lone 
pair into the aromatic ring, leading to loss of H-bond acceptor ability. 
 
Of the changes to the heteroaromatic ring, replacement of the pyridine ring to 
dimethylisoxazole (115) did not result in an active compound. Replacement to 
pyrimidine (116) showed inhibition of > 80% at 10 mM, which is comparable to the 
original compounds, 73 and 74, while the pyrazole (117) showed significant 
inhibition at 1, 5 and 10 mM, although interestingly the 5 mM inhibition was less 
than the 1 mM inhibition. Compound 117 was not, however, of high purity so these 
results must be interpreted with caution.  
 
Similarly, 120 and 121 showed significant inhibition at all three concentrations but 
due to the instability of the compounds, it cannot be known what the active species 
actually was, so again interpretation is difficult. 
 
 
3.6.7 Synthesis of fourth generation compounds 
 
Based on the results obtained from the third generation compounds, it was proposed 
to keep the pyrimidine ring as the heteraromatic portion of the compound. The 
constrainment of the amino side chain into a ring was felt to be interesting but 
needed modification to a more stable compound. Additionally, it was proposed to 
add additional functional groups onto the phenyl rings to increase the number of 
H-bond donors and acceptors (Figure  3.20).  
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Figure  3.20: Fourth generation target compounds. 
 
In compound 132, the β-position was to be blocked by conversion to an amide in 
order to prevent spontaneous conversion to the imine. A literature procedure170 was 
obtained for the conversion of 1,2,3,4-tetrahydroisoquinoline (127) to the amide 136 
via the imine 128 (Scheme  3.12). Using NBS, the amine was converted to the 
imine,169 a result that had been observed during attempts to directly brominate 127 
(Scheme  3.8). From this compound, sodium chlorite was used to oxidise the imine to 
an amide, resulting in the isolation of the desired amide in 50% yield. This reaction is 
thought to proceed through two different reaction mechanisms simultaneously: the 
first results in the direct formation of the amide, while the second goes via a 
chlorinated intermediate, which is then converted to the product, as shown in Scheme 
 3.13. This rate of conversion of the intermediate was reported to be increased greatly 
by the addition of sodium thiosulfate.170  
 
 
Scheme  3.12: Conversion of 1,2,3,4-tetrahydroisoquinoline (127) to the amide 136. Reaction 
conditions: i) 0BS (1.1 eq.), CH2Cl2, r.t., 1 h; ii) aq. 0aOH, r.t., 1 h, 61%; iii) 0aClO2 (5 eq.), aq. 
0aH2PO4 (1 M, 1.5 eq.), THF, r.t., 2 h; iv) aq. 0a2S2O3, r.t., 20 min, 50%. 
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Having established that the reaction conditions worked on the model system shown 
in Scheme  3.12, the same reaction was then carried out using the 7-bromo analogue 
(126) (Scheme  3.14), yielding 138 in an overall yield of 34%. At this stage a 
commercial source of 126 was identified and this was used for future reactions. The 
reactions proceeded as expected, with yields comparable to those obtained in the in 
the test reaction. Subsequent coupling to pyrimidine-5-boronic acid proceeded in 
68% yield.  
 
 
Scheme  3.14: Synthesis of 132. Reaction conditions: i) 0BS (2 eq.), CH2Cl2, 35 °C, 30 min; ii) aq. 
0aOH, r.t., 1 h, 67%; iii) 0aClO2 (5.4 eq.), aq. 0aH2PO4 (1 M, 1.5 eq.), THF, r.t., 1 h; iv) aq. 
0a2S2O3, r.t., 5 min, 51%; v) 138 (1.2 eq), pyrimidine-5-boronic acid (1 eq.), aq. 0a2CO3 (3 eq.), 
Pd(PPh3)4 (0.05 eq.), toluene/EtOH, 110 °C, 16 h, 68%. 
 
The second proposed compound in this series was 133, in which the amine is 
incorporated into a piperazine ring. Although this alteration required replacement of 
a secondary amine with a tertiary amine, which removes the H-bonding ability of this 
group and was previously found to be detrimental to its performance (see Section 
 3.6.4), it was hoped to prevent the elimination due to the lack of α-proton. To counter 
this loss of H-bond donor activity, the piperazine ring introduced an additional 
secondary amine, and it was hoped that this amine would be less susceptible to 
elimination as the driving force of conjugation with the aromatic system was not 
present. The synthesis of 133 was to be achieved through coupling of the 
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Scheme  3.15: Synthesis of 133. Reaction conditions: pyrimidine-5-boronic acid 123 (1 eq.), aq. 
0a2CO3 (3 eq.), Pd(PPh3)4 (0.05 eq.), toluene/EtOH, 110 °C, 20 h. 
 
Reaction of 123 and 139 under Suzuki coupling conditions led to the formation of a 
number of products and TLC analysis also indicated the presence of residual starting 
material, as had been seen in previous reactions. Low resolution mass spectrometry 
could not be used to determine the formation of product due to starting material and 
product being separated by only 0.1 mass unit. Due to the high polarity of the 
compound, purification by normal phase flash chromatography was not thought to be 
possible. Instead, reverse phase chromatography was attempted but separation of 
spots proved difficult and with the least polar spots appearing to elute first and 
several spots simultaneously. No satisfactory separation or isolation of product was 
achieved.  
 
An alternative approach to optimising the phenyl ring portion of the compounds was 
to increase the number of interactions possible by addition of further functional 
groups. Compound 134 was synthesised by coupling the commercially available aryl 
bromide 140 and precipitating as the hydrochloride salt.  
 
 
Scheme  3.16: Synthesis of 134. Reaction conditions: 140 (1.2 eq), pyrimidine-5-boronic acid 123 
(1 eq.), aq. 0a2CO3 (3 eq.), Pd(PPh3)4 (0.05 eq.), toluene/EtOH, 110 °C, 16 h; ii) CH2Cl2, HCl/Et2O, 
36%. 
 
Due to the limited commercial availability of suitable building blocks, it was hoped 
that existing building blocks could be modified by electrophilic aromatic 
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substitution. Starting with 90, a Friedel-Crafts acylation with selected as a test 
reaction to determine the position of substitution. Bromine is ortho and para 
directing, but is also deactivating towards electrophilic aromatic substitution. 
Therefore it was not clear whether or not substitution would occur on the ring 
(Scheme  3.17A). Mass spectrometry indicated the presence of a monoacylated 
product but no diacylated product. The diacylated product was not expected to form 
as the acyl group would deactivate the ring to further electrophilic aromatic 
substiution; in conjunction with the bromine, a second attack would be highly 
unlikely. TLC analysis showed the presence of a new spot, running less polar on the 
TLC plate. This product was isolated by flash column chromatography and identified 
by NMR as the 0-acetylated product 141. At room temperature the 1H NMR 
spectrum, however, apparently showed a mixture of products. Upon heating to 
373 K, these signals coalesced, indicating that the product exists as a mixture of cis- 
















Scheme  3.17: Friedel-Craft acylation. A) Possible sites of electrophilic attack; B) Acylation of 90; 
Reaction conditions: AlCl3 (2.2 eq.), acetyl chloride (1 eq.), anhydrous CH2Cl2, 40 °C, 3 d, 21%. 
 
As had been suspected, the bromide deactivated the phenyl ring to the extent that 
substitution on the 0 atom became more favourable. While it may be possible to 
prevent this by protection and subsequent deprotection of the amine, time constraints 
did not allow alternative routes to be explored. Due to the small mass obtained, the 
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3.6.8 Biological testing of fourth generation compounds.  
 
Due to time constraints, the fourth generation library contained only two final 
compounds for testing, 132 and 134 (Figure  3.21). Compound 132 had very low 
solubility in DMSO, meaning that final concentrations used for testing were 
considerably lower than stated. No significant ABAD inhibition by 132 was seen, but 
this result may just reflect the low concentrations. The only solvent found to dissolve 
132 was chloroform, which could not be used for preparation due to its immiscibility 
with the aqueous buffer required for the assay. Compound 134, as the hydrochloride 
salt, was easily solubilised in DMSO/buffer (1:1 ratio) for the assay. Addition of 1 or 
5 mM 134 was found to give significant inhibition of ABAD activity (47 and 94%, 
respectively, p > 0.001). As with some earlier library compounds, 134 was not tested 
at 10 mM concentration as a result of high baseline absorbance at 340 nm.  The pH 
of the final solution was not found to be altered by the presence of the HCl salt, 
indicating that the observed inhibition was as a result of the compound’s activity and 
not due to a decrease in pH denaturing the enzyme.  
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Figure  3.21: Inhibitory effect of fourth generation compounds on ABAD activity. A) Structures 
of fourth generation compounds. B) The rate of ABAD activity was measured by determining the rate 
of oxidation of NADH (ε = 6220 L mol-1 cm-1 at 340 nm) during the reduction of S-acetoacetyl-CoA 
and expressed as a percentage inhibition of baseline ABAD activity. Assays were performed in 
triplicate and errors are expressed as ± SEM. Statistical analysis was performed using a pairwise 
Student’s t-test. Baseline measurements were performed in the absence of test compound. Assay 
conditions: 5 µg mL
-1
 ABAD, 80 µM S-acetoacetyl-CoA, 250 µM 0ADH, 1, 5 or 10 mM (10 mM 132 
only) test compound and 0.5% DMSO in buffer containing 50 mM sodium phosphate, 300 mM sodium 
chloride, pH 7.4 at 30 °C. 
 
 
3.7 Computational docking studies 
 
Having synthesised a series of compounds that acted as inhibitors of ABAD activity, 
it was hoped that the structure of the compounds could be further refined in the 
future. This optimisation would be greatly assisted by knowledge of the mode of 
action of the compounds and the protein-ligand interactions occurring.  
 
The previously reported ABAD inhibitor, AG18051, exerts its inhibitory nature by 























       *** 
    *** 
*** p < 0.001 vs control 
B 
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(Scheme  3.18).119 This therefore provided one possible mechanism through which 
the present compounds could act. 
 
The most desirable method for examining the binding of ligands to a protein is X-ray 
crystallography. Successful crystallisation of ABAD with a ligand would have 
provided strong evidence of the interactions occurring between the fragments and 
ABAD, not only identifying the location of the binding site but also the specific 
ABAD-inhibitor interactions likely to be involved. However, crystallisation attempts 
were unsuccessful (Section  3.5.2, Appendix  B) and in light of this, it was decided to 
perform docking studies of ABAD with one of the newly synthesised ABAD 
inhibitors. These computational protein-ligand studies simulate binding between a 
protein and ligand and predict potential binding sites, ligand conformations and 
binding energies. 
 
Using ICM Pro software (Version 3.7-2a, Molsoft), the ABAD protein structure was 
analysed for potential binding sites. Docking studies require a pre-existing crystal 
structure on which to perform the calculations. The published structure of ABAD 
with bound AG18051 (protein data bank accession number 1U7T)119 has three 
monomers with the AG18051-NAD+ adduct bound and the fourth (subunit B) with 
only NAD+. To ease the complexity of calculations, a single monomer of ABAD, 
rather than the tetramer, was used and subunit B of this ABAD crystal structure was 
therefore selected for docking studies as it had NAD+ bound without the inhibitor.  
 
Three potential binding sites were identified on the ABAD monomer: these are 
labelled site 1 (grey), site 2 (red) and site 3 (blue) (Figure  3.22). Site 1 is located on 
the opposing face of the enzyme to the active site. Site 2 corresponds to the enzyme 
active site. Site 3 was found to be inaccessible when the other three monomers were 
added in to form the tetramer and was therefore excluded as a potential binding site.  
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Figure  3.22: Predicted ABAD binding sites in the presence of .AD
+
. A) ABAD monomer: Site 1 
(grey), site 2 (red) and site 3 (blue) were identified using ICM software (Molsoft); B) When viewed in 
tetramer form, binding site 3 was not accessible 
 
 
3.7.1 Docking of a ligand to binding site 1 
 
Compound 116 was selected as the ligand for docking studies; at the time of these 
studies being performed, it was the compound exhibiting the greatest inhibition 
against ABAD activity. Binding site 1 is located on the opposite face of the enzyme 
to the active site, raising the possibility that an allosteric binding site exists within the 
ABAD protein structure. To date, the presence of an allosteric binding site in ABAD 
has not been reported in the literature and, if confirmed, would present a novel 
method for targeting the activity of ABAD. 
 
 
Figure  3.23: Structure of compound 116, used for ABAD docking studies. 
 
Starting with the ligand in open space, 116 was docked into this binding site. The 
binding of twenty conformations were calculated and were found to have energies 
ranging from -51.3 to -43.7 kcal mol-1 (Table  3.7).  
 
A B 
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1 -51.33 11 -46.53 
2 -51.32 12 -46.33 
3 -48.07 13 -45.98 
4 -48.07 14 -45.92 
5 -47.97 15 -45.75 
6 -47.97 16 -45.46 
7 -47.51 17 -44.85 
8 -47.25 18 -44.67 
9 -47.23 19 -44.22 
10 -46.55 20 -43.69 
 
The ligand was found to bind in two different orientations, examples of which are 
shown in Figure  3.24. It can be seen that the ligand fits neatly into the binding 
pocket, with restricted options for structure expansion. 
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Figure  3.24: Selected conformations of 116 docked into predicted ABAD binding site 1. The 
ligand is shown in the foreground. A) Conformation 1, -51.33 kcal mol-1; B) Conformation 
2, -48.07 kcal mol-1. 
 
 
3.7.2 Docking of a ligand to binding site 2 
 
The second binding site (site 2) corresponds to the enzyme active site. Before 
docking, all water molecules not directly interacting or tightly bound to the protein 
were removed, leaving two water molecules buried in the NAD+ binding pocket. 
Starting again with 116 in space, the ligand was docked into the enzyme. Nineteen 
conformations were calculated, with binding energies of -44.4 to -40.2 kcal mol-1 
(Table  3.8).  
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1 -44.37 11 -41.87 
2 -43.94 12 -41.59 
3 -43.94 13 -41.39 
4 -43.79 14 -41.39 
5 -43.17 15 -40.58 
6 -42.64 16 -40.53 
7 -42.63 17 -40.19 
8 -42.4 18 -40.15 
9 -42.4 19 -40.15 
10 -42.39   
 
Images of selected conformations can be seen in Figure  3.25. The nine lowest energy 
conformations were found to have the amine side chain in the inner-most region of 
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Figure  3.25: Selected conformations of 116 docked into predicted ABAD binding site 2 in the 
presence of .AD
+
. The ligand is shown in the foreground; NAD+ can be seen further into the binding 
pocket. A) Conformation 1, -44.37 kcal mol-1; B) Conformation 2, -43.94 kcal mol-1; C) 
Conformation 10, -42.39 kcal mol-1. 
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It is proposed by Kissinger et al. that the formation of the NAD-AG18051 covalent 
adduct results from attack of the AG18051 N2 lone pair on the reactive carbon of the 
NAD+ nicotinamide ring and deprotonation of the pyrazole N–H by the deprotonated 
Tyr-168 residue of ABAD, which forms part of the conserved catalytic triad in the 
active site (Scheme  3.18).119  
 
 
Scheme  3.18: Proposed reaction between AG18051 and .AD
+
.
119 The inhibitor, AG18051, is 
shown in red, the nicotinamide portion of the co-factor, NAD+, is shown in blue and the ABAD 
Tyr-168 residue side chain is shown in black. The reactive carbon of nicotinamide is attacked by the 
N2 lone pair of AG18051; the deprotonated Tyr-168 residue then deprotonates the pyrazole N-H to 
quench the positive charge. 
 
In the present study of ABAD and 116, it was therefore of interest to determine 
whether or not the ligand 116 was able to react in a similar manner to AG18051. The 
distance between the ligand 0 atom (either in the pyrimidine ring or in the amino 
side chain) and the reactive carbon atom of NAD+ was determined. A typical C–N 
bond length is of the order of 1.46 Å;196 indeed this was the distance found in the 
NAD-AG18051 complex. The equivalent distance between carbon and nitrogen for 
the predicted ABAD/NAD-116 models was found to be 4.9, 3.8 and 3.4 Å for 
conformations 1, 2 and 10, respectively (Figure  3.25), making reaction unlikely. In 
addition, the reaction mechanism through which the nitrogen atoms of 116 could 
potentially react will be different to that of AG18051. Attack by the pyrimidine 
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nitrogen is unlikely owing to the lack of adjacent N–H group for deprotonation to 
quench the resulting negative charge, as was the case in AG18051. Attack by the 
amino nitrogen lone pair may be possible, although the large distance (~6 Å) 
between Tyr-168 and the resulting R3N
+–H make subsequent deprotonation unlikely.  
 
In the absence of NAD+, binding site 2 was extended to include the NAD+ binding 
site, creating a long channel through the enzyme. Compound 116 was essentially 
found to be able to bind along the entirety of this channel, so it was not thought to 
yield any useful predictions about the location of the ligand and its interactions 
(Figure  3.26).  
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Figure  3.26: Selected conformations of 116 docked into predicted ABAD binding site 2 in the 
absence of .AD
+
. A) Binding site 2 (red) is extended into the NAD(H) binding pocket in the absence 
of the co-factor; B) The extended binding site forms a channel through the enzyme. C–E) Compound 
116 was predicted to bind at several locations throughout this channel. 
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This study has revealed some interesting possibilities for the future synthesis of 
further ligand libraries. While docking studies do not replace the hard evidence 
obtained by crystallography, they are often useful as an indication of potential 
binding sites. Based on the binding predictions obtained, enzyme inhibition through 
the covalent interaction of 116 with NAD+ to form a covalent adduct, as with 
AG18051, was thought to be unlikely. However, the identification of a potential 
allosteric binding site on ABAD (site 1) was of particular interest for future studies 
as this may provide a novel mechanism for targeting the enzyme.  
 
 
3.8 Conclusions and future work 
 
Using thermal shift analysis as an initial screen, a group of small molecular 
fragments (MW <250 Da) were identified as inhibitors of ABAD activity. Two of 
these compounds shared a related structure so were selected first for further 
development. Using traditional medicinal chemistry approaches to determine the 
structure-activity relationship (SAR) of these compounds, a series of analogues was 
synthesised. Within this series, it was determined that the presence of both the 
pyridine ring and the amino side chain, found in the initial fragment hits, was critical 
for activity of the compounds. This was as expected; it has been previously reported 
that the original fragment structure is generally maintained throughout the 
development process. Due to the nature of hits identified by fragment-based 
screening approach, this observation is unsurprising; hits tend to be low in 
functionalisation, therefore the functional groups present are significantly involved in 
the compounds’ interactions. 
 
A summary of the progress made in the synthesis of 73 and 74 analogues can be seen 
in Scheme  3.19. The iterative process has begun to make progress in decreasing the 
IC50 of the compounds, with 134 having an IC50 of around 1 mM. It is hoped that 
having done the initial groundwork of determining the importance of the component 
regions of the molecules, future development will proceed at a greater rate. Docking 
studies have identified two potential binding sites, to which this series of compounds 
could bind. Further, more in depth analysis of more ligands using this technique may 
Chapter 3. Results and Discussion: Small molecule inhibitors of ABAD 
 151 
yield useful information about what route to take with the synthesis of future 
compounds. 
 
Initial investigations of the possible mode of action of these compounds were also 
made. While no co-crystal structures were obtained, docking studies indicated the 
presence of a potential allosteric binding site located well away from the enzyme 
active site. In addition, the existence of a known inhibitor of ABAD, AG18051, may 
assist with study of the current compounds in determining their mode of action. It is 
known that AG18051 sits in the active site of ABAD and forms a covalent bond with 
the co-factor, NAD+. Competition or displacement studies with AG18051 may 
therefore indicate whether or not the inhibitors are binding to the active site or an 
alternative allosteric site.  
 
There is therefore scope for future work in this area to continue. It is hoped that 
further iterative cycles of analogue synthesis will yield compounds with lower IC50 
values, in the micromolar and eventually nanomolar range, making them useful 
probes for the study of this enzyme.  







































































































































































Scheme  3.19: Summary diagram of synthesised ABAD inhibitors. Compounds are grouped by 
their structural characteristics and colour-coded by the library generation (first generation, blue; 
second generation, green; third generation, orange; fourth generation, magenta). Dotted lines represent 
compounds which showed no improvement in inhibition; solid lines represent compounds that showed 








Chapter 4: Investigation of (–)-CHANA, a fluorogenic probe 










Studying enzymes using purified protein is often a useful starting point for learning 
about the enzyme and characterising its function and mode of action. However, 
enzymes do not exist in isolation within cells and the actions associated with an 
isolated protein may be heavily influenced and affected by other upstream and 
downstream biochemical pathways within the cell. For this reason, the development 
of an appropriate cell-based assay is beneficial to assisting the design of drugs and 
probes which target intracellular processes. 
 
The development of a fluorogenic probe for monitoring the activity of ABAD in 
living cells was reported by Froemming and Sames in 2008.120 Based on the structure 
of the endogenous ABAD substrate, oestradiol (142), cyclohexenyl amino 
naphthalene alcohol (CHANA, 144), was found to be oxidised by ABAD in the 
presence of NAD+ to the corresponding ketone, cyclohexenyl amino naphthalene 
ketone (CHANK, 145). The design of this compound is shown in Scheme  4.1. 
 
 
Scheme  4.1: Development of a fluorogenic probe for ABAD activity.
120
 The structure of oestradiol 
142, a natural substrate for ABAD, was simplified to the generic structure, 143. From this, compound 
144, CHANA, was developed, which was found to be oxidised by ABAD to the corresponding 
ketone, 145. 
 
This probe was designed with specific photophysical properties in mind to allow its 
use as an in vitro reporter molecule: CHANK is fluorescent in non-aqueous 
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environments, while CHANA is non-fluorescent under the same conditions. These 
properties are ideally suited to the study of CHANA metabolism in cells as the 
hydrophobic product accumulates in hydrophobic cellular structures, where its 
accumulation can be detected by fluorescence microscopy.  
 
Froemming and Sames demonstrated that the racemic mixture of CHANA was a 
substrate for ABAD, both with recombinant purified protein and in living cells.120 
Using purified human ABAD they determined a specific activity of 
0.65 µmol min-1 mg-1 and a KM of 15 µM. A cellular assay indicated CHANA 
metabolism by living cells: in untransfected HEK293T cells treated with CHANA, 
the fluorescence observed in the cells increased over time as the fluorescence product 
accumulated. In cells that had been transfected with a plasmid encoding for HSD10 
(ABAD), this fluorescence was enhanced, indicating that the additional ABAD 
present was contributing to the CHANA metabolism (Figure  4.1).  
 
 
Figure  4.1: Metabolism of CHA.A by HEK293T cells. HEK293T cells were null-transfected (A–
C) or transfected with HSD10 (ABAD) (D–F) for 24 h before incubating with 20 µM CHANA for 0–
4.5 h. Images taken with fluorescence microscopy, emission filter 585 nm. Reprinted with permission 
from M. Froemming & D. Sames.120  Copyright 2007 American Chemical Society. 
 
Kinetic resolution of the racemic compound to (+)- and (–)-enantiomers revealed that 
ABAD was selective for the (–)-enaniomer, (–)-CHANA (Figure  4.2). (–)-CHANA 
0 h 2 h 4.5 h 
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was found to exhibit minimal activity in null-transfected cells and much greater 
levels of metabolism in cells over-expressing ABAD (Figure  4.2C, D). Meanwhile, 
(+)-CHANA was shown to be metabolised at similar rates in null-transfected and 
ABAD-transfected cells, indicating that the presence of additional ABAD did not 
lead to increased metabolism of the substrate (Figure  4.2A, B). This indicated that 
ABAD was able to utilise (–)-CHANA selectively as a substrate.121 
 
 
Figure  4.2: Metabolism of (+)- and (−)-CHA.A in ABAD-transfected HEK293T cells. A) 
Conversion of (+)-CHANA in ABAD and null transfected cells imaged by fluorescence microscopy 
and quantified by ImageJ (B). C) Conversion of (−)-CHANA in ABAD and null transfected cells 
imaged by fluorescence microscopy and quantified by ImageJ (D). Reprinted with permission from 
Muirhead et al.121  Copyright 2010 American Chemical Society. Experiment performed by 
M. Froemming. 
 
In addition, it was demonstrated that the oxidation of (–)-CHANA to CHANK could 
be inhibited by addition of a known inhibitor of ABAD. AG18051 was first reported 
by Kissinger et al,119 as an inhibitor of ABAD with an IC50 of 92 nM (see Section 
 3.7.2). Work by our collaborators demonstrated that when AG18051 was applied to 
cells in conjunction with (–)-CHANA, the production of fluorescence as a result of 
146 147 
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(–)-CHANA oxidation was reduced.121 It was found that AG18051 inhibited this 
process with an IC50 of 140 nM, a value which is comparable to that calculated from 
the inhibition of purified ABAD. 
 
It was therefore envisioned that the use of (–)-CHANA could be developed further to 
create a cellular based assay for studying the effects of amyloid and other molecules 
on the activity of ABAD.  
 
 
4.2 Chapter aims 
 
The aim of the work described in this chapter was to define the parameters and 
conditions under which (–)-CHANA could provide a simple fluorescence read-out as 
a measurement of the activity of ABAD within living cells. In particular, it was 
desirable to investigate the application of (–)-CHANA in the potential study of the 
ABAD-Aβ interaction. As it had already been shown that inhibition of ABAD 
activity using a small molecule inhibitor could be observed using this method, the 
inhibition by Aβ was investigated. This was of particular interest and significance as 
the ability to study Aβ-induced inhibition of ABAD activity within cells would then 
allow the detection of a subsequent “rescue” of ABAD activity by small molecule 
inhibitors of the ABAD-Aβ interaction. 
 
 
4.3 (–)-CHA.A metabolism by purified ABAD protein 
 
Before studying (–)-CHANA in cells, the ability of ABAD to oxidise (–)-CHANA 
was verified in vitro using purified ABAD protein. Modification of the previously 
described ABAD activity assay (Section  3.4, described in more detail in Section 
 5.3.1) allowed the oxidation of (–)-CHANA to be measured. The reduction of NAD+ 
to NADH was calculated by measuring the increase in NADH absorbance at 340 nm 
over time (Figure  4.3; see Materials and Methods, Section  2.7.1 for experimental 
detail). Conveniently, (–)CHANA and CHANK have identical extinction co-
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efficients at 340 nm,197 so the change in relative proportions of product and substrate 
over time did not interfere with the assay measurement.  
 
 
Figure  4.3: Oxidation of (–)-CHA.A by ABAD. Oxidation of (–)-CHANA (147) can be monitored 
by measuring the increase in absorbance at 340 nm, which results from the corresponding reduction of 
the co-factor NAD+ to NADH. 
 
Using this method, the enzyme parameters for ABAD using (–)-CHANA as the 
substrate were measured. The human recombinant protein used was available in two 
forms: with and without a His-tag. The His-tag was present to allow purification of 
ABAD protein by Ni-affinity chromatography and could be optionally removed 
during the purification process (see Materials and Methods, Section  2.2). As both 
forms were available, the activity of (–)-CHANA was examined with both 
His-tagged ABAD (His-ABAD, Figure  4.4) and native ABAD (Figure  4.5). Table 
 4.1 shows the calculated enzyme parameters for ABAD/(–)-CHANA. Notably, as 
had been seen in other activity assays that utilised S-acetoacetyl-CoA as the 
substrate, the presence of the His-tag decreased the activity of ABAD (Section 
 5.3.1).  
 




Figure  4.4: Kinetics of His-ABAD with (–)-CHA.A as substrate. A) Michaelis-Menten ([S] vs V) 
and B) Lineweaver-Burke (1/[S] vs 1/V) plots for the oxidation of (–)-CHANA by His-ABAD. The 
change in absorbance at 340 nm was measured (20 min) and the initial rate of NAD+ oxidation 
calculated. Measurements were performed in triplicate and errors shown as ± SEM. Assay conditions: 
(–)-CHA0A (2–50 µM), 0AD
+
 (500 µM), ABAD (5 µg mL
-1



































































Figure  4.5: Kinetics of native ABAD with (–)-CHA.A as substrate. A) Michaelis-Menten ([S] vs 
V) and B) Lineweaver-Burke (1/[S] vs 1/V) plots for the oxidation of (–)-CHANA by native ABAD. 
The change in absorbance at 340 nm was measured (20 min) and the initial rate of NAD+ oxidation 
calculated. Measurements were performed in triplicate and errors shown as ± SEM. Assay conditions: 
(–)-CHA0A (2–50 µM), 0AD
+
 (500 µM), ABAD (5 µg mL
-1
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Table  4.1: Enzyme kinetics for ABAD with (–)-CHA.A as substrate. Assay conditions: (–)-
CHA0A (2–50 µM), 0AD
+
 (500 µM), ABAD (5 µg mL
-1
) in buffer (0.1 M K2HPO4, pH 9.0)  
 His-ABAD .ative ABAD 
Vmax (µmol min
-1 mg-1) 0.096 0.75 
KM
 (µmol L-1) 20 97 
kcat (s
-1) 0.043 0.33 
kcat/KM (mol L
-1 s-1) 2150 3402 
 
Having confirmed independently that the probe was active with human ABAD, two 
approaches were to be investigated to develop a cellular assay: fluorimetry and 
fluorescent microscopy.  
 
Before this work was undertaken, it was desirable to be able to over-express ABAD 
within cells in order to boost the observed signal resulting from (–)-CHANA 
oxidation, as had been previously demonstrated by Froemming.120 This required the 
creation of an appropriate DNA plasmid encoding ABAD. 
 
 
4.4 Construction of a mitochondrial-targeted ABAD plasmid 
 
In order to over-express ABAD in cells, a DNA plasmid encoding human ABAD 
was required. The plasmid was designed to incorporate a mitochondrial targeting 
sequence (MTS) at the 0-terminus of the ABAD sequence in order to target 
increased ABAD expression to the region of the cell most relevant to the study of 
AD. The plasmid was created by amplifying the mito-ABAD region of the 
mito-ABAD-GFP plasmid157 using PCR, encoding HindIII and XhoI restriction sites 
at either end. The amplified DNA insert and empty vector, pcDNA3, were digested 
with HindIII and XhoI restriction enzymes before ligating with DNA ligase to 
generate the MTS-ABAD plasmid (Figure  4.6, see Materials and Methods, Section 
 2.1 and Appendix  C). 
































Figure  4.6: Construction of a mitochondrial-targeted ABAD plasmid (MTS-ABAD). The 
MTS-ABAD region was amplified from the mito-ABAD-GFP plasmid using PCR, encoding HindIII 
and XhoI sites at either end of the DNA insert. The insert and empty pcDNA3 vector were digested 
with the HindIII and XhoI restriction enzymes before ligating together using DNA ligase to create the 
MTS-ABAD plasmid. MTS = mitochondrial targeting sequence. 
 
Western blot analysis of MTS-ABAD-transfected HEK293 cells showed increased 
ABAD expression, with two bands detected at 27 and 30 kDa (Figure  4.7). These 
bands correspond to ABAD and MTS-ABAD, respectively. As MTS-ABAD enters 
the mitochondria, the MTS-tag is cleaved,198 resulting in the observed increase in 
untagged ABAD expression. 
 




Figure  4.7: Expression of ABAD in MTS-ABAD-transfected HEK293 cells.  HEK293 cells were 
transfected with pcDNA3 (left lane) or MTS-ABAD (right) for 48 h, after which time cells were 
harvested and the protein extracted for Western blot analysis. The blot was probed with anti-ABAD 
(rabbit, 1:5000) and anti-rabbit HRP (goat, 1:20000), revealing bands at ~27 kDa (ABAD) and 
~30 kDa (MTS-ABAD). Protein loading was controlled for by stripping and reprobing for β-actin 
(42 KDa) with anti-β-actin (mouse, 1:20000) and anti-mouse HRP (goat, 1:20000). 
 
With this plasmid in hand, it was then possible to begin cell-based experiments with 
(–)-CHANA using cells over-expressing ABAD. 
 
 
4.5 Fluorimetric measurement of (–)-CHA.A metabolism 
 
The simplest approach to quantifying the fluorescence produced by cells following 
treatment with (–)-CHANA was thought to be simply measuring the intensity of 
fluorescence emitted using a fluorimeter. One of the main advantages associated with 
this method was the potential for simple conversion to a high throughput assay as the 
technology for 96 or 384 well plate measurements is commercially available. 
 
The fluorimeter set-up, which consisted of a horizontal light beam, required the cells 
to be grown on removable coverslips to allow vertical mounting into the beam. 
HEK293 cells were grown on coverslips and treated with 20 µM (–)-CHANA before 
measuring the fluorescence emitted by the cells (Figure  4.8A, see Materials and 
Methods, Section  2.7.2 for experimental details). 
 
The results of this initial experiment looked promising: cells that had been 
transfected with MTS-ABAD emitted stronger fluorescence than untransfected cells, 
as did cells incubated with CHANA for 2 h compared with those incubated for 
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30 min (Figure  4.8B). As expected, this result indicated that the higher the ABAD 
expression in cells, the higher the rate of (–)-CHANA oxidation and hence a greater 
intensity level of fluorescence was observed. Similarly, the longer the (–)-CHANA 
incubation period, the greater the accumulation of CHANK, which again increased 
the fluorescence observed.  
 
 
Figure  4.8: Fluorimetery studies of (–)-CHA.A-treated cells. A) HEK293 cells (untransfected or 
transfected with mitochondrial-targeted ABAD [MTS-ABAD] for 24 h) were grown on coverslips and 
incubated with 20 µM (–)-CHANA for 30 min or 2 h before cooling at 0 °C to prevent further 
enzymatic activity. Coverslips were mounted in a fluorimeter and the fluorescence recorded (ex. 
405 nm, em. 470–600 nm); B) Quantification of fluorescence emission at λmax (500 nm). N=2, with 
the exception of tranfected, 2 h (N=3) and untransfected, 30 min (N=1). 
 
Froemming & Sames120 had previously reported that the increase of fluorescence was 
linear over at least 5 hours, and with this in mind, a longer period time course study 
was set up, with incubation periods of 0–19 hours. As can be seen in Figure  4.9, 
fluorescence did in fact decrease after the first hour. However, it was observed 
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number of cells present within the beam. Due to the fact that the samples were 
prepared and then stored on ice for transportation purposes, it was apparent that the 
cells were starting to detach from the coverslip before the measurements were taken 
(particularly for later samples measured, which were those of short incubation 
periods). As a result of detachment, the cells were visible to the naked eye and it 
could be seen that cell coverage on the coverslip was not even. Ensuring that an area 
of high cell density was in the beam resulted in higher fluorescence readings. It was 
therefore concluded that unless an even cell distribution could be guaranteed, this 
















































Figure  4.9: Time course fluorimetery study of (–)-CHA.A-treated cells. A) HEK293 cells were 
transfected with mitochondrial-targeted ABAD (MTS-ABAD, 24 h) and incubated with 20 µM (–)-
CHANA for 0–19 h before cooling at 0 °C to prevent further enzymatic activity. Coverslips were 
mounted in a fluorimeter and the fluorescence recorded (ex 405 nm, em 500 nm); 0 = 1–5. 
 
Due to instrument availability, these experiments had to be conducted using a 
horizontal beam fluorimeter. A downside of this method was that it required a 
separate dish of cells for each time point; therefore a more convenient method would  
be to continually monitor the same cells over a set time course, something that could 
be achieved using glass-bottomed dishes with a vertical beam instrument. This would 
not however remove the problems associated with inconsistent cell coverage and so 
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an alternative method was sought that could take into account the uneven cell 
coverage that occurs during cell culture. 
 
 
4.6 Fluorescence microscopy as a technique for studying realtime (–)-CHA.A 
metabolism in living cells 
 
The second approach to be investigated was fluorescence microscopy, which allowed 
the fluorescence produced by (–)-CHANA treated cells to be monitored in real time 
over a set time period.  
 
The fluorescent product, CHANK, emits its fluorescence over 450–600 nm; images 
obtained by Froemming & Sames (e.g. Figure  4.1)120 collected the fluorescence at 
585 nm, so only a tiny fraction of the total fluorescence emitted was actually detected 
(Figure  4.10). Current experiments were carried out using a Leica SP MP confocal 
microscope. The emission collection window on this microscope was able to collect 
fluorescence over any desired wavelength range; this allowed a larger proportion of 
the fluorescent emissions to be collected and hence provide a more sensitive method 
of measurement than previously reported.  
 
 
Figure  4.10: Excitation and emission spectrum of the fluorescent product, CHA.K. The 
emission spectrum of CHANK in chloroform is shown by the red line. The total emission available for 
collection is shaded in grey; the area under this curve is much larger than that collected by 
Froemming,120 shown by black line (585 nm). Spectra provided by M. Froemming, Columbia 
University, New York. 




A significant benefit of microscopy over fluorimetery was found in the analysis of 
results. In the case of fluorimetery, the reading obtained is the sum of all 
fluorescence emitted by the sample, which led to problems when cell coverage was 
non-uniform (Section  4.5). With microscopy, images were taken then analysed using 
ImageJ software (US National Institutes of Health). This process allowed the mean 
fluorescence rather than the total fluorescence of the image to be calculated. Setting a 
threshold fluorescence level for calculation of the mean removed non-fluorescent 
regions from the calculation (i.e. only cells were measured, non-cell regions of the 




4.6.1 Characterisation of cellular (–)-CHA*A metabolism 
 
Using Froemming’s original work on racemic CHANA as a framework for 




4.6.1.1 (–)-CHA0A metabolism in cells over-expressing ABAD 
 
Using standard fluorescence microscopy, (–)-CHANA metabolism had been shown 
to be enhanced in cells over-expressing ABAD (Figure  4.2A). Using confocal 
fluorescence microscopy, a time course study of (–)-CHANA metabolism in 
HEK293 cells, transfected with either pcDNA3 (empty vector) or MTS-ABAD, was 
set up. Due to the wider emission window of the microscope, the fluorescence 
resulting from the build-up of CHANK was more rapidly detected, leading to the 
required incubation period being reduced from 4–6 h to 1 h, with images being taken 
every 15 min. For further details on experimental procedure, see Materials and 
Methods, Section  2.7.3. As expected, a higher intensity of fluorescence was detected 
from the ABAD-transfected cells as the increased expression of ABAD enhanced the 
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rate of metabolism of (–)-CHANA (Figure  4.11A). Using ImageJ analysis, the 
images obtained by fluorescent microscopy were quantified and showed a significant 
increase in signal from MTS-ABAD-transfected cells compared with the pcDNA3 
(empty plasmid) transfected cells (p < 0.01) (Figure  4.11B). Western blotting 
confirmed the increase in ABAD protein expression (Figure  4.11C). 
 
 
Figure  4.11: (–)-CHA.A metabolism by HEK293 cells. A) HEK cells incubated with 2 µM (−)-
CHANA: untransfected cells (top) and MTS-ABAD transfected cells (1 µg, 24 h; bottom). Images 
obtained by confocal microscopy on live cells, 37 °C; excitation 405 nm, emission 500-520 nm; B) 
Quantification was performed using ImageJ. For each data point, three images per dish were taken and 
each dish was carried out in three separate experiments, giving a total of 9 intensity values, from 
which the mean and standard error was calculated. Errors are given as SEM. Statistical significance 
was determined using the Student’s t-test.; C) HEK293 cells were transfected with pcDNA3 (left lane) 
or MTS-ABAD (right) for 48 h, after which time cells were harvested and the protein extracted for 
Western blot analysis. The blot was probed with anti-ABAD (rabbit, 1:5000) and anti-rabbit HRP 
(goat, 1:20000), revealing bands at ~27 kDa (ABAD) and ~30 kDa (MTS-ABAD). Protein loading 
was controlled for by stripping and reprobing for β-actin (42 KDa) with anti-β-actin (mouse, 1:20000) 
and anti-mouse HRP (goat, 1:20000). Reprinted with permission from Muirhead et al.121  Copyright 








































** p < 0.01 
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Interestingly, low levels of (–)-CHANA metabolism were observed in the 
untransfected cells. While this had been observed with racemic CHANA, metabolism 
of the enantiomerically pure (–)-CHANA had not been previously observed in 
untransfected cells (Figure  4.2).121 The advantage of the increased sensitivity of 
confocal microscopy compared with standard fluorescence microscopy was clearly 
apparent in this instance. 
 
The HEK293 cells used in the experiments described above are a cell line derived 
from human embryonic kidney cells, transformed with adenovirus Ad5 DNA.199 
Despite originating from kidneys, more recent investigations of this cell line 
indicated that the cells share many characteristics associated with neuronal cells.200 
This cell line therefore represented an appropriate starting point for cellular studies 
investigating aspects of AD and had the advantage of being easy to grow and 
maintain. The experiments were then extended to the SK-N-SH cell line: a human 
neuroblastoma cell line, which is described as a “neuronal-like” cell line.201 
 
While HEK293 cells were easily transfected with MTS-ABAD, transfection of 
SK-N-SH cells proved rather more difficult. In this instance, electroporation was 
chosen as the transfection method. Nucleofection® (Amaxa) is an electroporation 
method that delivers DNA directly to the nucleus. Use of the nucleofection settings 
recommended by Amaxa, the nucleofector manufacturer, resulted in high levels of 
cell death, with too few cells remaining viable for further experiments. Switching to 
a different transfection medium (Mirus Ingenio solution) resulted in lower cell death. 
Analysis by Western blotting showed the expression of MTS-ABAD at 30 kDa 
(Figure  4.12A); however, the overall expression of ABAD was comparable to that of 
mock-transfected cells, which was in stark contrast to the obvious increase in ABAD 
expression in transfected HEK293 cells (Figure  4.11C). As expected, there was 
therefore no difference in fluorescence between transfected and untransfected cells 
upon addition of (–)-CHANA (Figure  4.12B).  
 




Figure  4.12: (–)-CHA.A metabolism by SK-.-SH cells. A) SK-N-SH cells were transfected with 
pcDNA3 (left lane) or MTS-ABAD (right) using Mirus BioIngenio electroporation solution and an 
Amaxa nucleofector. After 48 h, cells were harvested and the protein extracted for Western blot 
analysis. The blot was probed with α-ABAD (rabbit, 1:5000) and α-rabbit HRP (goat, 1:20000), 
revealing bands at ~27 kDa (ABAD) and ~30 kDa (MTS-ABAD). Protein loading was controlled for 
by stripping and reprobing for β-actin (42 KDa) with α-β-actin (mouse, 1:20000) and anti-mouse HRP 
(goat, 1:20000). B) SK-N-SH cells incubated were transfected with pcDNA3 or MTS-ABAD for 48 h. 
Cells were then treated with 2 µM (−)-CHANA before confocal fluorescence imaging: 37 °C 
excitation 405 nm, emission 470-540 nm. Fluorescence intensity was quantified using ImageJ. For 
each data point, three images per dish were taken and each dish was carried out in three separate 
experiments, giving a total of 9 intensity values, from which the mean and standard error was 
calculated. Errors are given as SEM. Statistical significance was determined using the Student’s t-test. 
 
As with HEK293 cells, background fluorescence was detected in untransfected 
SK-N-SH cells and native ABAD was detected by Western blotting, leading to the 
conclusion that it may be possible to measure endogenous ABAD activity rather 
relying on the over-expression of ABAD, which had proved to be difficult to achieve 
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The confirmation that (–)-CHANA metabolism could be observed in 
MTS-ABAD-transfected cells meant that ABAD activity could be easily monitored 
in HEK293 cells, which would prove useful for later applications (Section  4.8). 
However, the observation of (–)-CHANA metabolism by endogenous enzyme in 
untransfected HEK293 and SK-N-SH cells was also of interest, as this had not been 
expected. This aspect was therefore investigated further.  
 
 
4.6.1.2 Localisation of CHA0K accumulation  
 
An interesting observation during the studies outlined in Section  4.6.1.1 was that 
CHANK production was observed in untransfected cells, indicating the presence of 
endogenous ABAD activity. This had not been observed previously by standard 
fluorescence microscopy with (–)-CHANA (Figure  4.2) and was likely due to the 
increased sensitivity of the experimental set-up used. Further examination of the 
images revealed that CHANK fluorescence was not uniform throughout the cell and 
indeed appeared to accumulate within defined cellular structures (Figure  4.13).  
 
 
Figure  4.13: Localised accumulation of CHA.K fluorescence within cellular structures. 
Untransfected HEK293 cells were incubated with 2 µM (–)-CHANA for 60 min before imaging with 
confocal microscopy (63 × oil objective, 200 Hz, ex 405 nm, em 470–540 nm).  
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Although ABAD has been shown to be located within distinct cellular regions, 
including mitochondria, endoplasmic reticulum (ER) and the cell 
membrane,105,115,116,202 it is mitochondrial ABAD in particular that has been 
implicated in the progression of Alzheimer’s disease.105 It was therefore noted with 
interest that co-staining of (–)-CHANA treated cells with MitoTracker Deep Red 
(Invitrogen), a mitochondrial dye, revealed co-localisation of a proportion of the 
CHANK fluorescence with the mitochondrial marker, indicating its accumulation 
within the mitochondria. As well as HEK293 and SK-N-SH cells, this was also found 
to be the case in primary mouse cortical neurons (Figure  4.14).  
 
 
Figure  4.14: Localisation of (−)-CHA.A metabolism product in untransfected cells. HEK293 
(top), SK-N-SH (middle) and mouse cortical neurons (bottom) were stained with MitoTracker Deep 
Red (HEK/SK-N-SH 25 nM, neurons 100 nM, 40 min), then (−)-CHANA (2 µM, 1 h). Images of live 
cells were taken by confocal microscopy (63 × oil objective, 200 Hz): MitoTracker (left, red), ex. 633 
nm, em. 640-700 nm; CHANK (centre, green), ex. 405 nm, em. 470-540 nm; the merged image (right) 
shows co-localisation of MitoTracker and CHANK in yellow. 
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Figure  4.15 shows a close up image of an untransfected SK-N-SH cell co-stained 
with MitoTracker and (–)-CHANA. As had been expected, due to the photochemical 
properties and hydrophobic nature of the probe the mitochondrial accumulation 
occured on the outer most surface of the organelle, corresponding to the 
mitochondrial membrane region, as highlighted by the graphical representation of the 




Figure  4.15: Localisation of (–)-CHA.A metabolism. Co-localisation of MitoTracker Deep Red 
(red) and the (−)-CHANA metabolism product, CHANK (green), in SK-N-SH cells. A) Cells were 
stained with MitoTracker Deep Red (25 nM, 35 min) then (−)-CHANA (2 µM, 45 min) before 
imaging with confocal microscopy: MitoTracker (red, left), ex. 633 nm, em. 640–670 nm; CHANK 
(green, centre), ex. 405 nm, em. 470–560 nm; the merged image (right) shows co-localisation of 
MitoTracker and CHANK in yellow. B) Close-up of MitoTracker and CHANK fluorescence staining, 
showing co-localisation (yellow/orange) in the mitochondrial membrane. C) Fluorescence intensity of 
MitoTracker and CHANK along the transect line shown in panel B. Reprinted with permission from 
Muirhead et al.121  Copyright 2010 American Chemical Society. 
 
While some of the CHANK fluorescence was found to be localised to the 
mitochondria, a large proportion of it existed within other regions of the cell. This 
potentially included the ER, although an ER marker complementary to the 
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CHANK to the ER was indeed the case, then the observed distribution of 
fluorescence would remain consistent with the known cellular localisation of ABAD. 
This suggests that endogenous ABAD was responsible for (–)-CHANA oxidation in 
untransfected cells, although further investigation was required in order to confirm 
this hypothesis.  
 
 
4.6.1.3 Knockdown of ABAD expression 
 
Although it has been proven that (–)-CHANA is a substrate for ABAD and the 
observed endogenous activity was located to known cellular locations of ABAD and 
therefore proposed to result from endogenous ABAD, the possibility remained that 
other endogenous dehydrogenase enzymes may also act upon the substrate. In order 
to investigate this activity further, ABAD expression was down-regulated in 
HEK293 cells before treating with (–)-CHANA and imaging the cells. Endogenous 
ABAD expression was knocked down in HEK293 cells using short interference RNA 
(siRNA) targeted to ABAD. The siRNA oligonucleotides bind to the RNA-induced 
silencing complex (RISC), targeting the siRNA-RISC complex to the messenger 
RNA (mRNA) of the gene of interest. RISC then cleaves the mRNA, preventing its 
translation into protein (Figure  4.16). 
 





transfection of siRNA and binding to
RNA-induced silencing complex (RISC)
specif ic binding of siRNA to mRNA





Figure  4.16: Mechanism of short interference R.A (siR.A) knockdown of gene expression. 
siRNA oligonucleotides specific to the gene of interest are transfected into cells, where they bind to 
the RNA-induced silencing complex (RISC); specific binding of RISC/siRNA to the mRNA of the 
gene of interest occurs; bound mRNA is cleaved by RISC; protein expression is prevented by the 
degradation of mRNA.  
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Three commercially available siRNA oligonucleotides (HSS179169, HSS179170, 
HSS104674; Invitrogen) targeted against ABAD were investigated for their ability to 
knockdown ABAD expression. Using GeneEraser (Stratagene) as the transfection 
reagent, HEK293 cells were treated with the three siRNA oligonucleotides as 
described in Materials and Methods, Section  2.7.5. Knockdown of ABAD expression 
was determined by Western blotting, as shown in Figure  4.17. 
 
 
Figure  4.17: ABAD knockdown in HEK293 cells. Lane 1: untreated cells; lanes 2-4: 15 nM siRNA 
HSS179169 for 24, 48 and 72 h; lanes 5-7: 15 nM siRNA HSS179170 for 24, 48 and 72 h; lanes 8-10: 
15 nM siRNA HSS104674 for 24, 48 and 72 h. Cells were treated with siRNA as described before 
harvesting and extracting protein for Western blot analysis. The blot was probed with anti-ABAD 
(rabbit, 1:5000) and anti-rabbit HRP (goat, 1:20000), revealing bands at ~27 kDa (ABAD) and 
~30 kDa (MTS-ABAD). Protein loading was controlled for by stripping and reprobing for β-actin 
(42 KDa) with anti-β-actin (mouse, 1:20000) and anti-mouse HRP (goat, 1:20000). 
 
Individually, HSS179169 and HSS104674 were found to be effective at 15 nM for 
72 h; however the combination of the two was found to be less effective and also 
resulted in high levels of cell death. HSS179169 (15 nM, 72 h) was therefore 
selected for knockdown studies of ABAD activity. 
 
HEK293 cells were treated with siRNA for 72 h before being subjected to the (–)-
CHANA metabolism assay as before (Figure  4.18).  
 




Figure  4.18: (−)-CHA.A metabolism in ABAD-knockdown HEK293 cells. A) Cells were treated 
with ABAD siRNA (15 nM, 72 h) to knock down ABAD gene expression. Western blot analysis of 
ABAD (lower band) and β-actin (upper band) showed ABAD knockdown in cells treated with 
HSS179169 siRNA at 15 nM for 72 h  (lane 5) compared with controls: lane 1, untreated cells; lane 2, 
cells treated with GeneEraser [lipofection reagent] only; lane 3, siRNA only; lane 4, non-targeted 
siRNA transfection. B) (−)-CHANA activity over 1 h remains in ABAD-knockdown compared with 
controls. After ABAD knockdown (15 nM siRNA or appropriate control, 72 h), HEK293 cells were 
incubated with 2 µM (−)-CHANA in phenol red-free DMEM and the fluorescence produced was 
monitored over 1 h by confocal microscopy. Ex. 405 nm, emission 500–520 nm, 40 × oil objective, 
200 Hz. Quantification was performed using ImageJ. For each data point, three images per dish were 
taken and each dish was carried out in three separate experiments, giving a total of 9 intensity values, 
from which the mean and standard error was calculated. Errors are given as SEM. Statistical analysis 
was performed using the Student’s t-test and showed no significant difference between samples.  
 
Unexpectedly, this experiment did not reveal a decrease in fluorescence intensity in 
ABAD-knockdown cells, which still displayed a similar level of fluorescence to the 
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A similar response was observed in SK-N-SH cells. ABAD knockdown was 
achieved to ~80% using 15 nM siRNA for 48 h (Figure  4.19A). Upon treatment with 
(–)-CHANA, no loss of activity was observed; indeed it appeared that (–)-CHANA 
metabolism did in fact increase in the absence of ABAD (Figure  4.19B), although 
this increase was not found to be statistically significant. 
 
 
Figure  4.19: (−)-CHA.A metabolism in ABAD-knockdown SK-.-SH cells. A) Cells were treated 
with ABAD siRNA (HSS104674, 15 nM, 48 h) to knock down ABAD gene expression to ~80% 
(shown by red box). Western blot analysis of ABAD (lower band) and β-actin (upper band) showed 
ABAD knockdown (lane 9) compared with controls: lane 1, untreated cells; lane 2, cells treated with 
Lipofectamine only; lane 3, siRNA only; lane 4, non-targeted siRNA transfection. B) (−)-CHANA 
activity over 1 h remains in ABAD-knockdown compared with controls. After ABAD knockdown 
(15 nM siRNA or appropriate control, 48 h), SH-N-SH cells were incubated with 2 µM (−)-CHANA 
in phenol red-free DMEM and the fluorescence produced was monitored over 1 h by confocal 
microscopy. Ex. 405 nm, emission 470–540 nm, 40 × oil objective, 200 Hz. Quantification was 
performed using ImageJ. For each data point, three images per dish were taken, from which the mean 
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The reasons for this observation may be complex. It is possible that the remaining 
~5–20% expression of ABAD (Figure  4.18A and Figure  4.19A) could be responsible 
for the all of the observed activity seen; however, this is unlikely as the previous 
over-expression of ABAD increased activity, implying that a maximum had not been 
reached. This therefore led to the conclusion that the low level of background 
activity seen is potentially as a result of other enzymes, such as alternative 
hydroxysteroid dehydrogenases. After 48–72 hours it is also possible that the cells 
may have responded to the knockdown of ABAD by up-regulating enzymes that 
fulfil a similar metabolic role, thereby compensating for the loss of the enzyme. 
 
It can therefore be concluded from the results obtained that while (–)-CHANA is a 
substrate for ABAD, it is possible that other enzymes within the cells are also able to 
metabolise the substrate. It is therefore proposed that (–)-CHANA will be a useful 
tool for studying ABAD activity in cells over-expressing ABAD, where background 
metabolism by endogenous enzymes is negligible in comparison to the activity 
resulting from the over-expressed enzyme. 
 
 
4.7 Inhibition of (–)-CHA.A metabolism by β-amyloid 
 
Having established that ABAD activity in MTS-ABAD-transfected cells could be 
measured by fluorescence microscopy over a period of 1 h, the next step was to 
determine whether the inhibition of ABAD activity by Aβ was able to be observed 
by this method. Successful inhibition would be seen as a decrease in fluorescence. 
This was to be investigated using two different methods of amyloid addition: over-
expression of the amyloid precursor protein (APP) and topical addition of Aβ 
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4.7.1 In vitro production of amyloid 
 
The in vitro production of Aβ was to be achieved by transfection of cells with a 
plasmid encoding for APP, which is then processed by the intracellular secretase 
enzymes, β- and γ-secretase, to produce the Aβ peptide (see Introduction, Section 
 1.2.1).39,40 Plasmid transfection with subsequent in vitro production of amyloid as an 
alternative to the addition of synthetic amyloid peptide was used for a number of 
reasons. As previously discussed, amyloid can exist in a number of different states, 
such as monomers, low molecular weight oligomers and fibrils, and although known 
to be toxic to cells, their specific toxicity pathways remain largely undetermined and 
may differ depending on the species present (see Introduction, Section  1.2.2). It was 
hoped that by using in vitro production of Aβ, the forms which occur naturally in 
cells would be produced, thereby creating a more physiologically relevant model. 
The plasmid used for transfection encoded for a mutant form of the amyloid 
precursor protein (mAPP; containing the Swedish mutation [K595N, M596L]), 
which enhances the production of Aβ42 by around 6-fold.203  
 
HEK293 cells were transfected with pcDNA3 (empty vector control), MTS-ABAD 
or mAPP, or doubly transfected with MTS-ABAD and mAPP (MTS-ABAD/mAPP) 
for 48 h before subjecting to the (–)-CHANA assay as described in Materials and 
Methods, Section  2.7.3. It can be seen in Figure  4.20A that transfection with the 
mAPP plasmid did not affect ABAD expression. Figure  4.20B shows the quantified 
results of the (–)-CHANA assay. It was found that transfection of mAPP alone did 
not have any effect on the oxidation of (–)-CHANA, with no significant change in 
fluorescence intensity measured. Cells co-transfected with MTS-ABAD/mAPP 
appeared to show an increase in fluorescence compared with those transfected with 
ABAD alone, although this difference was not found to be statistically significant. In 
summary, no inhibition of ABAD activity was observed in the presence of over-
expressed mAPP.  




Figure  4.20: (–)-CHA.A metabolism by HEK293 cells over-expressing mAPP. A) HEK293 cells 
were transfected with pcDNA3 (lane 1), MTS-ABAD (lane 2), mAPP (lane 3) or MTS-ABAD/mAPP 
(lane 4). After 48 h, cells were harvested and the protein extracted for Western blot analysis. The blot 
was probed with anti-ABAD (rabbit, 1:5000) and anti-rabbit HRP (goat, 1:20000), revealing bands at 
~27 kDa (ABAD) and ~30 kDa (MTS-ABAD). Protein loading was controlled for by stripping and 
reprobing for β-actin (42 KDa) with anti-β-actin (mouse, 1:20000) and anti-mouse HRP (goat, 
1:20000). B) HEK293 cells were transfected with pcDNA3, MTS-ABAD, mAPP or 
MTS-ABAD/mAPP for 48 h. Cells were then incubated with 2 µM (−)-CHANA and imaged using 
confocal microscopy on live cells, 37 °C; excitation 405 nm, emission 500-520 nm. Quantification 
was performed using ImageJ. For each data point, three images per dish were taken and each dish was 
carried out in three separate experiments, giving a total of 9 intensity values, from which the mean and 
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The effect of over-expression of mAPP was then investigated in SK-N-SH cells, 
despite previous difficulties with transfection of this cell line. In this case, ABAD 
expression was found to be greatly reduced in the presence of mAPP, even when 
MTS-ABAD was co-transfected (Figure  4.21A). Despite this observation, no effect 
of mAPP was seen on the metabolism of (–)-CHANA (Figure  4.21B). 
 
 
Figure  4.21: (–)-CHA.A metabolism by SK-.-SH cells over-expressing mAPP. A) SK-N-SH 
cells were transfected with pcDNA3, MTS-ABAD, mAPP or MTS-ABAD/mAPP  for 48 h. Cells 
were then incubated with 2 µM (−)-CHANA and imaged using confocal microscopy on live cells, 
37 °C; excitation 405 nm, emission 470–540 nm. Quantification was performed using ImageJ. For 
each data point, three images per dish were taken and each dish was carried out in one (mAPP), two 
(pcDNA3, MTS-ABAD/mAPP) or three (MTS-ABAD) separate experiments, giving a total of 3–9 
intensity values, from which the mean and standard error was calculated. Errors are given as SEM. B) 
SK-N-SH cells were transfected with pcDNA3 (lane 1), MTS-ABAD (lane 2), mAPP (lane 3) or 
MTS-ABAD/mAPP (lane 4). After 48 h, cells were harvested and the protein extracted for Western 
blot analysis. The blot was probed with anti-ABAD (rabbit, 1:5000) and anti-rabbit HRP (goat, 
1:20000), revealing bands at ~27 kDa (ABAD) and ~30 kDa (MTS-ABAD). Protein loading was 
controlled for by stripping and reprobing for β-actin (42 KDa) with anti-β-actin (mouse, 1:20000) and 
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It had been anticipated that the over-expression of mAPP would lead to increased 
amyloid formation and hence inhibit ABAD activity; however this was not observed 
in transient transfection of either HEK293 or SK-N-SH cell lines. This may be as a 
result of a number of factors. Firstly, it had already been observed that transfection of 
SK-N-SH cells was difficult (Figure  4.12), so the lack of response of these cells to 
transfection with mAPP is perhaps unsurprising, although the decrease in ABAD 
expression in the presence of mAPP was unexpected and the reason for this remains 
unclear. Secondly, amyloid is known to take many years to build up in the cells of 
AD sufferers. The rate of production of Aβ using mAPP transfection was not 
investigated at this time; it could simply be that 48 h was not long enough for APP to 
be expressed, processed into Aβ, transported into the appropriate location and 
accumulate to a sufficient concentration within the cells to elicit an effect.  
 
 
4.7.2 Topical addition of amyloid 
 
Since use of the mAPP plasmid as a source of cellular amyloid was unsuccessful, 
attention was turned to synthetic Aβ peptide treatment. As has been previously 
mentioned, Aβ can exist in a number of forms (see Introduction, Section  1.2.2). The 
Aβ used in the experiments in the remainder of this chapter was monomerised Aβ42, 
prepared by treatment with hexafluoroisopropanol (see Materials and Methods, 
Section  2.3).160 
 
As HEK293 cells over-expressing ABAD had proved to be highly responsive in the 
(–)-CHANA assay, initial experiments were carried out with HEK293 cells 
transfected with MTS-ABAD. Twenty four hours after transfection, the cells were 
treated with 22 µM Aβ42 for a further 24 hours before incubating with (−)-CHANA 
for 15–60 min. The fluorescence observed in Aβ-treated cells was significantly 
(~20%) lower than that of untreated controls (p = 0.003 after 60 min; Figure  4.22), 
indicating that inhibition of (–)-CHANA metabolism, and hence inhibition of ABAD 
activity, within the cell was occurring. It appeared that there was a window of 
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opportunity for use of Aβ in such an assay: use of higher Aβ concentration (50 µM) 
resulted in cell death, while with lower concentrations (<10 µM) no inhibition was 
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Figure  4.22: (–)-CHA.A metabolism in MTS-ABAD transfected, Aβ42-treated HEK293 cells. 
HEK293 cells were treated with 0 or 22 µM Aβ42 for 24 h before incubating with 2 µM (-)-CHANA 
in phenol red-free DMEM. The fluorescence produced was monitored over 1 h by confocal 
microscopy (Ex. 405 nm, emission 500-520 nm, 40 x oil objective, 200 Hz). The mean fluorescence 
was quantified using ImageJ (3 images per dish per timepoint and 3 dishes per concentration, 0 = 3). 
Reprinted with permission from Muirhead et al.121  Copyright 2010 American Chemical Society. 
 
Similarly, untransfected HEK293 cells were also treated with 22 µM Aβ42, and once 
again a significant decrease in fluorescence of ~20% was observed after 60 min (–)-
CHANA incubation (p = 0.004, Figure  4.23A). ABAD protein expression was not 
altered in the presence of Aβ42 (Figure  4.23B) and the use of ImageJ to determine 
the mean fluorescence rather than the absolute fluorescence (see Section  4.6) meant 
that the measured decrease was not simply due to the Aβ treatment causing cell death 
and hence reducing the overall fluorescence intensity. Instead, it represented a 
decrease in the mean fluorescence emitted by all the living cells in the sample. The 
observation that endogenous (–)-CHANA metabolism decreased in the presence of 
Aβ42 was interesting as previous knockdown experiments (Section  4.6.1.3) were 




  * p < 0.05 
** p < 0.01 
*** p < 0.001 
*** 
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activity. The fact that the activity is inhibited in the presence of Aβ42 implies that at 
least a portion of the (–)-CHANA oxidation was due to endogenous ABAD.  
 
 
Figure  4.23: (–)-CHA.A metabolism in Aβ42-treated HEK293 cells. A) HEK293 cells were 
treated with 0 or 22 µM Aβ42 for 24 h before incubating with 2 µM (-)-CHANA in phenol red-free 
DMEM. The fluorescence produced was monitored over 1 h by confocal microscopy (Ex. 405 nm, 
emission 470–540 nm, 40 x oil objective, 200 Hz). The mean fluorescence was quantified using 
ImageJ (3 images per dish per timepoint and 3 dishes per concentration, 0 = 3); B) Western blot 
showing no change in ABAD expression in amyloid-treated cells (lane 2) compared with control cells 
(Lane 1). Aβ treated cells were harvested and the protein extracted for Western blot analysis. The blot 
was probed with anti-ABAD (rabbit, 1:6000) and anti-rabbit HRP (goat, 1:20000), revealing bands at 
~27 kDa (ABAD) and ~30 kDa (MTS-ABAD). Protein loading was controlled for by stripping and 
reprobing for β-actin (42 KDa) with anti-β-actin (mouse, 1:20000) and anti-mouse HRP (goat, 
1:20000). 
 
This work has therefore shown that the activity of ABAD, as detected by the 
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the addition of Aβ peptide. This is the first time that ABAD inhibition by Aβ has 
been demonstrated in living cells: all previous reports of inhibition resulted from in 
vitro studies using purified ABAD protein. Therefore this finding represents a great 
advance towards the development of a cell-based assay for studying modulation of 
the ABAD-Aβ complex. 
 
 
4.8 Potential applications of the (–)-CHA.A assay 
 
The ultimate aim of this work was to be able to use (–)-CHANA as a means to screen 
potential molecular probes and prototype drugs targeting ABAD and/or the 
ABAD-Aβ complex. With this in mind, it was decided to investigate the effects of 
small molecule inhibitors of ABAD, which had been identified through a fragment-
based screen in Chapter  3 (Section  3.4), on the cellular metabolism of (–)-CHANA 
(Figure  3.7). 
 
 
Figure  4.24: Inhibitors of ABAD enzymatic activity identified by fragment-based screening. 
 
Before proceeding with the (–)-CHANA assay, the effect of the compounds on 
untreated cells was first investigated. Incubation of cells with 10 mM 11 resulted in 
rounding up and detachment of cells in less than 5 min. Compounds 73 and 74 
resulted in cells rounding up but not completely detaching. Of the four compounds 
tested, only 17 did not appear to have an immediate effect on the cells, with the cells 
remaining attached to the glass dish. Representative images of treated cells can be 
seen in Figure  4.25. It was therefore concluded that 11, 73 and 74 were highly toxic 
to the cells. Despite this set-back, it was hoped that some of the compounds could be 
carried forward to testing with (–)-CHANA in order to get a feel for the suitability of 
(–)-CHANA in this application.  




Figure  4.25: Effect of small molecule ABAD inhibitors on HEK cell viability. HEK293 cells were 
incubated with compound 11, 17, 73 or 74 (10 mM, containing 0.5% DMSO) for 1 hour. Control cells 
(top) were treated with 0.5% DMSO. Representative images taken after 5 (left), 30 (centre) and 
60 min (right) incubation are shown.  
 
As a result of the toxicity observed, not all compounds were successfully used in the 
(–)-CHANA activity assay. Figure  4.26 shows the effect of fragments 17 and 73 on 
(–)-CHANA metabolism. It can be seen in both untransfected HEK293 cells (Figure 
 4.26A) and cells transfected with MTS-ABAD (Figure  4.26B) that compound 17 
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incubation, fluorescence was decreased by 21% in untransfected cells (p = 0.0031) 
and 26% in MTS-ABAD transfected cells (p = 0.0014). This complements what was 
observed in vitro with purified enzyme, where 17 showed the greatest degree of 
ABAD inhibition in the enzyme activity screens (see Section  3.4). Conversely, 73 
showed an increase in fluorescence in both untransfected (Figure  4.26A) and 
transfected cells (Figure  4.26B); however as can be seen in Figure  4.25, cells 
incubated with 73 do not look healthy, although they were not fully detached as had 
been the case with 11 and 73. It had been observed that dead/dying cells could lead 
to increases in the fluorescence in CHANA assays, therefore other factors, such as 
changes within the cell related to cell death, are likely to have contributed to the 
increase in fluorescence observed. 
 
It must be noted that these experiments show only preliminary data as only a single 
experiment was performed. Further verification by increasing the 0 number will be 
required in the future, but the results of this preliminary study are encouraging for 
further use of this technique for studying inhibitors of ABAD inside living cells, 
complementing the work carried out by M. Froemming on the inhibition of (–)-
CHANA metabolism using the ABAD inhibitor, AG18051.121 These studies have 
shown that (–)-CHANA is able to be used a probe for studying ABAD inhibitors that 
function over a range of affinities, from the nanomolar AG18051 to the millimolar 
17. 
 




Figure  4.26: Effect of small molecule inhibitors on (–)-CHA.A metabolism in HEK293 cells. A) 
HEK293 cells were incubated with 10 mM 17 or 73 and 2 µM (–)-CHANA in phenol red-free DMEM 
supplemented with 1% FCS. The fluorescence produced was monitored over 1 h by confocal 
microscopy (Ex. 405 nm, emission 470-540 nm, 40 x oil objective, 200 Hz). The mean fluorescence 
was quantified using ImageJ (3 images per timepoint). B) HEK293 cells were transfected with MTS-
ABAD for 24 h before incubating with 10 mM 17 or 73 and 2 µM (–)-CHANA in phenol red-free 
DMEM supplemented with 1% FCS. The fluorescence produced was monitored over 1 h by confocal 
microscopy (Ex. 405 nm, emission 500-520 nm, 40 x oil objective, 200 Hz). The mean fluorescence 
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4.9 Conclusions and future work 
 
This work has shown that it is possible to use the fluorogenic probe, (–)-CHANA, to 
study the activity of ABAD in living cells. Following on from initial work performed 
by Froemming and Sames,120 which identified racemic CHANA as a substrate for 
ABAD, and further studies that identified the (–)-enantiomer, (–)-CHANA, as the 
preferred enantiomer for oxidation by ABAD,121 the conditions and parameters under 
which (–)-CHANA could be used for studying ABAD activity within living cells 
were investigated. 
 
Using confocal fluorescence microscopy, it was demonstrated that the use of (–)-
CHANA as a probe for ABAD activity was well suited to cells over-expressing 
mitochondrial-targeted ABAD. In addition, and rather unexpectedly, activity was 
also observed using untransfected cells, highlighting the advantage of the highly 
sensitive confocal microscope over the previously used fluorescence microscope. 
Although the source of this endogenous activity could not be definitively identified, 
it was found to be localised within defined subcellular structures, including 
mitochondria and potentially the ER, which was consistent with the known 
localisation of ABAD. This has led to the potential for ABAD activity in 
untransfected cells to also be studied in this way. However, it was concluded that 
until the source of endogenous activity is confirmed, the most appropriate application 
of this new method for studying ABAD activity in cells is in systems over-expressing 
ABAD, where the contribution of endogenous activity is negligible.  
 
Crucially, demonstrated in living cells for the first time, the inhibition of intracellular 
ABAD activity by the Aβ peptide was observed. Previous studies116,117 reporting the 
inhibition of ABAD by Aβ did so using purified ABAD. The translation of this 
previous finding into a cellular context has demonstrated that the inhibitory effect of 
Aβ on ABAD is applicable in a cellular environment as well as in an in vitro setting, 
and that this interaction may be suitable for monitoring in a cell-based assay with a 
view to developing modulators of the interaction. Although the inhibition exerted by 
Aβ on intracellular ABAD was only partial (~20% decrease in observed 
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fluorescence), it is hoped that further optimisation of conditions will lead to greater 
inhibition, resulting in a more “on/off” response of (–)-CHANA oxidation in the 
presence of Aβ. As was briefly mentioned (Section  4.7.2), a balance between finding 
Aβ conditions that inhibit ABAD activity without causing cell death must be met; 
indeed, for this reason it may not be possible to achieve complete inhibition of the 
enzyme under assay conditions. The form of Aβ used may affect its response; in the 
work reported here only monomeric Aβ42 was investigated. Preparations of different 
species of amyloid, for example, low molecular weight oligomers, may elicit a 
greater or lesser response from the cells.  
 
Preliminary data also showed that a novel inhibitor of ABAD, identified through a 
fragment based screening approach, inhibited the metabolism of (–)-CHANA, 
suggesting that this inhibitory effect of the compound was elicited on intracellular 
ABAD, as well as the purified enzyme. This finding was backed up by work carried 
out by collaborators, who demonstrated that the oxidation of (–)-CHANA was 
inhibited by the addition of AG18051, a known inhibitor of ABAD activity, with an 
IC50 of 140 nM.
121 Together, these data indicate the potential of (–)-CHANA for 
screening series of compounds for their inhibitory properties against ABAD, 
compounds which may prove useful as molecular probes of the enzyme, as described 
in Chapter  3. In particular, it is proposed to use this technique to screen compounds 
that have shown to inhibit purified ABAD protein in order to determine that the 
compounds are capable of crossing the cell membrane and remaining active once in 
the cell.  
 
Taking this idea one step further, it may be possible to extend this concept to screen 
compounds that interfere with the formation of the ABAD-Aβ complex; i.e. can 
addition of new compounds be seen to “rescue” ABAD activity from Aβ-induced 
inhibition. 
 
There is also potential to adapt this experimental set-up further to develop the basic 
technique described here into a high throughput cell-based assay for screening 
compounds capable of modulating ABAD activity. Using a 96 well plate rather than 
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individual cell culture dishes would increase the number of samples being analysed 
at a given time, although careful consideration would have to be given to the 
sensitivity of timings when dealing with a large number samples simultaneously. 
With microscopy, this may prove difficult as it must be ensured that the sample is in 
focus before each image is taken. In addition, analysis of images is relatively time-
intensive, so may not be suited to analysing large numbers of samples. An alternative 
may be to re-investigate fluorimetery in a 96 well format. This would require the use 
a temperature-controlled fluorimeter with a plate-reader, which would allow 
continual measurement of the same cells over a set time period, something that was 
not possible with the fluorimeter used in the work described earlier (Section  4.5). 
Fluorimeters of this nature are capable of rapid measurements (< 0.2 s), making it 
much faster than microscopy and the issues described before with uneven cell 
coverage may be eliminated by increasing the number of samples measured, which is 
more favourable in a 96 well format than in 35 mm dishes due to the reduced 
experimental volume.  
 
In summary, the work reported here outlines the development of use of (–)-CHANA 
as a probe for intracellular ABAD activity. This work has developed a useful 
laboratory tool, which will enable further exploration of the ABAD-Aβ complex as a 
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The ABAD-Aβ binding interaction was first identified by Yan et al. in 1997 using a 
yeast two-hybrid screen.105 However, it was not until 2004 that the nature of the 
physical interaction between the two was described.84 As has been previously 
discussed (see Introduction, Section  1.3.3), it has been proposed that the LD loop 
region of ABAD is the likely binding site of amyloid. Synthesis of this region of 
ABAD as a discrete peptide was shown to block the binding of amyloid to ABAD in 
SPR competition studies.84 This peptide was thought to act as a “decoy” by binding 
to Aβ, preventing Aβ binding to ABAD, and is hence termed the “decoy peptide” 
(DP). Significantly, this peptide, when injected into mice over-expressing mAPP 
showed a reduction of elevated peroxiredoxin II, an AD biomarker, back to levels 
comparable to non-transgenic mice.137 Similarly, elevated endophilin I levels in 
Tg ABAD/mAPP mice also returned to normal.138 Subsequently these results have 
been further strengthened by the observation that the peptide, either through systemic 
injection or by creation of a transgenic mouse over-expressing the decoy peptide, 
improved the performance of Tg mAPP mice in the radial-arm water maze test 
compared with untreated transgenic mice,139,204 indicating an improvement in spatial 
memory and hence a reversal of AD-like symptoms in these animals.  
 
With this evidence that the ABAD-Aβ interaction is a potential therapeutic target, it 
was therefore aimed to develop a compound that can prevent the formation of the 
ABAD-Aβ complex. Two different approaches were proposed: modification of the 
existing decoy peptide into a more “drug-like” molecule; and identification and 
development of a small molecule inhibitor of the interaction. There are different 
advantages associated with each strategy. The decoy peptide is already known to 
interact with the ABAD-Aβ system and due to its identification being based on the 
interaction that occurs intracellularly between the protein and peptide, is likely to be 
highly selective for this particular interaction. However, peptides are not ideal as 
drug molecules as they tend to be easily broken down by the body and difficult to 
administer to the site of action. Modification of the structure, such as incorporation 
of non-natural amino acids or replacement of susceptible amide bonds with 
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bioisosteres, may alleviate this issue. The present size of the decoy peptide, ranging 
from 2.7 KDa for DP(93-116) to 3.2 KDa for DP(92-120), is much larger than 
typical drug molecules, which are mostly under 500 Da (see Section  3.1). Reduction 
in peptide size may therefore also prove beneficial, decreasing the number of 
residues within the peptide to include only the essential residues. This would also 
simplify the subsequent peptide modification process.  
 
The alternative approach involves designing a small molecule inhibitor of the 
interaction through screening of appropriate compound libraries. This allows the 
design of a compound with properties suited to drug delivery from the outset. To 
date, two small molecule inhibitors of the ABAD-Aβ have been reported in the 
literature. Inbar et al.133 have reported the ability of thioflavin T (ThT) and its 
derivatives to prevent binding of ABAD to Aβ fibrils using an enzyme-linked 
immunosorbent assay (ELISA). Similarly, Xie et al.132 used ELISA to screen a 
compound library and also identified ThT as an inhibitor of this interaction (IC50 
230 µM), along with a related compound, frentizole (IC50 200 µM), which is licensed 


















Figure  5.1: The structure of previously identified small molecule inhibitors of the ABAD-Aβ 




ThT is a dye for identifying amyloidic structures (of the Aβ peptide as well as other 
amyloidogenic peptides) and is thought to bind to the β-sheet region of aggregates. 
Therefore, a compound based on the structure of ThT is unlikely to be able to target 
small soluble Aβ oligomers, the species that is of interest in this work. It was 
therefore proposed to identify new molecules capable of preventing the binding of 
small oligomeric forms of Aβ to ABAD. 
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5.2 Chapter aims 
 
The aim of the work reported in this chapter was two-fold. Firstly, in order to study 
effects of compounds on the ABAD-Aβ complex, a method was required for 
monitoring this interaction. A number of techniques were considered, including 
measuring the direct binding (e.g. by surface plasmon resonance) and measuring the 
consequence of ABAD-Aβ binding (e.g. measuring inhibition of ABAD enzymatic 
activity by Aβ). Secondly, after a suitable assay for monitoring the ABAD-Aβ 
interaction had been developed, it was aimed to identify and develop compounds that 
were capable of disrupting the ABAD-Aβ complex formation. As mentioned above, 
this was to take two different approaches – development of a small molecule 
inhibitor and modification of an existing peptide.   
 
It was envisaged that the work performed here would lay the foundations for 
designing and developing future drugs that target the ABAD-Aβ interaction, 
providing a range of tools that will aid subsequent work.  
 
 
5.3 Studies of the ABAD-Aβ interaction 
 
In order for the ABAD-Aβ interaction to be targeted as a therapeutic intervention for 
treating AD, a simple, robust method for studying the interaction between ABAD 
and Aβ, as well as its subsequent modulation by newly developed compounds, was 
required. Ideally this would result in an assay with a relatively high throughput in 
order to allow screening of a compound library and also provide rapid feedback into 
the design of future compounds.  
 
 
5.3.1 ABAD activity assay 
 
One of the most widely reported methods for studying the function of ABAD is to 
measure its catalytic activity in reduction or oxidation reactions.114-119,122,124 ABAD is 
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known to catalyse the oxidation and reduction of a large range of alcohols and 
ketones, 115,117-119,122,124 using NAD(H) as a co-factor (Figure  5.2A). The involvement 
of the co-factor in the reaction can be exploited to easily monitor the reaction rate by 
following the rate of production/consumption of NADH at 340 nm 
(ε = 6220 M-1 cm-1) using a simple set-up in a UV-vis photospectrometer, as shown 









plot change in absorbance over time







Figure  5.2: Measuring ABAD activity. A) General reaction catalysed by ABAD. Reduction of 
ketones/oxidation of alcohols are catalysed with the corresponding oxidation of NADH/reduction of 
NAD+, respectively; B) Instrumental set up for measuring ABAD activity. Enzyme, substrate and 
co-factor are mixed in a cuvette and the absorbance at 340 nm measured. The change in absorbance 
with time is proportional to the rate of consumption of NADH. 
 
ABAD is a multifunctional enzyme and as such can utilise a large range of 
substrates.115,117-119,122,124 Using the experimental set up described in Figure  5.2 (see 
Materials & Methods, Section  2.8.1 for further detail of experimental procedure), a 
number of substrates were investigated as possible substrates for an ABAD activity 
assay (Figure  5.3). 
 









































Figure  5.3: Selected substrates for ABAD activity assay. S-acetoacetyl-CoA (88); ethyl 
acetoacetate (148); acetoacetone (149); cortisone (150).  
 
Immediately upon investigation, it became apparent that S-acetoacetyl-CoA 
(AcAcCoA) was a far more reactive substrate than the other compounds tested. 
While assays using AcAcCoA were carried out over 100 s, in order for a rate for the 
other three substrates to be calculated, much higher substrate concentrations and 
longer reaction times were required (~20 min). The calculated rates are shown in 
Table  5.1.  
 
Table  5.1: Effect of substrate identity on ABAD reduction activity. Assay conditions: substrate 
(40–4000 µM), 0ADH (100 µM) and ABAD (4.2 µg mL
-1
) in buffer (50 mM 0aH2PO4, 300 mM 0aCl, 










S-acetoacetyl-CoA 88 40 3.87 
Ethyl acetoacetate 148 4000 0.0296 
Acetyl acetone 149 4000 0.0210 
Cortisone 150 100 0.0150 
 
By comparison of the three linear substrates, it can be seen that the coenzyme A 
group is important for the substrate to be reduced effectively. This is in agreement 
with published data124 and is most likely due to how the substrate fits into and is held 
inside the long narrow active site of the enzyme.118 It was therefore confirmed that S-
acetoacetyl-CoA was the best substrate to use for measuring ABAD activity in 
purified protein.  
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5.3.1.1 Calculation of enzyme parameters 
 
From the results above (Table  5.1), it was decided to continue using AcAcCoA as the 
assay substrate, as is widely reported in the literature.115-119,122 By varying the 
substrate concentration, and assuming the enzyme obeys Michaelis-Menten kinetics, 
it was possible to calculate enzyme parameters for ABAD from a Lineweaver-Burk 
graph, which plots the reciprocal substrate concentration (1/[AcAcCoA]) against 
reciprocal velocity (1/V) using both His-tagged ABAD (His-ABAD, Figure  5.4) and 
untagged native ABAD (Figure  5.5). As previously described in Section  4.3, ABAD 
was expressed with an 0-terminal His-tag to aid purification. This tag could either be 
removed during purification (requiring an additional overnight incubation at room 
temperature, which may prove detrimental with regards to protein stability) or 
retained throughout (see Materials & Methods, Section  2.2). Both the tagged and 
untagged proteins were used in the following experiment. 
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Figure  5.4: Kinetics of His-ABAD with S-acetoacetyl-CoA as substrate.  A) Michaelis-Menten 
plot, showing reaction rate vs substrate concentration. B) Lineweaver-Burk plot, showing reciprocal 
reaction rate vs reciprocal substrate concentration. Assay conditions: S-acetoacetyl-CoA (4–80 µM), 
0ADH (100 µM) and His-ABAD (5 µg mL
-1
) in buffer (50 mM 0aH2PO4, 300 mM 0aCl, pH 7.4), 
30°C. The change in absorbance at 340 nm was measured (100 s) and the initial rate calculated. 
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Figure  5.5: Kinetics of native ABAD with S-acetoacetyl-CoA as substrate. A) Michaelis-Menten 
plot, showing reaction rate vs substrate concentration. B) Lineweaver-Burk plot, showing reciprocal 
reaction rate vs reciprocal substrate concentration. Assay conditions: S-acetoacetyl-CoA (4–80 µM), 
0ADH (250 µM) and ABAD (5 µg mL
-1
) in buffer (50 mM 0aH2PO4, 300 mM 0aCl, pH 7.4), 30°C. 
The change in absorbance at 340 nm was measured (100 s) and the initial rate calculated. 
 
From Figure  5.4 and Figure  5.5 the maximum velocity (Vmax [1/y-intercept]), 
Michelas constant (KM [-1/x-intercept]), turnover number (kcat [Vmax/total enzyme 
concentration]) and enzyme efficiency (kcat/KM) were calculated (Table  5.2). 
 



























































Chapter 5. Results and Discussion: In vitro ABAD-Aβ interactions 
 205 
Table  5.2: Calculated enzyme parameters for ABAD with S-acetoacetyl-CoA as substrate 
 Experimental values 
 His-ABAD ABAD 
Literature values 
Vmax (µmol min
-1 mg-1) 11 11 430 117 
    
KM (µmol L
-1) 112 43 68 117 
53 118 
89 114 
    
kcat (s
-1) 4.9 5.0 190 117 
11.1 118 
37 114 
    
kcat/KM (mol L
-1 s-1) 4.3 × 104 1.2 × 105 2.8 × 106 117 
 
Comparison of calculated enzyme parameters with those values available in the 
literature show a number of differences, as well as highlighting differences between 
the His-tagged and untagged versions of ABAD. Firstly, the observed maximal 
velocity (Vmax) for both ABAD and His-ABAD is around 40-fold lower than that 
reported by Yan et al.117 The KM, the substrate concentration required to reach half-
maximal velocity, was found to be different for ABAD and His-ABAD, despite both 
versions of the enzyme having the same Vmax. This means that His-ABAD required a 
higher concentration of substrate in order to obtain the same level of activity. This 
finding was reflected in the catalytic efficiency, kcat/KM, which was ~2.8 times higher 
for the native protein compared with the His-tagged protein. KM values quoted in the 
literature are comparable to that obtained for untagged ABAD in this study. The data 
obtained indicate ABAD enzyme activity was lower than has been previously 
reported. This observation was also indicated by the catalytic turnover number, kcat, 
which is up to 40 fold lower than previously reported, while the catalytic efficiency 
is also much lower (23 fold difference). These differences may have resulted from 
the data being obtained under different conditions. Factors such as the storage of the 
enzyme may have a large effect on its activity. 
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5.3.2 Inhibition of ABAD activity by Aβ 
 
Having established the measurement of ABAD activity, it was then aimed to create 
an assay where ABAD activity was inhibited by amyloid, as reported previously in 
the literature.116,117 The development of an assay based on Aβ suppression of ABAD 
activity would then allow for study of potential ABAD-Aβ modulators: 
 
ABAD + Aβ = reduction in activity, 
ABAD + Aβ + modulator = recovery of activity 
 
thus demonstrating prevention of the ABAD-Aβ interaction upon the addition of a 
suitable compound.  
 
Previous work carried out by Yan et al.117 and Oppermann et al.116 reported the 
inhibition of ABAD activity by addition of β-amyloid. Reduction of S-acetoacetyl-
CoA by ABAD was inhibited by 40% and 70% on addition of 1 µM and 3 µM Aβ40, 
respectively. Similar results were reportedly obtained for Aβ42, although data was 
not shown.117 Meanwhile, the oxidation of 3-hydroxy-butyryl-CoA by ABAD was 
shown to be inhibited by approximately 50% upon addition of 0.5 µM Aβ40.116 
 
It was first proposed to investigate inhibition of His-ABAD activity by Aβ42, as this 
is the isoform of amyloid most commonly associated with AD. The amyloid was 
firstly treated with hexafluoroisopropanol (HFIP) to ensure monomerisation of the 
peptide.160 Monomers were selected for these experiments as it was thought that the 
most likely route to ABAD inhibition was the aggregation of Aβ onto the enzyme 
surface (see Introduction, Section  1.3.3). Preformed aggregates may produce widely 
variable results. The monomerised peptide was dissolved in DMSO and 
pre-incubated with His-ABAD for 0, 2 or 4 hours before measuring ABAD activity. 
The purpose of pre-incubation of amyloid and enzyme was two-fold. Firstly, it is 
known that while amyloid can inhibit NADH binding, NADH can also inhibit 
amyloid binding.135 In this case, the cryogenic storage solution used to preserve His-
ABAD contained NADH. Attempts to remove the stored NADH prior to assay using 
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a Sephadex spin column resulted in denaturation of the enzyme. It was therefore 
anticipated that an incubation period would allow displacement of stored NADH. 
Secondly, it has been suggested that aggregation of amyloid is necessary for 
inhibition to occur, a process which requires time to occur from monomeric amyloid. 
Therefore it was hoped that an incubation period prior to measuring ABAD activity 
may also allow this to occur. It is known that DMSO, used to dissolve amyloid, can 
itself cause enzyme inhibition.205 For this reason the final DMSO content was kept 
below 1% and the appropriate controls were carried out. In addition, solvation of 
Aβ42 in 1% NH4OH solution instead of DMSO was investigated as an alternative. 
Figure  5.6 shows the results of these experiments. Of the conditions tested, only 
three showed statistically significant inhibition, but results were not consistent, 
taking into account concentration and incubation time. For example, 2 µM Aβ42 in 
1% DMSO showed 33% inhibition at 2 h incubation; 20 µM under the same 





















2 µM Aβ42 (1% DMSO)
20 µM Aβ42 (1% DMSO)
2 µM Aβ42 (NH4OH)
2 µM Aβ42 (NH4OH)
 
Figure  5.6: Inhibition of His-ABAD activity using Aβ42. Aβ42 monomers were dissolved in 
DMSO or 1% NH4OH solution. His-ABAD was incubated with Aβ42 for 0, 2, 4 or 24 h (24 h, 2 µM 
in NH4OH only) before measuring the enzyme activity. Inhibition is expressed as a percentage of the 
activity measured in the absence of Aβ42. Assays were performed in triplicate and errors are 
expressed as ± SEM. Assay conditions: 2 or 20 µM Aβ42, 2.4 µg mL-1 His-ABAD, 40 µM acetoacetyl-
CoA and 200 µM 0ADH in buffer containing 50 mM sodium phosphate, 300 mM sodium chloride, pH 
7.4 at 30°C. Final [DMSO] 1% or [0H4OH] 0.01%. 
 
   * 
  * 
  * 
* p < 0.05 
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These assays were repeated using Aβ40, as this isomer has also been shown to 
inhibit ABAD activity.116,117 Aβ40 was dissolved in either DMSO or 10% DMSO in 
water before incubating with ABAD for 0, 2 or 4 h before measuring ABAD activity. 
The results of this are shown in Figure  5.7 and again do not show any significant 

























2 µM Aβ40 (1% DMSO)
2 µM Aβ40 (0.1% DMSO)
 
Figure  5.7: Inhibition of His-ABAD activity using Aβ40. Aβ40 monomers were dissolved in 
DMSO or 10% DMSO in water. His-ABAD was incubated with Aβ40 for 0, 2 or 4 h before 
measuring the enzyme activity. Inhibition is expressed as a percentage of the activity in the absence of 
Aβ40. Assays were performed in triplicate and errors are expressed as ± SEM. Statistical analysis was 
performed using a pairwise Student’s t-test.  Error bars are ± SEM. Assay conditions: 2 µM Aβ40, 2.4 
µg mL
-1
 His-ABAD, 40 µM acetoacetyl-CoA and 200 µM 0ADH in buffer containing 50 mM sodium 
phosphate, 300 mM sodium chloride, pH 7.4 at 30°C.  
 
Despite the fact the both Yan117 and Opperman116 used monomeric amyloid in their 
assays, it has been shown that monomeric amyloid is not sufficient to induce binding 
and subsequent conformational change.135 It was assumed that pre-incubating the 
enzyme with the amyloid would be sufficient to allow the nucleation of Aβ 
aggregates, which would then inhibit the enzyme activity. This did not appear to 
happen in the assays carried out. One possible reason for this is the presence of a 
large amount of NADH. As previously mentioned, it is known that the binding of 
amyloid to ABAD distorts the NADH binding site and hence inhibits the binding of 
NADH and it has also been shown that the presence of NADH can inhibit the 
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binding of amyloid.135 Since the ABAD used in the present assays was stored in a 
solution containing 10 mM NADH, this may have inhibited the binding of and 
subsequent inhibition by amyloid. 
 
Another point to consider is the nature of the Aβ itself. As previously discussed (see 
Introduction, Section  1.2.2) Aβ is known to exist in many different forms, which are 
all thought to react in different ways. It is therefore possible that the form of amyloid 
used in these studies is significantly different to that used in the literature and hence 
unable to replicate literature findings. Indeed, within the Alzheimer’s research 
community there is a wealth of anecdotal evidence of problems with replicating 
amyloid behaviour between different sources or batches of the peptide. 
 
While this inhibition study did not yield the development of a useful assay, there 
remains scope for future work to improve its reproducibility. This may involve use of 
different forms of amyloid and use of untagged ABAD protein (see Section  5.5). 
 
 
5.3.3 Surface plasmon resonance as a method for measuring the ABAD-Aβ 
interaction 
 
The use of an ABAD activity assay for measuring the inhibition of activity by Aβ is 
an indirect method of measuring the binding between ABAD and Aβ. This does not 
take into account that binding may occur without inhibition,116,117 so a direct method 
for studying the binding between the two was also desirable. 
 
Surface plasmon resonance (SPR) is a technique for studying the binding interactions 
between a protein and its ligands. The protein of interest is immobilised onto a gold 
surface and light is reflected onto the back surface of the chip. At a particular angle 
of incident light, the photons will interact with the gold surface, reducing the 
intensity of the reflected light (Figure  5.8A). The angle at which the maximum 
interaction and hence minimum reflected light intensity occurs is known as the SPR 
angle (Figure  5.8B) and is determined by the mass bound to the chip. As a solution 
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of ligand is passed over the chip surface, any ligand binding that occurs results in an 
increased mass on the chip, which in turn changes SPR angle. Therefore, the 
measured response is proportional to the mass of ligand bound to the protein and can 
therefore be used to calculate binding affinities (Figure  5.8C). 
 
gold film























Figure  5.8: Surface plasmon resonance as a technique for studying protein-small molecule 
interactions. A) Light is reflected off the rear surface of a gold chip; at a particular angle of incident 
light, interaction with the the gold surface occurs, reducing the intensity of the reflected light. B) The 
angle at which the intensity of reflected light is at its minimum is known as the SPR angle. C) The 
protein of interest is immobilised onto a gold chip; light is reflected off the rear surface of the chip and 
the SPR angle of the light is measured (shown in green). Upon binding of a ligand, the SPR angle 
changes as a function of mass bound to the chip, allowing the dissociation curve of ligand binding to 
be determined.  
 
Two methods are available for the immobilisation of protein onto the gold surface. 
For proteins containing a His-tag, non-covalent immobilisation onto an 
Ni2+-nitrilotriacetic acid (NTA) chip can be used. This method requires fresh protein 
to be immobilised after each regeneration step (Figure  5.9A). Alternatively, the 
protein can be covalently attached to the chip surface by the reaction of a protein 
primary amine group with carboxymethylated dextran groups on the chip (CM5), 
allowing regeneration of the protein surface after binding (Figure  5.9B).  
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Figure  5.9: Immobilisation of protein for surface plasmon resonance studies. A) Non-covalent 
immobilisation of His-proteins onto a Ni2+-nitrilotriacetic acid (NTA) chip. The chip is activated with 
NiCl2; a solution containing the His-protein is passed across the chip surface and the protein 
immobilised; ligand is bound to the protein; washing with EDTA removes the Ni2+, resulting in 
regeneration of the chip surface. B) Covalent immobilisation of protein onto a carboxymethylated 
dextran (CM5) chip. The chip surface is activated with 0-ethyl-0′-(3-
(dimethylamino)propyl)carbodiimide (EDC) and 0-hydroxysuccinimide (NHS); the protein is 
covalently attached to the chip surface by reaction of free primary amine group with the activated chip 
surface, unreacted sites are blocked with ethanolamine; ligand is bound to the protein; washing with 
guanidine HCl removes ligand, regenerating the protein surface. 
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SPR was considered to be a suitable technique for measuring the ABAD-Aβ 
interaction. Not only is it possible to use SPR to measure the binding affinity of two 
proteins, but the technique also allows adaptation to a high throughput screening 
assay.  Previous work by Lustbader et al.84 and Yan et al.135 used SPR to show and 
quantify amyloid binding to ABAD. In the case of the work performed by Lustbader, 
ABAD was immobilised and Aβ was passed over the chip; work by Yan et al. used 
the opposite approach, where Aβ peptides were immobilised onto the chip and a 
solution of ABAD was bound to the immobilised peptide. Both of these approaches 
were investigated by the work reported here. Additionally, Lustbader reported that 
the ABAD-Aβ binding interaction, measured by SPR, could be prevented by the 
presence of the decoy peptide [residues 92-120 of ABAD, DP(92-120)] in the ligand 
solution. It was therefore hoped to develop this work further by investigating the 
inhibitory effects of smaller fragments of the decoy peptide in order to elucidate the 
residues that are essential for binding (see Section  5.4.2). 
 
Initial experiments were carried out using His-tagged ABAD (His-ABAD). The 
His-tag was present to assist protein purification and, while it can be removed by a 
Tev cleavage reaction (see Materials & Methods, Section  2.2.2), it was decided to 
retain the His-tag to allow non-covalent immobilisation onto an NTA chip.  
 
Immobilisation was successfully carried out to give ~400 response units (RU) 
immobilisation using 500 nM His-ABAD, although this level of immobilisation was 
lower than ideal (~1000 RU). Regeneration with 0.35 M EDTA removed all protein 
from the chip surface (Figure  5.10). 
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Figure  5.10: .on-covalent immobilisation of His-ABAD on a .i
2+
-.TA chip. The chip was 
activated with NiCl2 (500 µM, 10 µL min
-1, 60 s) before flowing over His-ABAD solution (31–
500 nM, 10 µL min-1, 60 s). Regeneration of the chip surface was achieved by EDTA (0.35 M, 
10 µL min-1, 60 s) between cycles. Maximum immobilisation (~400 RU) was achieved with 500 nM 
ABAD.  
 
In an attempt to improve the level of protein immobilisation, His-ABAD was also 
covalently immobilised on a CM5 chip. Scouting experiments are used to determine 
the optimal conditions for covalent immobilisation of protein onto a CM5 chip by 
ascertaining the level of interaction between protein and chip without covalently 
linking them at that stage. For covalent immobilisation of His-ABAD, scouting 
experiments gave 2 µM His-ABAD at pH 4 (in 10 mM sodium acetate) as the 
optimal immobilisation conditions, resulting in ~1200 RU immobilisation (Figure 
 5.11). 
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Figure  5.11: Optimisation of the covalent immobilisation of His-ABAD onto a CM5 chip. A) pH 
scouting: 500 nM His-ABAD in 10 mM sodium acetate, pH 4.0, 4.5, 5.0, 5.5; B) concentration 
scouting at pH 4.0: 1.25, 2.5, 5, 10 µM ABAD-His in 10 mM sodium acetate, pH 4.0; C) His-ABAD 
immobilisation: 2 µM His-ABAD in 10 mM sodium acetate, pH 4.0. 
 
After successful immobilisation of ABAD onto a CM5 chip, the first aim was to 
replicate the nanomolar binding of Aβ to ABAD, as reported by Lustbader et al.84 
Both Aβ40 and Aβ42 were passed over the chip, but neither nanomolar (6.2–
100 nM) nor micromolar (0.66–10 µM) Aβ showed any binding to His-ABAD. As a 
A B 
C 
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positive control for ABAD binding, the enzyme co-factor, NAD+, was used. 
However, no binding was observed at micromolar concentrations, while non-specific 
binding was observed at millimolar concentrations. This led to the conclusion that 
the lack of binding of Aβ to ABAD may have resulted from a problem with the 
immobilised protein, such as denaturation during the immobilisation procedure.  
 
In order to determine whether or not immobilisation of His-ABAD at pH 4 had 
damaged the protein structure in some way, binding studies were repeated on the 
Ni-NTA (non-covalent) immobilised His-ABAD. Despite low immobilisation levels 
using this method (see above), this method eliminated the use of low pH. At a 
concentration of 200 µM NAD+, no binding was observed with ABAD on the NTA 
chip, while ~70 RU binding was observed at 25 mM NAD+, although at this high 
concentration non-specific binding was likely. Aβ42 did also not bind to 
NTA-immobilised His-ABAD at 2.5 µM. Therefore it was unlikely that denaturation 
of His-ABAD during immobilisation onto the CM5 chip was responsible for the 
problems encountered. 
 
The enzymatic activity of His-ABAD was also measured to ensure that the 
purification process had not denatured the enzyme. Reduction of acetoacetyl-CoA 
using NADH as the co-factor resulted in consumption of NADH (as previously 
described, Section  5.3.1) indicating that the enzyme was active. The UV spectrum of 
NAD+ used for binding studies was checked and gave the expected absorption (λmax 
260 nM).  
 
Focus then moved to the possibility that the His-tag was interfering somehow with 
protein binding. While small tags are generally not considered to interfere with the 
function and activity of proteins,206 there are a few reports in the literature that show 
exceptions to this rule, such as the presence of a C-terminal His-tag on tropinone 
reductase, another short chain dehydrogenase.207 To rule out the possibility of the 
His-tag interfering with binding, the binding experiments were repeated with 
untagged ABAD.  
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Immobilisation conditions for ABAD were determined by pH scouting at pH 4.0, 
4.5, 5.0 and 5.5. Immediately, differences in the binding behaviour between His-
ABAD and ABAD were apparent. While pH 4.0 was found to be optimal for His-
ABAD and pH >5.0 showed little/no interaction with the chip, pH 4.0 during 
untagged ABAD scouting experiments resulted in the protein “sticking” to the chip, 
indicating non-specific interactions between chip and protein. However, use of pH 
5.0 and pH 5.5 solutions with ABAD this time resulted in good interaction with the 
chip surface and came off cleanly (Figure  5.12A). 
 
Using the optimised conditions (2 µM ABAD, pH 5.5), ABAD was successfully 
immobilised to ~8000 RU (Figure  5.12B). This is a much higher level of 
immobilisation than would normally be used for the instrument, but it was hoped that 
it would enhance the small signals previously observed and due to time constraints, 
the benefits of an enhanced signal were considered to outweighed the risk of mass 
transfer issues.  
 




Figure  5.12: Immobilisation of ABAD to CM5 chip. A) pH scouting using 2 µM ABAD in 10 mM 
sodium acetate, pH 4.0, 4.5, 5.0, 5.5; B) ABAD immobilisation at pH 5.5, 2 µM ABAD, 
immobilisation level ~8000 RU. 
 
This time binding with NAD+ as a positive control resulted in specific binding at 
NAD+ concentrations below 62.5 µM (3.9–62.5 µM) and non-specific binding at 
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Figure  5.13: Binding of .AD
+
 to immobilised ABAD. NAD+ (3.9–500 µM) was passed over ABAD 
immobilised onto a CM5 chip (8000 RU). Assay conditions: sample injection, 60 s, 30 µL min-1; 
dissociation time, 180 s; buffer, HBS + 1 mM EDTA + 0.005% Tween20.  
 
Having demonstrated that NAD+ was capable of binding ABAD, Aβ binding was 
then investigated. Freshly prepared Aβ40 monomer solution (0.65 – 10 µM) did not 
result in any observed binding to ABAD. Aβ40 and Aβ42 solutions, prepared 4 days 
previously, did also not bind at micromolar concentrations. Therefore, while it was 
shown that NAD+ was able to bind to immobilised ABAD, no amyloid binding was 
observed and the findings published by Lustbader et al.84 were not successfully 
replicated. This failure to replicate the Lustbader experiments has also been reported 
by others.208 
 
At this point, the reverse set-up with Aβ immobilised on the chip and ABAD passed 
over the surface, as reported by Yan et al.,135 was considered. Aβ40 was immobilised 
onto a CM5 chip (pH 4.5, 5 µM Aβ40) to a level of ~400 RU. His-ABAD and 
ABAD were both flowed over the cell at 4 µM. His-ABAD gave a signal of 4 RU, 
while ABAD gave a signal of 15 RU (Figure  5.14A). As suspected, this indicated 
that the presence of a His-tag interfered with ABAD-Aβ binding, a finding which 
was later confirmed by other researchers.209 
 
Chip regeneration was successfully performed using 4 M guanidine hydrochloride 
and it was shown that this treatment did not affect the amyloid binding surface 
(Figure  5.14B). 
 





Figure  5.14: Binding of ABAD to immobilised Aβ40. A) His-ABAD (4 µM), followed by ABAD 
(4 µM,) were passed over a CM5 chip immobilised with Aβ40 (400 RU). His-ABAD resulted in an 
increase of 4 RU, while ABAD resulted in the addition of 15 RU. Washes of NaCl (250 mM and 5 M) 
did not remove bound ABAD. Running conditions: sample injection 60 s, 10 µL min-1; buffer, HBS + 
1 mM EDTA + 0.005% Tween20.  B) Repeated generation of the Aβ40 surface. ABAD was bound to 
the immobilised Aβ40 (4 µM) before regeneration with guanidine HCl (4 M guanadine HCl in 10 mM 
Tris, pH 7.7). Binding was consistent, indicating that the Aβ surface was not adversely affected by the 
regeneration conditions. Running conditions: sample injections, 60 s, 10 µL min-1;  regeneration, 10 s, 
30 µL min
-1
; buffer, HBS + 1 mM EDTA + 0.005% Tween20.   
 
Doubling the Aβ immobilisation from 400 to 920 RU resulted in an increase in 
ABAD binding from 15 to 47 RU, showing that doubling the Aβ40 doubled the 
A 
B 
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ABAD binding response, as was expected. However, the response shown upon 
binding is much smaller than would be expected. Assuming a 1:1 binding ratio 
between ABAD monomer and amyloid, the theoretical maximum response of ABAD 
binding was ~2500 RU (for 400 RU Aβ immobilised). The experimental value 
obtained was ~1% of this, leading to the conclusion that the majority of Aβ is in an 
“inactive” form, unable to bind ABAD. As Aβ is known to exist in a number of 
oligomeric/aggregated states, each with different interactions with proteins, this 
observation is perhaps not surprising.  
 
Having shown that ABAD-Aβ binding could be observed using SPR, it was hoped to 
obtain dissociation constants (Kd values) for the interactions. In order to maximise 
signals, immobilisation levels of amyloid (Aβ40 and Aβ42) were increased to around 
6000 RU. This high level of immobilisation is not ideal, as the high surface coverage 
can lead to mass transport problems; however, due to the low signals observed, it 
was decided that this would benefit the experiment. Previous immobilisation of 
amyloid had used ammonium hydroxide to solublise Aβ40; the presence of a 
competing primary amine may have led to low Aβ immobilisation. In this instance, 
Aβ40 was solublised in trifluoroacetic acid (TFA), while Aβ42 was solublised in 
DMSO. After immobilisation of Aβ40 (5700 RU) and Aβ42 (6300 RU), binding 
experiments with His-ABAD (98 nM – 12.5 µM) and ABAD (1.5 nM – 25 µM) were 
carried out and the dissociation constants (Kd) calculated (Table  5.3). 
 
In all cases data points from the lower ABAD concentrations were used to carry out a 
kinetic fit to a conformational change model, as has been carried out previously by 
Yan et al.135 It was found that both His-ABAD and ABAD bound both Aβ40 and 
Aβ42, albeit at lower binding RUs than the theoretical maximum (as previously 
discussed). This gave Kd values in the lower nanomolar range (Table  5.3). Bearing in 
mind that these results were not obtained under ideal conditions, the results compare 
favourably with previously published data (ABAD/Aβ40, Kd = 64 ± 9 nM,
117 
172 nM,135 38.4 ± 4.6 nM,84; ABAD/Aβ42, Kd = 42 ± 8 nM
117, 55.8 ± 10.9 nM84).  
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Table  5.3: Calculated Kd values for binding of ABAD to Aβ. Aβ40 (10 µM in 10 mM sodium 
acetate pH 4, 5712 RU) or Aβ42 (10 µM in 10 mM sodium acetate, pH 4, 6284 RU) was immobilised 
on a CM5 chip. His-ABAD (serial dilutions of 12.5–0.098 µM) or ABAD (25–0.0015 µM) were 
passed over the cell. Binding conditions: ABAD sample injection 30 µL min-1, 45 s; dissociation time 
300 s; regeneration 4 M guanidine HCl, pH 7.7, 30 µL min
-1
, 10 s; stabilisation 200 s. 
 Aβ40 Aβ42 
ABAD ~6 nM ~4 nM 
ABAD-His ~30 nM ~40 nM 
 
These experiments therefore demonstrated the potential of SPR as a technique to 
measure the ABAD-Aβ interaction. However, it has emerged from this work that the 
interaction between ABAD and Aβ is dependent on the properties of both the ABAD 
and Aβ peptides. The presence of a histidine tag on the ABAD protein significantly 
affected its ability to bind Aβ. This effect may also have been responsible for the 
lack of Aβ-induced inhibition of ABAD activity, as reported in Section  5.3.2. In 
addition, it was suspected that the binding ability of Aβ is likely to be strongly 
influenced by the state in which it exists prior to immobilisation. However, it was 
envisaged that with further optimisation, a robust assay could be developed for 
screening the ability of compounds to block the ABAD-Aβ interaction. This 
technique was also further explored as a method for studying the direct binding of 
the decoy peptide to Aβ (see Section  5.4.2.2). 
 
 
5.4 Prevention of the ABAD-Aβ interaction 
 
The second aspect of the work in this chapter was to identify and develop a way to 
prevent the interaction of ABAD and Aβ. Two possible routes to achieve this were 
investigated: the identification of a small molecule modulator of the ABAD-Aβ 
complex to prevent the binding of the peptide and enzyme to each other, and the 
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5.4.1 Small molecules inhibitors of the ABAD-Aβ interaction 
 
Thermal shift analysis (TSA) has already been described as a technique for screening 
libraries of small molecules to discover binding partners of ABAD (see Section  3.3). 
This technique was therefore used again, this time to screen for compounds able to 
interrupt the ABAD-Aβ complex with the view to subsequently developing small 
molecule inhibitors of the interaction.  
 
Addition of 22 µM monomeric Aβ42 to ABAD resulted in a 5 ºC positive shift in the 
unfolding temperature (Tm) of ABAD (Figure  5.15), indicating that binding was 
occurring between ABAD and Aβ42. Control experiments using Aβ42 in the absence 
of ABAD did not result in a signal being observed (Figure  5.15, magenta line), 
suggesting that either Aβ does not contain any significant tertiary structure or that 
there is limited hydrophobicity within the peptide to which the dye can bind. In either 





























Figure  5.15: Effect of Aβ42 on the unfolding temperature of ABAD. Thermal shift analysis of 
ABAD in the absence (blue) and presence (red) of Aβ42. Aβ42 alone (magenta) did not elicit a signal. 
The unfolding temperature, Tm, is given as the bottom of the curve. Assay conditions: 11.7 µM ABAD, 
10 mM 0ADH, 1 × Sypro Orange, 5% DMSO in 10 mM sodium phosphate, pH 7.4. Data is the 
average of 6 (ABAD and ABAD+Aβ42) or 4 (Aβ42) experiments.  
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Addition of small molecule fragments into this system could result in a number of 
potential scenarios: Aβ binds to ABAD, preventing fragment binding; both the 
fragment and Aβ bind to ABAD; the fragment binds to ABAD, preventing Aβ 
binding; the fragment and Aβ bind to each other, preventing either species binding to 
ABAD.  
 
Using the system outlined below (Figure  5.16), it was aimed to classify the 
fragments’ activity into these four categories. Molecules which prevent amyloid 
binding to ABAD, either by blocking the binding site on ABAD or by binding 
directly to Aβ itself, were of particular interest. 
 
 
Figure  5.16: Possible binding scenarios resulting from the addition of small molecular fragments 
to an ABAD-Aβ42 system. A) Control samples: no ligand present (top), Tm = T1; fragment binding 
to ABAD (middle), T2; Aβ bound to ABAD (bottom), T3. B) Potential scenarios resulting from 
introduction of fragment to a preformed ABAD-Aβ complex: i) Aβ prevents fragment binding and 
fragment remains in solution, unfolding temperature remains the same, T3; ii) Fragment binds ABAD 
at an alternative site in addition to Aβ, changing the Tm to an unknown temperature, Tx; iii) Fragment 
binds ABAD, displacing Aβ, Tm is that of ABAD + fragment, T2; iv) Fragment and Aβ bind each 
other and are displaced from ABAD, Tm is that of native ABAD, T1. 
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The fragments selected for screening were a subset of the Maybridge Ro3 library, 
which had already been identified as binding partners of ABAD (see Section  3.3, 
Table  3.2). The Tm of ABAD after the addition of 10 mM fragment to the ABAD-






























Figure  5.17: The effect of small molecular fragments on the unfolding temperature of a 
preformed ABAD-Aβ complex. The unfolding temperature was measured in the presence (solid) and 
absence (hashed) of Aβ42. ABAD was preincubated with Aβ42 before the addition of 10 mM 
fragment. Assay conditions: 11.7 µM ABAD, 22 µM Aβ42, 10 mM fragment, 1 × Sypro Orange, 6% 
DMSO in 10 mM sodium phosphate, pH 7.4. Samples were run in duplicate. 
 
It can be seen that in some cases, for example, 17, 58, 73 and 74, the Tm is the same 
in the presence and absence of Aβ42. In others, such as 54 and 69, the addition of the 
fragment does not change the Tm in the presence of Aβ42. Based on the categories 
described in Figure  5.16, the fragments tested were divided into their possible 
binding modes (Figure  5.18). Using this classification system, the first group of 
fragments (17, 58, 73 and 74) can be interpreted as preventing Aβ binding, while the 
second group (54, 69) cannot bind in the presence of Aβ. No compounds fell into the 
final category, where the Tm is that of native protein (i.e. fragment and Aβ bind to 
each other, preventing either species binding to the enzyme). However the fragments 
were present in great excess compared to amyloid (~500 fold). Assuming a 1:1 
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binding of fragment to amyloid, the vast majority of fragment would still be 
available to bind to ABAD, altering its Tm.  
 






































Figure  5.18: Classification of fragments based on their influence on the unfolding temperature 
of the preformed ABAD-Aβ complex. Fragments shaded in purple were previously identified as 
inhibitors of ABAD (Section  3.4). 
 
These results were obtained from the addition of fragment to a pre-incubated mixture 
of ABAD and amyloid. Based on the observation that ABAD and amyloid bind 
under the given conditions (Figure  5.15), it was therefore assumed that the complex 
was already formed before the fragment was added. Therefore, it was possible that 
fragments may have to displace Aβ in order to bind if the two molecules bind to a 
common site. As the binding affinity of small molecule fragments is generally 
considered to be low (~mM)177 while the affinity of Aβ is in the nanomolar range,135 
the ability of the fragments to displace Aβ may be limited. 
 
However, in order to investigate this effect further the experiment was repeated, this 
time pre-incubating the ABAD and fragment to allow fragment binding before 
addition of Aβ42 (Figure  5.19).  
 






























Figure  5.19: The effect of small molecular fragments on the unfolding temperature of ABAD in 
the presence of Aβ. The unfolding temperature of ABAD complexes in the presence (solid) and 
absence (hashed) of Aβ42. ABAD was preincubated with fragment before the addition of Aβ42. Assay 
conditions: 11.7 µM ABAD, 22 µM Aβ42, 10 mM fragment, 1 × Sypro Orange, 6% DMSO in 10 mM 
sodium phosphate, pH 7.4. Samples were run in duplicate. 
 
The compounds were grouped based on their Tm as before, resulting in a few changes 
in classification (Figure  5.20). Under these conditions, the addition of amyloid did 
not affect the Tm of ABAD in complex with 10, 11, 73 and 74, suggesting that the 
fragment blocked amyloid binding. Meanwhile, 8, 54 and 69 resulted in a Tm of that 
of ABAD+Aβ, suggesting that amyloid is able to displace the fragment.  
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Tm = ABAD + fragment  Tm = something else 
 
  






























     
54 
 
       
Figure  5.20: Classification of fragments based on their influence on the unfolding temperature 
after the introduction of Aβ42 to the preformed ABAD-fragment complex. Fragments shaded in 
purple were previously identified as inhibitors of ABAD (Section  3.4). 
 
Comparing the two sets of data, it was found that 73 and 74 consistently showed no 
change in Tm between the presence and absence of Aβ, suggesting that the fragment 
is preventing the binding of ABAD to Aβ42. Interestingly, these two compounds 
were earlier identified as inhibitors of ABAD (see Section  3.4). Docking studies 
(Section  3.7) identified two possible sites to which these compounds may bind: the 
enzyme active site and a potential allosteric binding site. One can imagine that 
binding to an allosteric site may alter the loop D conformation as well the active site 
conformation, altering the Aβ binding ability. Meanwhile, 54 and 69 consistently 
showed no effect in the presence of amyloid, suggesting perhaps that amyloid is 
blocking fragment binding. These two pairs of compounds therefore merit further 
investigation as modulators of the ABAD-Aβ complex due to the apparent 
competition between the molecules and Aβ for binding sites on ABAD.  
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Figure  5.21: Compounds identified through thermal shift analysis as potential modulators of the 
ABAD-Aβ interaction. 
 
The compounds will require verification of their binding influence by another 
method, such as SPR, in order to overcome the limitations of TSA as an analytical 
tool. TSA is an indirect method of measuring a binding interaction, i.e. it is not 
measuring the direct binding of the two components themselves, but rather 
measuring the effect that the fragment has on a property (in this case the Tm) of the 
protein. It is likely that the classification system used above is over-simplistic; since 
binding occurs as an equilibrium-based interaction, it is possible to have intermediate 
states between those shown. It also does not allow for the likely differences in 
binding affinities between small molecule fragments (~mM) and amyloid (~nM), 
where it may be considered unlikely that a mM-binding fragment would be capable 
of displacing a nanomolar binder such as Aβ. It is however a useful starting point for 
identifying inhibitors of the ABAD-Aβ interaction, as it has identified two pairs of 
compounds that appear to influence or be influenced by the presence of Aβ. In 
conjunction with complimentary techniques, it is proposed that these compounds will 
be a useful starting point for the identification of ABAD-Aβ modulators.  
 
 
5.4.2 The decoy peptide as a strategy for preventing the ABAD-Aβ interaction 
 
An alternative strategy, and the original method for investigating the consequence of 
preventing the interaction of ABAD and Aβ, is the use of the ABAD “decoy 
peptide”. The decoy peptide consists of the residues of ABAD thought to be 
responsible for Aβ binding and has been shown in animal mouse models to reverse 
biochemical and behavioural symptoms associated with AD.137-139 However, the 
current size of the peptide is in the region of 3 kDa. It was aimed to decrease the size 
of the peptide to include only the amino acid residues essential for disrupting the 
interaction. Therefore, before studies were carried out using the decoy peptide, 
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crystallography was explored as a method to identify the crucial residues required for 
binding, in order to decrease the decoy peptide’s size and simplify its structure. 
 
 
5.4.2.1 Co-crystallisation of ABAD and amyloid 
 
The original DP was identified using a range of techniques that identified the Loop D 
region of ABAD as being the likely binding site of Aβ. In order to narrow this region 
down further to the specific residues and atomic interactions involved, the ideal 
source of information on binding would come from a co-crystal structure of amyloid 
bound to the enzyme. Identification of ABAD resides important for binding Aβ can 
be directly translated into the required residues for activity of the decoy peptide. The 
crystal structure of an ABAD-Aβ complex was published by Lustbader in 2004,84 
however, electron density for the amyloid peptide was not observed. As has been 
previously discussed (Introduction, Section  1.3.3), it was proposed that the binding 
site for amyloid was a region of the enzyme known as the LD loop, which was found 
to be disordered within the crystal structure and hence no electron density observed. 
Based on the evidence that although Aβ binds to ABAD at nanomolar 
concentrations,84,117,135 it only inhibits at micromolar concentrations,116,117  it is 
therefore not unreasonable to suggest that amyloid inhibits by its aggregation onto 
the enzyme, leading to a detrimental conformational change. The lack of order within 
the LD loop may, therefore, have resulted either from the formation of a disordered 
aggregate of amyloid around this region or as a result of a high degree of flexibility 
of the amyloid peptide bound to the loop.  
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Figure  5.22: PyMol representation of the ABAD-Aβ complex. The region between Ile94 and 
Phe114 (residues highlighted in red), thought to be the binding location of Aβ, is disordered. Protein 
databank ascession number 1SO8.84 
 
In order to obtain the desired information about the specific interactions at an atomic 
level between ABAD and Aβ it was therefore proposed to improve upon the existing 
crystal structure by obtaining a structure detailing the interaction site. As it was 
thought that the disorder may have resulted from a high degree of flexibility in the 
amyloid peptide (40 aa residues), a truncated form of amyloid was used instead. The 
Aβ20 peptide (DAEFRHDSGYEVHHQKLVFF) consists of only the first 20 amino 
acids of the full length Aβ peptide and still contains the residues thought to be 
responsible for aggregation and binding to ABAD.116,141 This peptide has been 
shown to bind to ABAD with a Kd of  89 ± 20 nM.
84 
 
Preliminary work carried out by the Scottish Structural Proteomic Facility based at 
the University of St Andrews identified two sets of crystallisation conditions for 
ABAD-Aβ, which were to be taken as a starting point for further optimisation (Table 
 5.4).  
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Table  5.4: Preliminary conditions for the co-crystallisation of ABAD and Aβ20. 




17.5% PEG 4000 
0.24 M magnesium sulfate 
0.1 M MES, pH 6.5 
 
40% PEG 400 
0.1 M lithium sulfate 
0.1 M sodium citrate, pH 5.5 
 
Protein solution 20 mg mL-1 ABAD 
1 mM DTT 
5 mM NAD+ 
2 molar excess Aβ20 
10 mg mL-1 ABAD 
1 mM DTT 
5 mM NAD+ 
2 molar excess Aβ20 
 
Ratio (protein:crystallisation soln) 2 + 1 1 + 1 
Drop size 150 nL 150 nL 
Time 4 days 4 days 
Diffraction 4 Å 3 Å 
 
Each of these conditions was to be optimised to obtain crystals with a higher 
diffraction; the optimisation conditions are shown below (Table  5.5). However, no 
diffracting crystals were obtained from these optimised screens.  
 
Table  5.5: Optimisation of initial crystalisation conditions 
Condition 1 0.1 M MES, pH 6.5 0.24 M magnesium sulfate 17.5% PEG 4000 
Optimisation 
conditions 
0.1 M MES, pH 5.5–6.5 
0.1 M sodium acetate, pH 5.6 
0.1 M sodium citrate, pH 5.5 
0.175–0.3 M magnesium sulfate 
0.18–0.3 M lithium sulfate 
0.16–0.3 M ammonium sulfate 
15.5–25% PEG 3500 
12.6–22% PEG 4000 
12.8–22.4% PEG 6000 
    
Condition 2 0.1 M sodium citrate, pH 5.5 0.1 M lithium sulfate 40% PEG 400 
Optimisation 
conditions 
0.1 M sodium citrate, pH 4.5–
5.5 
0.1 M sodium acetate, pH 5.6 
0.1 M MES, pH 5.5 
0.06–0.26 M lithium sulfate 
0.08–0.26 M ammonium sulfate 
0.06–0.22 M magnesium sulfate 
35–46% PEG 400 
36–45% PEG MME 550 
28–37% PEG 1500 
    
Protein solution 10 or 20 mg mL-1 ABAD 
1 mM DTT 
5 mM NAD+ 
2 molar excess Aβ20 
  
Ratio  1 + 1   
Drop size 150 nL (sitting drop) 
1 µL (hanging drop) 
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A number of further attempts at optimisation were made, including: the addition of 
additives such as β-mercaptoethanol, DMSO, ethylene glycol, glycerol, 1,6-
hexanediol and lauryldimethylamine 0-oxide (LDAO); changing the salt anion to 
acetate, chloride and formate; and variation of the protein:crystallisation buffer ratio; 
all of which proved to be unsuccessful. 
 
The original crystal obtained (Condition 2, Table  5.4) was at this point subjected to a 
higher resolution data collection using a synchrotron. This revealed that no Aβ20 
electron density was observed within the crystal structure, although Loop D was 
found to be ordered, suggesting that Aβ20 was not bound to the enzyme. Therefore, 
screening was repeated using a higher Aβ20 concentration (5 or 20 molar excess, 
compared with 2 molar excess used previously). These screens were also prepared in 
the presence and absence of NAD+. It was thought that that NAD+ was required for 
protein stability; the mutual exclusivity of binding of NAD+ and amyloid to ABAD 
may mean that the presence of NAD+ in the crystallisation solution prevented the 
binding of amyloid.  
 
None of the strategies tried above resulted in the formation of crystals with sufficient 
diffraction to allow analysis of the ABAD-Aβ interface. It is possible that future 
work will result in a suitable co-crystal demonstrating the specific interactions 
between ABAD and amyloid and this achievement will aid modification of the decoy 
peptide immensely. In the meantime, however, alternative approaches were taken in 
order to achieve progress in studying the actions of the DP. 
 
 
5.4.2.2 Surface plasmon resonance studies of the decoy peptide 
 
Having established SPR as a technique for measuring the direct binding of Aβ and 
ABAD (Section  5.3.3), the technique was then further used for studying the ability of 
the decoy peptides to disrupt this interaction. Lustbader et al.84 used SPR to study the 
interactions of ABAD, Aβ and the DP by showing that addition of the decoy peptide 
into the injected ligand solution prevented binding of Aβ to immobilised ABAD.  
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However, as explained above in Section  5.3.3, their system set-up with immobilised 
ABAD was not successfully replicated. However, binding was observed using 
immobilised Aβ and so it was proposed to look at the direct binding of the decoy 
peptide to this immobilised Aβ. This is in contrast to the Lustbader study, where 
evidence for the DP interaction was indirectly obtained by the lack of Aβ binding to 
ABAD. It was therefore hoped that direct evidence of binding between Aβ and the 
decoy peptide could be observed, confirming the recent finding by Yao et al.139, who 
observed the formation of the DP-Aβ complex using immunoprecipitation. This 
finding demonstrated that the mode of action of the decoy peptide is through binding 
to Aβ, preventing its interaction with ABAD. To date there has been no quantitative 
analysis of direct DP binding to Aβ. Smaller portions of the decoy peptide were to be 
analysed by this method in order to elucidate the essential residues involved, to allow 
for future modification of the peptide structure to optimise its interaction with Aβ.  
 
As with the Aβ-ABAD binding studies, Aβ40 and Aβ42 were immobilised onto a 
CM5 chip to ~6000 RU immobilisation. As well as the 92–120 peptide [DP(92–120)] 
and its reverse sequence 120–92 [RP(120–92)], which were used in the Lustbader 
study, a series of shorter peptides consisting of ABAD residues 100–110 [DP(100–
110)], 98–102 [DP(98–102)] and 107–111 [DP(107–111)] were also measured. 
These peptides were selected on the basis of mutagenesis studies, which identified 
that residues 98–101 and 108–110 contained vital residues.84  
 
Due to instrumentation and time restrictions, the experimental conditions were not 
optimised. For example, immobilisation onto the chip surface at ~6000 RU was 
substantially higher than standard conditions, where around 1000 RU would typically 
be used. A lower immobilisation level of Aβ40 (~400 RU) resulted in no peptide 
binding being observed, potentially as a result of the majority of Aβ being in an 
“inactive” form for ligand binding (see Section  5.3.3). It was therefore hoped that use 
of a much higher Aβ immobilisation would increase the observed binding signal, 
which were consistently significantly lower than the theoretical maximum. This 
advantage however must be weighed up against the issues resulting from high 
immobilisation, such as mass transfer problems. However it was hoped that some 
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useful data could be obtained. The calculated Kd values for the binding of the 
peptides to Aβ40 and Aβ42 are shown in Table  5.6.  
 
Table  5.6: Calculated Kd values for binding of peptides to Aβ. Aβ40 (10 µM in 10 mM sodium 
acetate pH 4, 5712 RU) or Aβ42 (10 µM in 10 mM sodium acetate, pH 4, 6284 RU) was immobilised 
on a CM5 chip. Decoy peptides DP(92–120), DP(120–92), DP(100–110), DP(98–102) or DP(107–
111) were passed over the cell. The region of the full length (92-120) decoy peptide tested is 
highlighted in bold. Binding conditions: peptide sample injection, 30 µL min-1, 45 s; dissociation time, 
300 s; regeneration, 4 M guanidine HCl, pH 7.7, 30 µL min
-1
, 10 s; stabilisation, 200 s. 




















steady state, affinity 
analysis at low conc 
non-specific at high 
conc 
~10 mM 






non-specific ~80 µM (very poor 
data) 
steady state, affinity 
analysis at low conc 
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The preliminary data, shown in Table  5.6, shows the binding of DP(92–120) to Aβ42 
with a Kd of ~100 µM, while the reverse peptide, RP(120–92), did not show any 
binding. The rest of the results however are mixed and are somewhat difficult to 
interpret meaningfully. The full length DP(92–120) and reverse sequence appear to 
both bind to Aβ40 and with the shorter peptides there appears to be little pattern to 
explain which peptides bind and which do not, and whether they bind to Aβ40 or 
Aβ42. It is however possible that with further optimisation, more reliable data may 
be obtained, allowing the binding residues of the DP to be identified.  
 
 
5.4.2.3 A cellular approach to investigating the decoy peptide 
 
One of the problems with using peptides in cellular studies is the need to transport 
the peptide across the cell membrane. A common solution to this is the addition of a 
protein transduction domain (PTD) to create a fusion peptide that is able to cross cell 
membranes. One of the most common PTD in use is the transactivator of 
transcription (Tat) PTD of the human immunodeficiency virus (HIV), an 11 amino 
acid residue peptide, which has been shown to transport fusion peptides across cell 
membranes.210  
 
While the addition of 11 amino acid residues to a large protein may not result in a 
significant structural change, the proposed decoy peptide, encompassing residues 93–
116 of ABAD, is much smaller, with only 24 amino acids. Clearly, increasing the 
number of residues by almost 50% raises the possibility that the fusion peptide no 
longer resembles the target peptide. In addition, it would be favourable to target such 
a peptide into the mitochondrial matrix. Again this is possible using an additional 
peptide sequence, known as a mitochondrial targeting sequence (MTS) (reviewed by 
Omura211). This will, of course, increase the size of the fusion peptide. For example, 
the MTS from subunit VIII of human cytochrome c oxidase (COX8) is used in the 
commercially available pDsRed2-mito plasmid, which encodes for a red 
mitochondrial marker. This sequence is 29 amino acids long, although is thought to 
be cleaved upon entry to the mitochondria.198  
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As an alternative to adding synthetic peptide to cells, an intracellular peptide 
synthesis approach was investigated. As the decoy peptide is relatively small, it 
would be advantageous to remove the need for additional peptide domains, such as 
Tat, as their presence may have significant impact on the resulting peptide. By 
creating a plasmid encoding for a mitochondrial-targeted decoy peptide, the cells are 
able to produce their own peptide, removing the need to get the peptide across the 
cell membrane and hence removing the need for a Tat domain. 
 
The plasmid was constructed as shown in Figure  5.23. The decoy peptide sequence 
was produced by PCR amplification of residues 93–116 of ABAD from the 
mito-ABAD-GFP plasmid previously produced in the group.157 BamHI and 0otI 
restriction sites were incorporated at either end of the DNA fragment, which was 
then digested with the appropriate restriction enzymes. The vector was based on 
DsRed2-mito, a plasmid encoding the MTS of COX8 fused to a red fluorescence 
protein (DsRed2). The DsRed2 gene was removed by restriction digest with BamHI 
and 0otI, allowing ligation of the vector and insert DNA to form a plasmid encoding 
for the mitochondrial-targeted decoy peptide (MTS-DP(93–116)). The plasmid DNA 
sequence was confirmed by sequencing. 
 





































Figure  5.23: Construction of the mitochondrial-targeted decoy peptide, MTS-DP(93–116). 
Residues 93-116 of ABAD were amplified from a mito-ABAD-GFP plasmid using PCR, encoding 
BamHI and 0otI sites at either end of the DNA insert then digested with the appropriate restriction 
enzymes. DsRed2-mito was digested with BamHI and 0otI to remove the DsRed2 gene. The mito 
vector and DP(93–116) were ligated together using DNA ligase to create the MTS-DP(93–116) 
plasmid. MTS = mitochondrial targeting sequence. 
 
With the MTS-DP(93–116) plasmid in hand, it was important to check that the 
fusion decoy peptide was produced by cells in vitro. A commercial antibody that 
recognises ABAD residues 110-116 was available (Sigma); it was proposed that as 
this region fell within the decoy peptide sequence the antibody would bind the decoy 
peptide. A fluorescent secondary antibody could then be used to image the peptide 
distribution to ensure localisation to the mitochondria. As a positive control, 
HEK293 cells were transfected with MTS-ABAD-GFP, then fixed and stained using 
anti-ABAD primary and Alexa 568 secondary antibodies. Co-localisation of the GFP 
(green) and Alexa 568 (red) signals confirmed that the anti-ABAD(100–110) 
antibody recognised ABAD within the mitochondria (Figure  5.24). 
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Figure  5.24: Immunostaining of mito-ABAD-GFP. HEK293 cells were transfected with 
mito-ABAD-GFP for 48 h before fixing and staining with α-ABAD(110–116) (1 µg mL-1) and 
Alexa 568-congugated α-rabbit (1:5000). 
 
HEK293 cells were then transfected with MTS-DP(93–116) for 48 h before fixing 
and staining. While it was expected that some background fluorescence would be 
detected due to the presence of native ABAD, it was hoped that expression of the 
transfected decoy peptide would cause a large increase in the signal detected. Both 
Alexa 568 (red) and FITC (green) labelled secondary antibodies were used and in 
neither case was any fluorescence detected. Similarly, SK-N-SH, a human 
neuroblastoma cell line, was also investigated for its ability to express the decoy 
peptide. Transfection of SK-N-SH cells was carried out using the Amaxa 
Nucleofector system, an electroporation system which delivers DNA into the 
nucleus. While a positive control transfection of MTS-ABAD-GFP showed that the 
transfection method worked, no immunostaining of MTS-DP(93–116) by anti-
ABAD primary antibody and fluorescent secondary antibody was detected. 
 
As an alternative to immunocytochemistry, the peptide was also probed for using 
Western blotting, again using the anti-ABAD(110-116) antibody. It had been a 
concern that the small size of the peptide (~6 kDa) would make it unsuitable for 
detection on a gel. However, the 6 kDa protein band within the molecular weight 
marker was easily detected on an SDS-PAGE gel by Instant Blue stain. Once again, 
the peptide was not detected, neither by protein gel nor by Western blot.  
 
The apparent failure of both HEK293 cells and SK-N-SH cells to express the decoy 
peptide may be due to a number of reasons. Firstly, it may be that the peptide is 
expressed, but is recognised as a “foreign” peptide by the cells and is therefore 
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immediately broken down by proteases within the cell; secondly, the peptide may be 
toxic so kills any cells that express it. These possibilities are, however, thought to be 
unlikely as this peptide has been used in live animals both without any apparent 
toxicity and with the ability to elicit both biochemical and behavioural 
changes.84,137,138 Although the antibody was shown to be reactive against ABAD 
(Figure  5.24), a more likely possibility was that the primary anti-ABAD antibody 
does not recognise the decoy peptide as the secondary structure of the decoy peptide 
may be different to that of the corresponding region of ABAD. 
 
In order to detect production of the DP in cells, it was decided to make two tagged 
versions of the peptide, labelled with either green fluorescent protein (GFP) or a 
FLAG epitope tag212 [MTS-DP(93–116)-GFP and MTS-DP(93–116)-FLAG, 
respectively]. The GFP tag was selected for its easy visualisation by fluorescence 
microscopy, although the size of the GFP, at 238 amino acids, had the potential to 
affect the properties of the peptide. The FLAG tag, at 8 amino acids, was much 
smaller and was selected for this reason.  
 
The MTS-DP(93–116)-GFP plasmid was created by amplifying the MTS-DP(93–
116) gene from the MTS-DP(93–116) plasmid using PCR, encoding for EcoRI 
(forward) and SalI (reverse) in the primers. The insert and pEGFP-N3 vector were 
then digested with EcoRI and SalI restriction enzymes before ligating to give the 
complete plasmid (Figure  5.25). This plasmid was prepared by R. Björfors.158  
 






































Figure  5.25: Construction of the mitochondrial-targeted decoy peptide, MTS-DP(93–116)-GFP. 
The MTS-DP(93–116) region of the MTS-DP(93–116) plasmid were amplified using PCR, encoding 
EcoRI and SalI sites at either end of the DNA insert, then digested with the appropriate restriction 
enzymes. pEGFP-N3 was digested with EcoRI and SalI before ligating with MTS-DP(93–116) using 
DNA ligase to create the MTS-DP(93–116)-GFP plasmid. MTS = mitochondrial targeting sequence. 
 
The MTS-DP(93–116)-GFP plasmid was transfected into HEK293 and primary 
cortical neurons, where green mitochondrial staining was observed with fluorescence 
microscopy (Figure  5.26). Co-transfection of MTS-DP(93–116)-GFP and 
pDsRed2-mito, a mitochondrial-targeted red fluorescent protein, showed 
colocalisation of red and green fluorescence, indicating that the fusion peptide was 
indeed targeted to the mitochondria (Figure  5.27).  
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Figure  5.26: Expression of MTS-DP(93–116)-GFP in HEK293 cells and mouse primary cortical 
neurons. HEK293 cells (top) and mouse primary cortical neurons (bottom) were transfected with 
MTS-DP(93-116)-GFP for 48 h, fixed and mounted with mowiol/DAPI before imaging using standard 
fluorescence microscopy.  Left: MTS-DP(93–116)-GFP (green); centre: DAPI (blue); right: merge. 
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Figure  5.27: Colocalisation of MTS-DP(93–116)-GFP with DsRed2-mito. HEK293 cells were co-
transfected with MTS-DP(93–116)-GFP and DsRed2-mito for 48 h before fixing and mounting in 
mowiol/DAPI. Imaging with confocal microscopy: A) DAPI, blue (ex 405 nm, em 440–475 nm); 
B) DsRed2, red (ex 543 nm, em 580–680 nm); C) GFP, green (ex 488 nm, em 505–540); D) Merge, 
colocalisation of DsRed2 and GFP shown as yellow. 
 
This provided reassurance that the MTS-DP(93-116) gene is transcribed and 
translated correctly (as both the MTS at the start of the peptide and the GFP at the 
end were expressed), despite it not being detected when using the original MTS-
DP(93–116) plasmid. While the GFP-tagged version has proved very useful for 
confirming the expression of the peptide, caution must be exercised in investigating 
the properties of the decoy peptide as a GFP fusion protein, due to the large size of 
the GFP in comparison to the DP portion of the protein. However, one must also bear 
in mind that the presence of GFP on the mito-ABAD-GFP protein did not prevent the 
function of the short MTS region of the protein, and still successfully directed the 
protein to the mitochondria (Figure  5.24). However, as an alternative to the GFP tag, 
a similar approach to that described above was taken to produce a FLAG-tagged 
peptide. As before, the MTS-DP(93–116) gene was digested from the MTS-DP(93–
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116) plasmid then ligated into the pCMV5-Tag 4A vector to produce a MTS-DP(93–
116)-FLAG construct (B. Powell), which is now available for future experiments.  
 
It is hoped that the DP plasmid will prove useful in the future as a tool for studying 
cellular aspects of AD; for example, are cells transfected with the plasmid protected 
against amyloid toxicity? If the peptide proves to be protective, it is possible to 
envisage creating a series of plasmids encoding for decreasing peptide lengths in 
order to determine the minimum DP sequence required for activity, or by creating 
plasmids for peptides identified by other means, such as through the SPR work.  
 
 
5.5 Conclusions and future work 
 
A large proportion of the work reported in this chapter has left opportunities for 
further development and progress to be made. Studying the interactions of amyloid is 
not always an easy task, given its tendency to aggregate with itself to give a variety 
of species under different conditions, the very property that results in the 
manifestation of Alzheimer’s disease when this process occurs in the brain. Despite 
this, progress has been made towards being able to study this interaction in vitro and 
potentially disrupting the complex, in order to prevent downstream effects.  
 
The failure to replicate previous work demonstrating the inhibition of ABAD by 
amyloid was particularly frustrating, as this would have provided a straight-forward 
read-out of the interaction occurring between ABAD and Aβ. However, the 
subsequent discovery by SPR that the presence of a His tag on the 0 terminus of 
ABAD affects its ability to bind Aβ peptides may provide an explanation for 
observed lack of inhibition. It is optimistic that future attempts at developing an 
ABAD-Aβ based activity assay using untagged ABAD may prove more successful. 
Similarly, SPR revealed that although ABAD and Aβ were binding under the 
conditions tested, the observed signal was far smaller than the maximum theoretical 
signal. This led to the conclusion that only ~1% of the Aβ present was in a form able 
to bind ABAD, while the vast majority remained unbound. While this level of 
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binding was sufficient for the above studies to be performed, the question of why the 
majority of the immobilised amyloid did not bind still remains. Future work will 
investigate further the use of different preparations of amyloid for use in binding 
experiments in order to maximise the signal obtained, which will benefit the study of 
smaller binding molecules by amplifying the signal.  
 
With regards to the development of molecules or peptides that are able to disrupt the 
ABAD-Aβ complex formation, four compounds have been identified that may 
influence the binding between ABAD and Aβ (Figure  5.21), although further 
analysis will be required to verify these hits before structural modification can take 
place. The decoy peptide approach, meanwhile, resulted in the creation of a number 
of plasmids encoding for the full length DP, but problems with detecting the 
expression of the resulting fusion peptide in cells delayed experiments investigating 
the effect that the peptide had on cells experiencing Aβ-induced toxicity. SPR was 
successfully used to observe direct binding of the full length decoy peptide [DP(92–
120)] to Aβ42; it is hoped that future studies related to this work can be carried out, 
in order to decrease the decoy peptide to its minimal essential sequence. 
 
As with the design of all drugs, the ability of molecules to pass across cell 
membranes and to reach the desired cellular target is a major consideration and the 
intracellular production of the DP was investigated as one way of avoiding this issue 
for cellular studies. In a recent advance, Horton et al.213 has reported the 
development of a four amino acid tag, which directs molecules not only across the 
cell membrane, but also across the mitochondrial membrane. This represents a 
massive reduction in size from the combined Tat plus mitochondrial targeting 
sequence peptide and may prove to be a useful tool for targeting both peptides and 
small molecule compounds directly into the mitochondria. This, along with strategies 
to enhance the bioavailability of compounds, should benefit the design of new 
compounds to target intracellular processes.  
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It is therefore hoped that this work described in this chapter has formed the basis for 
future work within this field in order to begin to develop serious contenders as 
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The work described in this thesis has laid the foundations for targeting the ABAD-
Aβ interaction as strategy for treating Alzheimer’s disease. This research was 
focused broadly on two main aspects: firstly, the measurement of ABAD activity and 
monitoring of its interactions with Aβ; and secondly, the design of probes for 
studying the enzyme and its interactions with Aβ, working towards the aim of 
providing a novel therapeutic strategy for treating Alzheimer’s disease. 
 
 
6.1 Measurement and monitoring of ABAD activity and interactions 
 
A crucial requirement for being able to develop and test compounds targeting the 
ABAD-Aβ interaction was the ability to monitor the effect that such compounds had 
on the function and interactions of ABAD. This required development of a rapid and 
robust assay that measured the interactions of ABAD and Aβ in some way. 
 
A number of approaches were therefore investigated as part of this work with the aim 




6.1.1 ABAD activity as a measure of enzymatic function 
 
The first of these approaches measured the catalytic activity of ABAD as a measure 
of its function, a method that has been widely reported in the literature.114-119,122,124 
Use of a simple enzymatic activity assay, which involved measuring the reduction of 
S-acetoacetyl-CoA by ABAD by monitoring the absorbance of the co-factor NADH, 
was able to provide a robust quantitative method for calculating the activity of 
purified ABAD protein. Extension of this assay into one that incorporated the 
inhibitory effect of Aβ did, however, prove more difficult. Despite being previously 
reported in the literature,116,117 the inhibition of ABAD activity by addition of Aβ 
was not successfully replicated in the present work. Subsequent work carried out 
using surface plasmon resonance (SPR) showed that there was a difference in the 
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ability of ABAD and a His-tagged version of ABAD to bind Aβ. As His-ABAD was 
used in these Aβ inhibition studies, it was therefore possible that the presence of the 
His-tag interfered with the ability of the peptide to bind to and inhibit the activity of 
ABAD. While small tags are generally not considered to interfere with the function 
and activity of proteins,206 there are a few reports in the literature that show 
exceptions to this rule, such as the presence of a C-terminal His tag on tropinone 
reductase, another short chain dehydrogenase.207 Due to times restraints, this avenue 
was not pursued further but it is hoped that future attempts to develop this assay 
using untagged enzyme will prove successful.  
 
The ABAD activity assay was also successfully translated from a cuvette scale 
(1 mL) to 96 well plate format (160 µL). The short assay time meant that samples 
still had to be set up and measured individually within the plate, meaning that no 
improvement in sample through-put was achieved. However, the reduction in sample 
size proved to be advantageous and the sample through-put remained satisfactory for 
testing small sets of conditions (for example, eight sets of conditions plus controls, in 
triplicate, took around 7 hours in total).  
 
One of the major advances reported herein was the development of a method for 
monitoring the activity of intracellular ABAD in intact living cells. Building on the 
work published by Froemming and Sames in 2007,120 which described the use of a 
novel fluorogenic probe to study the activity of ABAD in living cells, our 
collaborators determined that ABAD was selective for the single enantiomer of this 
compound, (–)-CHANA. With this probe in hand, it was possible to explore the 
conditions under which (–)-CHANA could be used to study ABAD activity within a 
living cellular environment.  
 
The (–)-CHANA assay was performed using a confocal fluorescence microscope, a 
technique, which although highly sensitive and effective, proved to be relatively time 
and material intensive. Samples were set up in individual 35 mm dishes and analysed 
individually, resulting in an experimental time of 1 hour per sample. When it was 
taken into account that each sample was to be run in triplicate, this led to a low 
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throughput and was not suitable for analysing large numbers of sample 
simultaneously.  However, there may be scope for transfer to a higher through-put 
96 well plate format, as described in Section  4.9. It is anticipated that this could be 
achieved through use of a fluorimetric plate reader, rather than the horizontal 
fluorimeter beam used in earlier work. Plate readers of this kind can give rapid 
measurements (< 0.2 s), which would allow multiple samples to be analysed 
simultaneously. The use of a fluorimeter to quantify the fluorescence would also 
remove the rather time-consuming image analysis associated with microscopy. The 
problems associated with uneven cell coverage, described in Section  4.5, would 
hopefully be eliminated by use of a 96 well plate rather than 35 mm dishes as the 
smaller surface area allows the fluorescence emitted from the entire sample to be 
measured. In addition, the miniaturisation of the assay would greatly simplify the 
running and analysis of samples, reduce the amount of reagents required and increase 
the throughput of experiments.  
 
Using (–)-CHANA to probe ABAD activity, it was demonstrated that the topical 
addition of Aβ42 inhibited intracellular ABAD activity in HEK293 cells. This 
represented the first report of such inhibition being recorded inside living cells and is 
thus highly significant for future work. While purified protein studies are useful in 
order to establish the function of enzymes such as ABAD, the development of a cell-
based assay is of great benefit for drug development as it allows study of the whole 
cell and its influence on the response of the protein of interest to the compounds 
being tested.   
 
 
6.1.2 Measurement of ABAD, Aβ, small molecule and peptide binding 
 
In addition to measuring ABAD activity, which provided an indirect method of 
monitoring interactions of ABAD with other species that bind to it, possible methods 
of measuring direct binding interactions of ABAD were also investigated. Initially 
this focussed on the interaction between ABAD and Aβ, although was later expanded 
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include the binding of ABAD to small molecules and the binding between Aβ and 
decoy peptides.  
 
Thermal shift analysis (TSA) is an indirect method used to show binding of a ligand 
to a protein and utilises the change in the stability of a folded protein upon binding of 
a ligand. This technique is regularly used for screening molecular fragment libraries 
and in the present work was used to identify a number of compounds that bound to 
ABAD. These compounds were subsequently investigated as potential inhibitors of 
ABAD activity and of the ABAD-Aβ interaction. In addition, TSA was used to 
demonstrate binding of Aβ42 to ABAD, an interaction that resulted in a 5 °C 
increase in the unfolding temperature of ABAD. TSA does not lend itself to 
straightforward quantitative analysis, although precedent exists in the literature 
detailing how this may be possible.183,185 In its application for screening libraries of 
compounds however, TSA used here to provide a “yes/no” answer to whether or not 
each library compound bound to ABAD and for more in depth analysis of 
interactions, alternative methods were sought.  
 
Isothermal titration calorimetry (ITC) was used to investigate the binding of small 
molecules identified through the TSA screen. The interactions resulting from 
fragment screening are generally predicted to be in the millimolar range; their weak 
interactions resulting from limited functionality with which to form non-covalent 
intermolecular bonds. The ability of ITC to detect low affinity binding, such as that 
described here, is a relatively recent development187 and as such the extensive 
optimisation required to obtain such measurements was not achieved in the time 
available.  
 
Surface plasmon resonance (SPR) proved to be a more successful technique for 
studying the binding interactions of interest. During SPR experiments, it was found 
that the presence of a His-tag on the ABAD protein was found to hinder the binding 
of Aβ. This finding had not been anticipated and may have accounted for the lack of 
Aβ-induced inhibition during the ABAD activity assay using His-tagged ABAD, as 
noted above. The difference between ABAD and His-ABAD interactions was 
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immediately apparent upon immobilisation of the protein onto the SPR chip, where 
different conditions were required for optimal immobilisation of the protein.  
 
Ultimately, it was demonstrated herein that ABAD bound to immobilised Aβ40 and 
Aβ42. Original work by Lustbader et al.84 showed binding of Aβ to immobilised 
ABAD; however this binding was replicated in the present work. This observed 
binding had also failed to be replicated by other researchers,208 who successfully saw 
the interaction using immobilised Aβ40 instead135 and it was a similar set-up that 
proved successful in this instance. ABAD was found to bind Aβ40 and Aβ42 with Kd 
values of 6 and 4 nM, respectively. Another interesting point to note from this work 
was that the observed binding signal was only ~1% of the theoretical signal. This 
implied that the vast majority of Aβ was in a form unable to bind ABAD. As the 
response detected is proportional to the molecular weight of the species bound, this 
“inactive” Aβ may have been the reason that no binding of Aβ to immobilised 
ABAD was observed: the signal was simply too small to be seen. SPR was also used 
to show binding between Aβ and decoy peptides. 
 
Despite the initial difficulties encountered during setting up the SPR experiments, 
with optimised conditions and protocols in place, this should prove to be a very 
useful technique for future studies. It is capable of measuring the binding of small 
molecules, which is critical for assessing the binding of potential drug molecules.  
 
With a range of assays in place, it was then possible to begin development and 
characterisation of potential molecular probes of ABAD and identification of 
molecules targeting the interaction of ABAD with Aβ.  
 
 
6.2 Development of molecular probes of ABAD and its interaction with Aβ 
 
With a range of analytical techniques in hand, focus moved to the identification and 
development of compounds as molecular tools for further study of ABAD, as well as 
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preliminary work identifying compounds that had the ability to prevent the ABAD-
Aβ interaction.  
 
 
6.2.1 Molecular probes for studying ABAD  
 
The first class of compounds investigated in this study were inhibitors of ABAD 
activity. It was desirable to develop such compounds as they would allow ABAD to 
be selectively “switched off” during cellular studies, as well as acting as a positive 
control for ABAD inhibition.  
 
The experimental process that aimed to achieve this is summarised in Figure  6.1. 
 
 
Figure  6.1: Design process of compounds.  Hits identified through TSA were fed into iterative 
cycles of compound design, synthesis and testing. Optimised compounds from this process can be 
taken through into cell-based assay and investigated for their mode of action.  
 
Using TSA, a small molecular fragment library was screened for binding to ABAD, 
resulting in the identification of 16 compounds. Further screening of these 
compounds in the ABAD activity assay identified seven compounds that inhibited 
ABAD activity, four of which were highlighted for further development. It had been 
hoped to obtain more information on the binding of these compounds to ABAD 
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through the use of ITC and X-ray crystallography; however, these attempts have 
unsuccessful to date.  
 
Two of the compounds identified (73 and 74), which had related chemical structures, 
were used as a starting point for iterative cycles of design, synthesis and testing in 
order to increase the potency of the compounds. The resulting compound, 134, 
represented a 10-fold increase in the potency of the original compounds (Figure  6.2). 
 
 
Figure  6.2: Development of the ABAD inhibitor, 134. Through structural modifications, the IC50 of 
the original hits, 73 and 74, was decreased 10-fold.  
 
It was found that both the pyridine nitrogen atom and the hydrogen-bonding 
properties of the amine group were essential for activity. Having established the 
essential regions of the compounds 73 and 74 required to elicit their action, it is 
hoped that future work will result the IC50 being rapidly decreased to micromolar or 
nanomolar concentration by further structural modification. Using the simple ABAD 
activity assay described above, rapid evaluation of biological activity is possible, 
allowing the results to be fed back into the iterative design process.  
 
Once compounds with a high efficacy (IC50 of low µM or nM) have been identified, 
their effect on intracellular ABAD activity will be assessed using the (–)-CHANA 
assay to measure the degree of intracellular ABAD inhibition. This method was used 
in a preliminary study using 17, which showed a significant decrease in ABAD 
activity of ~25% at 10 mM. 
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It was also proposed to investigate the mode of action of the enzyme inhibitors. 
Molecular docking software was used to identify a potential allosteric binding site 
within the ABAD structure, and showed that an intermediate compound, 116, could 
potentially bind to either this site or the enzyme active site in a number of different 
conformations. Future use of docking studies may also provide information on how 
best to modify the compounds’ structure in order to optimise binding between 
ABAD and the inhibitor.  
 
The mode of action of the existing ABAD inhibitor, AG18051, is known to occur 
through covalently linking to NAD+ within the enzyme active site.119 This 
knowledge may prove beneficial to determining the binding site of new compounds, 
by performing competition or displacement studies with AG18051 to determine the 
active site role in binding. 
 
 
6.2.2 Inhibition of the ABAD-Aβ complex formation  
 
Having made significant progress on developing inhibitors of ABAD activity, focus 
then moved to development of compounds that prevent the interaction between 
ABAD and Aβ. Two different approaches were investigated for this avenue of work: 
small molecule inhibitors, identified through a fragment-based screening approach; 
and modification of the previously reported84,137-139 decoy peptide.  
 
The development of small molecule inhibitors for the prevention of the ABAD-Aβ 
interaction was thought to have a number of advantages over the use of peptides. The 
intrinsic properties of peptides mean they are often unsuitable as drug molecules; for 
example the presence of peptidases in the digestive system makes orally delivery of 
peptides impossible. Injection of peptide-based drugs, for example insulin, is 
possible; however, in the case of drugs targeting neurological disorders such as AD, 
getting molecules across the blood brain barrier presents an additional obstacle. It 
was therefore hoped that a low molecular weight (< 500 Da) compound would be 
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capable of fulfilling the role of the decoy peptide while removing the challenges that 
peptides present.  
 
In a similar manner to the identification of ABAD inhibitors (Section  3.3), TSA was 
used as an initial screening process. This proved to be more complex than before, as 
the binding mixture now comprised of three components. However, preliminary 
screens of ABAD-Aβ using TSA identified two pairs of compounds that may 
influence the interactions between ABAD and Aβ (Figure  5.21). It was found that 
compounds 73 and 74 consistently showed no change in Tm in the presence or 
absence of Aβ, suggesting that the fragment is preventing the binding of ABAD. 
Interestingly, these two compounds were earlier identified as being inhibitors of 
ABAD (Section  3.4). Likewise, 54 and 69 consistently showed no effect in the 
presence of amyloid, suggesting perhaps that amyloid is blocking fragment binding. 
Whatever the mechanism, this data suggests that the molecules are interfering with 
ABAD-Aβ interaction, or that the fragment and Aβ are competing for the same 
binding site on ABAD. 
 
 
Figure  6.3: Compounds identified through thermal shift analysis as potential modulators of the 
ABAD-Aβ interaction. 
 
In future work, compounds that are found to bind to ABAD or influence the 
ABAD-Aβ interaction without themselves inhibiting ABAD activity will prove to be 
an interesting group of compounds to investigate. It proposed that these compounds 
may bind in such a way that they do not cause the conformational change seen upon 
binding of Aβ or block the enzyme active site (and hence leave the underlying 
ABAD activity intact), yet may bind in a manner that prevents the further binding of 
Aβ.  
 
Due to the indirect indication of binding events provided by TSA, hits identified in 
this manner will require further verification through alternative methods. This will 
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include use of SPR and the ABAD-Aβ inhibition activity assay. SPR will provide 
direct measurement of binding, while the activity assay will determine the ability of 
compounds to protect against Aβ-induced inhibition of ABAD activity, i.e. does 
addition of library compounds to the ABAD-Aβ assay prevent the inhibition of 
activity. 
 
Once the initial hits have been verified, future work will then focus on iterative 
cycles of analogue design, synthesis and testing in order to improve the compounds 
efficacy. This will be carried out in a similar manner to that detailed for the 
development of ABAD inhibitors in Figure  6.1. 
 
The second approach for this section of work was to take forward the development of 
the decoy peptide (DP) as a method for inhibiting ABAD-Aβ binding. The majority 
of previous work in this area has been performed at a cellular84,154 or in vivo level,137-
139 while a single in vitro study by Lustbader et al.84 used SPR to demonstrate the 
prevention of ABAD-Aβ binding by the DP. To date, no work has been published on 
the direct molecular interactions that occur in order for the DP to elicit its effect. It 
was therefore desirable to understand more about how the DP bound to Aβ. A better 
understanding of the interactions occurring would allow optimisation of the peptide 
structure, with a reduction in size to include only those residues essential for binding, 
followed by structural modification to yield a more “drug-like” molecule. 
 
Again, a number of strategies were pursued in order to achieve progress in the 
development of these compounds, leading to a good foundation for future progress in 
this area. In contrast to the work carried out by Lustbader, which showed that the 
binding of Aβ to ABAD could be prevented by the DP (i.e. indirect evidence of DP 
binding),84 SPR was employed to study the direct binding of decoy peptides to Aβ. 
Plasmids encoding for the DP were also created, allowing an alternative delivery 
system for the peptides in cell-based studies.  
 
This work has great scope for future development. It is hoped that SPR can be used 
to measure binding of truncated DP sequences to Aβ, allowing the minimal required 
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peptide sequence to be determined. From there, a series of structural modifications 
will be performed. These approaches include peptidomimetic modification and 
peptide cyclisation, in order to improve compound stability, bioavailability and 
efficacy. 
 
Building on the success achieved so far and using the strategies outlined above, it is 
hoped that an inhibitor of the ABAD-Aβ interaction can be developed. 
 
 
6.3 The outlook for Alzheimer’s disease treatments 
 
The results reported herein have set the foundations for future work on targeting the 
ABAD-Aβ as a novel therapeutic strategy for treating Alzheimer’s disease.  
 
The number of cases of Alzheimer’s disease is rapidly increasing due to an ageing 
population and is placing an ever-increasing burden on the healthcare system. 
Current treatments do not target the underlying cause; instead, they simply help the 
brain make the most of the remaining function. Inevitably, this effect is short-lived 
and as the disease progresses, drug treatment fails. Focusing research towards a 
causative rather than symptomatic pathway will allow drugs to be developed that 
target the underlying cause rather than simply temporarily masking the symptoms; it 
will be this type of approach that is likely to lead to an effective treatment for this 
devastating disease.  
 
The ABAD-Aβ interaction has been shown to be a valid target for potential AD 
drugs, with previous research showing that disruption of this interaction in animal 
models of AD can reverse the associated memory deficits and biochemical markers. 
This work has, therefore, built upon these findings by returning to the molecular 
level in an attempt to determine what is occurring in these animals to cause these 
changes and how this approach can be extended into a suitable therapeutic 
application. The results from the work reported here, along with future work, 
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represent a promising advance towards an effective disease-modifying drug for the 
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Table  A.1: .ames and structures of initial short-listed ABAD-binding compounds. Compounds 
were identified from the initial screen of the Maybridge Ro3 library as being binding partners of 
ABAD in a thermal shift assay. Compounds with ∆Tm >2 °C were short-listed for investigation. Assay 
conditions: 11.7 µM ABAD, 10 mM fragment, 1 × Sypro Orange, 5% DMSO in 10 mM sodium 




































































































































































































75 4-pyrid-3-ylbenzoic acid 
 




















83 4-(3-thienyl)benzoic acid 
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Co-crystallisation trials were set up in the presence and absence of NAD+. To date, 
all published crystal structures of ABAD have had NAD+ present within the 
structure; it may be that it is necessary for stabilising the structure. However, the 
possibility that the fragments bound to ABAD in the co-factor binding site could not 
be ruled out, so NAD+ was removed in some trials to avoid competition effect.  
 
Using 96 well plates, sitting drop crystallisation trials were set up using a number of 
different screens (Table  B.1). 
 
Table  B.1: Co-crystallisation trials of ABAD and fragments. Drop size: 200 nL mother liquor + 










JCSG 12.5 5  11, 17, 73, 74 
JCSG 10 - 11, 17, 73, 74 
JMAC 12.5 5  11, 17, 73, 74 
JCSG 10 - 11, 17, 73, 74 
Stoichastic PEGS 1 12.5 5 11, 17, 73, 74 
Stoichastic screen 20 12.5 5 11, 17, 73, 74 
Stoichastic PEGS 2 10 - 11, 17, 73, 74 
 
From these trials, four crystals were obtained that were thought to be suitable for 
analysis (Table  B.2). 
 
Table  B.2: Well conditions for crystals obtained during co-crystallisation trials. 
Screen 
(well) 




0.1 M potassium thiocyanate 
30% PEG MME 2000 




0.2 M diammonium citrate, pH 5.0 
20% PEG 3350 




0.2 M lithium sulfate 
0.1 M bis-Tris, pH 5.5 
25% PEG 3350 




2.7 M potassium sodium phosphate 
0.1 M sodium acetate, pH 4.6 
18% PEG 400 
74 - 
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Unfortunately none of the above crystals diffracted when subjected to X-ray 
diffraction. Further optimisation is required in order to obtain co-crystals of ABAD 
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73  0-Methyl-0-(3-(pyridin-4-yl)benzyl)amine  
74  0-Methyl-0-(3-(pyridin-3-yl)benzyl)amine  
100  0-Methyl-0-(2-(pyridin-4-yl)benzyl)amine  
101  0-Methyl-0-(2-(pyridin-3-yl)benzyl)amine  
102  0-Methyl-0-(4-(pyridin-4-yl)benzyl)amine  
103  0-Methyl-0-(4-(pyridin-3-yl)benzyl)amine  
104  0,0-Dimethyl-0-(3-(pyridin-4-yl)benzyl)amine  
105  0,0-Dimethyl-0-(3-(pyridin-3-yl)benzyl)amine  
106  0,0-Dimethyl-0-(4-(pyridin-4-yl)benzyl)amine  
107  0,0-Dimethyl-0-(4-(pyridin-3-yl)benzyl)amine  
108  4-(3-(Methoxymethyl)phenyl)pyridine  
109  3-(3-(Methoxymethyl)phenyl)pyridine  
110  0-Methyl-0-(3-phenylbenzyl)amine  
111  0-methyl-0-(4-phenylbenzyl)amine  
115  0-Methyl-0-(3-(3,5-dimethylisoxazol-4-yl)benzyl)amine  
116  0-methyl-0-(3-(pyrimidin-5-yl)benzyl)amine  
117 0-Methyl-3-(1H-pyrazol-4-yl)benzyl)amine  
118  0-Methyl-0-(3-(pyridin-4-yl)phenyl)amine  
119  0-Methyl-0-(3-(pyridin-3-yl)phenyl)amine  
132  7-(Pyrimidin-5-yl)-3,4-dihydroisoquinolin-1(2H)-one  
134  0-(3-(Pyrimidin-5-yl)-4-fluoro-benzyl)amine hydrochloride  
137  7-Bromo-3,4-dihydroisoquinoline  
138  7-Bromo-3,4-dihydroisoquinolin-1(2H)-one  
141  0-(3-Bromobenzyl)-0-methylacetamide  
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